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Summary 
Acute myocardial infarction (AMI) remains a common and serious manifestation of 
coronary artery disease. The development of heart failure (HF) and/or evidence of left 
ventricular systolic dysfunction (LVSD) following AMI increases both in-hospital and 
longer-term mortality. A series of structural and functional changes occur within the 
heart in general and within the left ventricle (LV) in particular following AMI, 
initially providing a stabilising mechanism to maintain the cardiac output but over 
time becoming maladaptive and leading to progressive ventricular dilatation, 
dysfunction, HF and premature death. This process is termed remodelling. It is now 
understood that a complex series of mechanical, genetic and neurohormonal factors, 
including the mineralocorticoid hormone aldosterone, are implicated in its 
pathogenesis. Aldosterone antagonism reduces cardiovascular morbidity and mortality 
in patients with advanced chronic HF and survivors of large AMI who develop HF 
and/or are diabetic. These benefits could, at least in part, be due to an anti-remodelling 
action, although this was uncertain at the time I began my research project.  
 
The work contained in this thesis examines cardiac remodelling, and the effects of the 
mineralocorticoid receptor antagonist eplerenone, in a cohort of 100 patients admitted 
with AMI, with depressed LV ejection fraction (LVEF) but without HF or diabetes 
mellitus, using a gold standard modality for LV functional assessment and infarct 
imaging: late gadolinium-enhanced cardiac magnetic resonance (LGE-CMR). Patients 
were treated with (double-blinded) eplerenone or placebo for 24 weeks, and 
underwent serial LGE-CMR scanning and measurement of haematological, urinary 
and genetic markers thought to be of pathophysiological importance in post-infarction 
remodelling.   22 
 
There was, by chance, a significant imbalance in LV function at baseline between the 
randomised groups. After pre-specified covariate-adjustment, however, I found a 
significant effect of eplerenone on LV remodelling. Moreover I found that the use of 
eplerenone in addition to an angiotensin-converting enzyme inhibitor or angiotensin 
receptor blocker was well-tolerated. I also found an effect of eplerenone on two 
matrix metalloproteinases (MMPs) considered key enzymes in extracellular matrix 
turnover. Specifically, eplerenone decreased MMP-2 and attenuated the drop in 
MMP-9 seen in the placebo group, changes that are protective against remodelling. 
These findings suggest a potential anti-remodelling effect of eplerenone in 
‘asymptomatic’ LVSD after AMI, i.e. patients in whom eplerenone is not currently 
indicated.  
 
Patients with limited functional recovery early after AMI resulting in a persistently 
reduced LVEF require stringent monitoring and may qualify for an implantable 
cardioverter defibrillator. The use of predictive biomarkers to identify such patients is 
gaining popularity. I found that two biomarkers, tissue plasminogen activator (tPA) 
antigen and tissue inhibitor of metalloproteinase-4 (TIMP-4), measured in a blood 
sample taken a mean of 3 days after AMI, were independent predictors of adverse 
remodelling. These findings are novel, provide further pathophysiological insights 
into the inter-related biological systems that underlie remodelling, and may inform 
future trials aimed at modulating these pathways in order to attenuate remodelling. 
 
LGE-CMR affords detailed characterisation of myocardium. In keeping with previous 
studies, infarct volume, endocardial extent and transmurality predicted LV   23 
remodelling. In addition I also found that the presence of microcirculatory 
dysfunction, defined as persistent microvascular obstruction (MVO) within the 
infarcted region on baseline LGE-CMR, divided my study population into two distinct 
groups with opposite remodelling outcomes. Patients with late MVO progressively 
remodelled, while those without reverse remodelled over 24 weeks. From these results, 
I propose that late MVO be used as an indicator of adverse ventricular remodelling. 
This may enhance the risk-stratification of survivors of AMI. 
 
Aldosterone has a number of detrimental effects on the cardiovascular system and is 
strongly implicated in the pathogenesis of remodelling. I observed direct correlations 
between aldosterone sampled at baseline and CMR parameters of remodelling. 
Analysis by treatment group revealed an association between change in aldosterone 
over time and parameters of remodelling in placebo- but not eplerenone-treated 
patients, despite higher circulating aldosterone concentrations in the latter group. We 
propose that the cardiac effects of aldosterone display a temporal variation after AMI, 
specifically that circulating aldosterone in the first few days after infarction is key in 
selecting a remodelling pathway but that over the following weeks and months 
circulating aldosterone is less influential in potentiating the remodelling process. I 
also found a novel relationship between aldosterone and infarct volume, which merits 
further investigation as the role of aldosterone in the pathophysiology of remodelling 
is further described.  
 
My trial design afforded the opportunity to examine the relationships of certain novel 
biomarkers with LV function and other established biomarkers after AMI. I 
demonstrated that circulating concentrations of the peptide apelin were reduced over   24 
24 weeks after AMI compared to healthy controls but bore no relationship to LV 
function. Separately, I showed that concentrations of the soluble interleukin-1 
receptor family member ST2 fell significantly over time after AMI and correlated 
with early and medium-term LV function and infarct volume. I detected a novel 
relationship between ST2 and aldosterone, which may suggest a pathophysiological 
role for ST2 in post-infarction remodelling and merits further investigation. 
 
These studies provide further insights into the roles of aldosterone and of selective 
mineralocorticoid receptor antagonism in cardiac remodelling in a relatively under-
studied population: survivors of AMI with ‘asymptomatic’ LVSD. The primary 
results may inform clinical trials powered to detect a mortality benefit in this patient 
group. The data provided on the use of established and recently-discovered 
biomarkers in the prediction of medium-term LV function after AMI represents a 
highly topical area for further studies. Finally, pre-discharge CMR was safe in AMI 
patients, and facilitated the detection of additional findings that positively influenced 
the management of almost one-quarter of the trial cohort. These findings may lead to 
greater uptake of this increasingly-available modality, to enhance the early 
management and risk stratification of survivors of large AMI.  
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Chapter 1 
 
Introduction 
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1.1     Background 
Improvements in the primary prevention of coronary artery disease, predominantly 
through more rigorous diagnosis and aggressive control of cardiac risk factors, have 
led to a decline in premature coronary heart disease (CHD) in most Western countries. 
Despite this, acute myocardial infarction (AMI) remains an important global clinical 
and socio-economic problem. In the United Kingdom, based on incidence rates of 
AMI of 600 per 100 000 in men and 200 per 100 000 in women under the age of 70 
years, an estimated 123 000 persons aged 75 or less will suffer an AMI in 2008; this 
figure would be expected to rise further if elderly patients were included.
1, 2 Data from 
USA estimate that 770 000 Americans will suffer a first AMI, and a further 430 000 
will experience a recurrent AMI, by the end of 2008, during which as many as 175 
000 will suffer a silent AMI.
3 The combined expense of direct treatment of, loss of 
earnings/workforce by, and informal caring for CHD patients is estimated at over £7.9 
billion per year to the UK economy.
1 
 
In Scotland, although the age-standardised mortality rates following AMI have fallen 
between 1994 and 2004 (from 223 to 140 per 100 000), cardiovascular morbidity and 
mortality remain high.
1, 4 Moreover, clinical evidence of heart failure or imaging 
evidence of left ventricular systolic dysfunction (LVSD) following AMI further 
impair the prognosis.
5-10 In a recent international registry incorporating data from 
5573 patients admitted consecutively with AMI to one of 84 centres in 9 countries 
between 1999 and 2001, collected in conjunction with the VALsartan In Acute 
myocardial iNfarcTion (VALIANT) trial, the adjusted hazard ratio for death during 
admission with AMI complicated by heart failure, LVSD or both was 4.12.
10 The   27 
development of heart failure, LVSD or both after AMI is therefore of considerable 
clinical and prognostic relevance. 
 
Review of epidemiologic and clinical trial data suggest that heart failure will 
complicate 30-40% of admissions with AMI.
11 The incidence of LVSD after AMI is 
less well-documented and subject to variability in definitions and modes of 
assessment, but overall LVSD will occur in 25-60% of AMI, while heart failure will 
occur in at least 50% of patients with LVSD.
11 There is strong evidence that heart 
failure 
6, 7, 10, 12-15 and LVSD 
10, 16-18 early after AMI are independently and additively 
detrimental to short- and long-term prognosis. LVSD in the absence of heart failure 
early after AMI (“asymptomatic LVSD”) is also a significantly morbid condition, 
carrying a higher in-hospital mortality than patients displaying signs of heart failure 
post-AMI in the context of preserved LV systolic function.
10  
 
What happens over time to patients with LVSD after AMI? In response to the acute 
deterioration in LV systolic function precipitated by AMI, a series of mechanical, 
neurohormonal and genetic processes are stimulated, the combined result of which is 
the promotion of complex changes in the architecture and function of the LV, in an 
initial compensatory response to maintain cardiac output: this process is post-
infarction LV remodelling.
19, 20 If left unchecked, this early adaptive response will 
result in progressive LV dilatation, geometric alteration and dysfunction, leading 
inexorably towards the development of heart failure, with its associated morbidity and 
mortality. Results of several AMI studies have consistently shown a close relationship 
between LV remodelling and long-term clinical outcomes, which have led to the 
acceptance of LV remodelling as a major predictor of the clinical course of heart   28 
failure.
21 From evidence derived from several studies performed over the last two 
decades, it is now apparent that a single measure of LV volumes and LV ejection 
fraction (LVEF) early after AMI predicts major cardiovascular outcomes, and that 
serial changes in LV volumes and LVEF correlate closely with progression to heart 
failure, cardiogenic shock, recurrent AMI and short- and long-term survival.
22-27 
 
Studies of AMI patients designed to detect a mortality benefit following a specific 
intervention generally require large patient numbers to allow adequate power. The 
strong relationship between LV remodelling and major cardiovascular end-points, 
however, raises the possibility that the results of a relatively small study of 
remodelling can be used to inform larger clinical trials powered to assess the effects 
of that intervention on hard clinical end-points.  
 
The pathophysiology of post-infarction LV remodelling is being increasingly 
described, and provides multiple insights into the natural history of myocardial 
infarction in addition to providing several targets for strategies to ameliorate LV 
function, cardiovascular morbidity and survival. This thesis will focus on post-
infarction LV remodelling in a cohort of patients with ‘asymptomatic’ LVSD early 
after AMI.     
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1.2  Cardiac remodelling: 
Cardiac remodelling has been defined by the International Forum on Cardiac 
Remodelling as the alterations in genome expression, molecules, cells and interstitium 
that are manifested clinically as changes in the size, shape and function of the heart 
after cardiac injury.
21 Physiological remodelling occurs in normal growth from 
infancy to adulthood, and in pregnancy, in which the remodelling is not only an 
appropriate physiological response to the increased circulating blood volume, but is 
also reversible. Pathophysiological remodelling can occur in a variety of 
environments, including pressure overload (eg. hypertension, aortic stenosis, 
hypertrophic obstructive cardiomyopathy), volume overload (eg. valvular 
regurgitation), myopericarditis, idiopathic dilated cardiomyopathy and AMI. In many 
of these conditions, remodelling is an adaptive phenomenon which allows 
maintenance of an adequate cardiac output despite abnormal loading conditions, but 
in post-infarction remodelling the early adaptive response is rapidly superseded by a 
chronic maladaptive process. Post-infarction remodelling of the LV is the most 
extensively studied of these processes, and is the focus of this thesis. 
 
1.2.1  Post-infarction remodelling 
Acute occlusion of a coronary artery, especially in the absence of a collateral 
circulation, results in an abrupt cessation of systolic contraction within the region of 
myocardium subtended by the infarct-related artery.
28 This is caused by a combination 
of acute myocyte loss and stunned myocardium, ie. viable myocytes which retain the 
potential to recover contractility but which are rendered severely hypo- or non-
contractile due to the acute deterioration in their pericellular environment.
29 Within 
one hour of coronary occlusion, geometric changes occur due to the abrupt increase in   30 
loading conditions – the infarct zone stretches and the LV begins to dilate.
30 This 
response is in part adaptive – stretching of myocytes in the non-ischaemic regions of 
the LV allows partial compensation for the acute reduction in stroke volume and 
LVEF caused by the infarct via the Frank-Starling mechanism.
24, 31, 32 Ongoing 
myocyte loss and chronic increases in ventricular wall stress, however, lead to 
progressive LV dilatation and dysfunction.
19 
 
Studies examining the timecourse of LV geometric changes following AMI have led 
to an arbitrary division of post-infarction remodelling into early (<72 hours after 
coronary occlusion) and late (≥72 hours) phases.
30, 33, 34 Although there is some 
overlap, the major geometric alterations that occur in early remodelling are largely 
confined to the infarct zone and consist of stretching, infarct expansion and thinning, 
while late remodelling involves stretching of the entire LV myocardium, including the 
peri-infarct zone and remote, non-ischaemic myocardium, with subsequent 
hypertrophy, distortion of ventricular shape, and deterioration in systolic function. 
 
While acute thrombotic occlusion of the infarct-related artery is the index event, what 
actually stimulates the remodelling process? As a direct consequence of acute regional 
myocardial dysfunction, two functionally disparate triggers have been identified – 
mechanical and neurohormonal.  
 
1.2.2  Mechanical triggers 
Regional wall stress has been shown consistently to be a major precipitant of post-
infarction LV remodelling.
19, 24, 31, 32, 35 As described above, the initial changes in LV 
morphology are in part compensatory as they improve cardiac output in the acute   31 
stages of infarction, but as the LV dilates, further demands are made on the surviving 
non-ischaemic myocardium due to increased wall stress. The law of La Place states 
that wall stress is directly proportional to the product of intracavitary pressure and 
radius, and inversely proportional to wall thickness.
36 As the cavity dilates, wall stress 
therefore increases to maintain intracavitary pressure, and hypertrophy of the non-
infarcted myocardium occurs. 
 
Intact myocardium consists of three major components: myocytes, extracellular 
matrix (ECM) and the capillary microcirculation derived from the coronary arteries. 
The ECM is an essential structural component of healthy myocardium, and is 
composed of predominantly type I collagen, with lesser amounts of type III 
collagen.
37 The ECM acts as a stress-tolerant scaffold which maintains the structural 
relationship between myocytes, contractile filaments and capillaries. Excessive wall 
stress, which develops very early after coronary occlusion, can directly and indirectly 
influence the ECM. Direct stretch as the LV enlarges can cause lengthening and 
weakening of collagen fibres; indirectly, stretch of surface mechanotransducers 
known as integrins can result in intracellular signalling triggering the release of 
growth factors and cytokines which, in turn, activate a family of enzymes responsible 
for the natural turnover of the ECM – the matrix metalloproteinases (MMPs); these 
will be described separately.
38  
 
Various components of the LV remodelling process are therefore stimulated 
mechanically as a consequence of increased wall stress following AMI. There is, 
however, an overlap between the mechanical and neurohormonal stimulation of 
remodelling. Mechanical stretch of myocytes in vitro provoked accumulation of   32 
angiotensin II, a key neurohormonal influence on remodelling, within 30 minutes 
suggesting that in the dilating heart such stretch might provide a separate means of 
angiotensin II activation outwith the renin-angiotensin-aldosterone system (RAAS).
39 
 
1.2.3  Neurohormonal triggers 
Plasma levels of several neurohormones rise rapidly early after AMI. The acute 
reduction in haemodynamic stability caused by regional infarction stimulates the 
sympathetic nervous system. Plasma noradrenaline (NA) levels rise acutely in an 
initial compensatory response to maintain a perfusing cardiac output.
40 Continued 
sympathetic overactivity leads, however, to further increased wall stress; NA excess 
also stimulates release of inflammatory cytokines, atrial natriuretic peptide (ANP) and 
brain natriuretic peptide (BNP).
40-42 Hypoperfusion of renal glomeruli promotes 
feedback renin release and activation of the RAAS; excess NA contributes by 
stimulating β1-receptors on cells of the juxtaglomerular apparatus (JGA), promoting 
further renin secretion.
43 Plasma angiotensin II and aldosterone levels rise, both of 
which have specific roles in remodelling. The major neurohormonal triggers of LV 
remodelling in the early post-infarction period are therefore the sympathetic nervous 
system and the RAAS. The respective roles of NA, the hormones of the RAAS, 
natriuretic peptides and cytokines in post-infarction remodelling will be discussed 
separately. 
 
1.2.4  Changes within myocytes during LV remodelling 
Myocyte loss occurs not only at the time of the acute myocardial injury, but continues 
thereafter as an ongoing feature of the remodelling process. For many years, necrosis 
was thought to be the sole method of myocyte death following AMI, but evidence   33 
from a series of animal models has led to new insights into the changes that occur in 
myocytes after coronary occlusion.
44 
 
The classical necrosis model of acutely ischaemic myocytes undergoing cell 
membrane lysis, influx of extracellular fluid, swelling, activation of proteolytic 
enzymes, and leakage of intracellular contents has been modified by the combined 
apoptosis-necrosis model.
45, 46 Within the peri-infarct zone and within non-ischaemic 
myocardium remote from the infarct, there is evidence of apoptosis acutely (within 
hours) and continuing into the late remodelling phase.
47, 48 Apoptosis is an energy-
requiring process triggered by the activation of a family of cysteine proteases known 
as caspases; leakage of myocyte contents, especially cytochrome C, is thought to 
stimulate these caspases which then promote apoptosis.
46, 49 The relative contributions 
of apoptosis and necrosis to myocyte loss are probably species-specific; interesting 
data from the rat infarction model suggest that apoptosis is the predominant mode of 
myocyte death within the first 2-4 hours following AMI, with necrosis predominating 
from 6-24 hours.
50, 51 
 
Myocyte death is an ongoing process, but non-ischaemic myocytes also undergo 
structural changes. Myocardial stretch has been shown to promote angiotensin II 
accumulation within myocytes, but also to induce expression of various hypertrophy-
associated genes, including c-fos, c-jun, c-myc and Erg-1, in addition to a number of 
growth factors including transforming growth factor β1 (TGF-β1), insulin-like growth 
factor-1 and endothelin-1 (ET-1).
39, 52, 53 Myocytes are terminally differentiated cells 
and as such have limited if any potential for further division. Their response to these 
trophic stimuli is therefore to undergo hypertrophy, which contributes to the   34 
progressive structural changes within the LV and maintains wall stress, further 
exacerbating the remodelling process. 
 
Changes within myocytes at a molecular level are beyond the scope of this thesis. 
 
1.2.5  Consequences of remodelling on global LV function 
Following AMI the combination of mechanical stimulation and neurohormonal 
activation promotes morphologic changes within the LV in an initial attempt to 
stabilise cardiac output. Ongoing myocyte loss, hypertrophy of existing myocytes and 
persistently elevated wall stress continue to drive remodelling, leading to progressive 
LV impairment, heart failure and death. Replacement fibrosis within the infarct zone 
occurs early in the remodelling process, and is an appropriate healing response, but 
fibrosis is also seen in myocardium remote from the infarct, where it is termed 
reactive fibrosis.
54-58 Such reactive fibrosis is detrimental to cardiac function and 
contributes to progressive diastolic and systolic dysfunction. Aldosterone has been 
strongly implicated in its pathogenesis and will be described separately.
59 
 
Post-infarction remodelling is therefore a complex process, the end result of which is 
a progressive deterioration in LV function. The RAAS in general and aldosterone in 
particular have been the subject of several recent studies on LV remodelling, and will 
provide the focus for this thesis. 
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1.3  The RAAS and the role of aldosterone in LV remodelling: 
 
1.3.1  The classical RAAS 
The classical description of the RAAS depicted a cascade of neurohormonal 
activation that occurred mainly within the bloodstream, but which was dependent on 
important tissue-based factors.
60 In this model, the precursor α2-globulin 
angiotensinogen, synthesised and stored in the liver, is released into the bloodstream 
where it is converted by kidney-derived plasma renin activity to form angiotensin I, 
an inactive decapeptide (Figure 1.1). 
 
 
Figure 1.1  The classical renin-angiotensin-aldosterone system, illustrating the pathologic 
effects of angiotensin II. 
 
   36 
Angiotensin-converting enzyme (ACE), a dipeptidyl-carboxypeptidase, then cleaves 
off an octapeptide histidyl-leucine from the inactive angiotensin I, producing 
angiotensin II. ACE also inactivates bradykinin. ACE is endothelial-based and found 
in greatest quantities in the lungs although it is found in endothelium elsewhere. 
Angiotensin II is a biologically active molecule with a wide range of actions (Figure 
1.1). In addition it stimulates aldosterone synthesis within the zona glomerulosa of the 
adrenal cortex. A counter-regulatory response to RAAS activation is mediated by 
ACE2, the newly-described homologue of ACE, which hydrolyses angiotensin I to 
angiotensin-(1-9) and angiotensin II to angiotensin-(1-7).
61 ACE2 appears to have a 
protective role: ACE2 knockout mice undergo progressive ventricular dilatation and 
dysfunction, while ACE2 expression is up-regulated in macrophages, smooth muscle 
cells, cardiomyocytes and endothelial cells within the heart in the setting of AMI, and 
in chronic heart failure (CHF).
62, 63 
 
For many years this classical pathway was accepted as the sole means of angiotensin 
II and subsequently aldosterone production. Observations that drugs that block the 
RAAS continued to exert beneficial effects on LV function, progression to heart 
failure and death even after the initial increases in circulating RAAS components 
following large AMI had returned to baseline, independent of blood pressure-lowering 
effects, led to theories of non-circulatory RAAS.
40, 64-68 Several body tissues, 
including the heart, contain or synthesise various components of the RAAS in a 
variety of animal models, suggesting a role for tissue-based RAAS.
69-72 Growing 
evidence suggests that cardiac RAAS not only exists but is regulated independently of 
circulatory RAAS: tissue-based RAAS responds experimentally to myocardial stretch 
and growth factors rather than the systemic factors related to changes in blood   37 
pressure and circulating volaemia which regulate circulatory RAAS.
73-76 Moreover, 
non-ACE dependent pathways of angiotensin I conversion to angiotensin II have been 
identified, the best described of which involves the enzyme chymase, which is 
released from cardiac and vascular mast cells, mesenchymal and endothelial cells.
77 
That a combination of an ACE inhibitor and a chymase inhibitor was necessary to 
inhibit the vasoconstrictor response to angiotensin I infusions in patients with CHF 
confirms a dual pathway of angiotensin II synthesis.
77, 78 
 
The RAAS is therefore more complex than the classical theory suggests. Two of its 
effector hormones merit particular attention as they have been shown to be of critical 
importance in the pathogenesis of post-infarction remodelling: angiotensin II and 
aldosterone. 
 
1.3.2  Angiotensin II 
Following large AMI, the combination of increased renin release in response to renal 
hypoperfusion, sympathetic activation of β1-receptors on JGA cells, mechanical 
stretching of myocytes, and non-ACE dependent synthesis results in increased local 
and circulating angiotensin II. The effects of angiotensin II serve to potentiate and 
exacerbate post-infarction remodelling. Angiotensin II is a potent vasoconstrictor and 
promotes salt and water retention, both directly and through aldosterone release, 
further increasing LV wall stress and promoting hypertrophy. It has direct toxic 
effects on myocytes in addition to stimulating apoptosis, further increasing the 
demands on the remaining viable myocytes.
79 Cardiac fibroblasts have a high density 
of angiotensin II type 1 (AT1) receptors.
80 Activation of these AT1 receptors 
stimulates the release of not only enzymes that lyse and degrade collagen but also   38 
cytokines, including tumour necrosis factor-α (TNFα) and interleukin (IL)-1β, which 
feed back to up-regulate fibroblastic expression of the AT1 receptor making the cells 
more sensitive to angiotensin II.
81 In this way, angiotensin II promotes progressive 
disordering of the ECM, myocyte loss and ongoing pressure and volume loading of 
the infarcted heart. 
 
Angiotensin II was not measured in the study on which this thesis is based. 
Aldosterone, the release of which is influenced by angiotensin II levels, provides the 
focus of this research and is described in detail in the following section. 
 
1.3.3  Aldosterone 
Biosynthesis: 
Aldosterone is a mineralocorticoid hormone synthesised in the zona glomerulosa of 
the adrenal cortex. Its main endocrine function is sodium and potassium homeostasis, 
which it achieves through reabsorption of sodium and excretion of potassium through 
the distal tubules and collecting ducts of the nephron.
82, 83 The biosynthetic pathway 
requires the sequential activity of several enzymes; deoxycorticosterone is ultimately 
converted to aldosterone by a sequence of hydroxylation reactions, all of which are 
catalysed by aldosterone synthase (Figure 1.2). 
 
Release of aldosterone from the adrenal cortex is stimulated mainly by increased 
potassium and angiotensin II levels, and to a lesser extent by sodium deficiency, 
adrenocorticotrophic hormone (ACTH), catecholamines and serotonin.
83 
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Figure 1.2  Adrenal cortical biosynthesis and degradation of aldosterone and cortisol. Urinary steroid 
metabolites are shown in purple. THDOC = tetrahydrodeoxycorticosterone, THAldo = 
tetrahydroaldosterone, THS = tetrahydrodeoxycortisol. 
 
 
Cardiovascular effects of aldosterone: 
Excess circulating aldosterone has numerous adverse effects on the cardiovascular 
system, including promotion of myocardial interstitial and perivascular fibrosis, 
stimulation of myocyte apoptosis, mediation of baroreceptor dysfunction, prevention   40 
of myocardial neuronal re-uptake of norepinephrine, increase in sympathetic drive, 
and potentiation of fluid overload and electrolyte imbalance.
84-89 Many of these 
deleterious effects on the cardiovascular system in general are pertinent to post-
infarction pathophysiology and remodelling. 
 
Aldosterone production following AMI: 
The increase in circulating angiotensin II in the early aftermath of AMI described 
above promotes aldosterone release from the adrenal cortex. Local intracardiac 
production of aldosterone has also been demonstrated in the rat heart, and has been 
confirmed in the failing human heart and in hypertensive patients without LVSD, 
although it is noteworthy that doubt has been cast on the pathophysiological 
significance of cardiac steroid production by separate research groups.
90-94 
Intracardiac aldosterone synthesis is triggered shortly after AMI in the rat heart, 
allowing local intracardiac aldosterone concentrations far in excess of systemic 
levels.
92 Additionally, plasma aldosterone extraction across the acutely infarcted 
human heart has recently been demonstrated, and the transcardiac aldosterone 
gradient correlates with left ventricular volumes and plasma levels of PIIINP, a 
marker of matrix collagen turnover, suggesting that aldosterone extraction stimulates 
remodelling in patients with AMI.
94 Through a variety of mechanisms, therefore, 
circulating and local aldosterone levels increase significantly early after AMI. 
Aldosterone is therefore in a prime position to influence remodelling. Elevated 
aldosterone levels correlate directly with mortality in CHF.
95 
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Effects of aldosterone following AMI: 
Aldosterone exerts its tissue effects via the mineralocorticoid receptor. These 
receptors have been identified in the kidney, colon, brain, lung and heart.
96 Within the 
heart, mineralocorticoid receptors are present on myocytes, fibroblasts and the 
endothelial cells of large vessels.
97, 98 The high aldosterone state that develops acutely 
after AMI exerts a wide range of actions through these target organs which contribute 
to and exacerbate LV remodelling. The mineralocorticoid receptor, however, has a 
similar affinity for aldosterone and cortisol; for aldosterone to interact with the 
mineralocorticoid receptor, the receptor has to be ‘protected’ by the cellular enzyme 
11-β hydroxysteroid dehydrogenase.
99 This enzyme is expressed in a variety of organs 
including the kidney, but the burden of evidence suggests that it is not expressed in 
the heart, thus potentially exposing the intracardiac mineralocorticoid receptors to the 
effects of circulating cortisol.
100  
 
The most dramatic and best-documented effect of aldosterone in the heart is the 
development of significant fibrosis.
84, 101, 102 Myocardial fibrosis is experimentally 
induced in the rat by aldosterone in salt-loaded conditions; this effect is attenuated by 
concomitant administration of the selective mineralocorticoid receptor antagonist 
(MRA) eplerenone.
86 Interestingly these profibrotic effects of hyperaldosteronism 
only appear to occur in the presence of a high salt environment.
103 The exact 
mechanisms by which aldosterone and sodium combine to promote fibrosis are 
unclear, but the resultant effect appears to be stimulation of mineralocorticoid 
receptors on cardiac fibroblasts, promoting pathological ECM turnover. Post-
infarction fibrosis was traditionally considered to develop as a reparative phenomenon 
to strengthen the infarcted segment, but it is now clear that in addition to replacement   42 
fibrosis at the site of the scar, reactive fibrosis occurs elsewhere, in myocardium 
remote from the infarct zone.
37, 104, 105 Such widespread fibrosis contributes to 
progressive diastolic dysfunction, systolic dysfunction, geometric alteration and 
arrhythmic potential. The causative relationship between aldosterone and fibrosis has 
been confirmed by several animal and human studies in which aldosterone 
antagonism has led to attenuation or even reversal of fibrosis, with concomitant 
improvement in LV function. 
106, 107 
 
Through mineralocorticoid receptor activation in the kidney, vasculature and 
endothelium, excess aldosterone following AMI also leads to sodium/water retention 
(aggravating the loading conditions on the infarcted LV), potassium loss (increasing 
risk of arrhythmia), perivascular fibrosis and endothelial dysfunction, all of which are 
deleterious in this crucial post-infarction phase.
86   
 
1.4      ‘Upstream’ inhibition of the RAAS – the roles of ACE inhibitors and  
   ARBs 
Neurohormonal modulation of the RAAS has become a key component in the 
management of patients with left ventricular systolic dysfunction LVSD, in the 
context of both CHF and AMI. Following early work confirming an anti-remodelling 
effect of the ACE inhibitor captopril in a rat AMI model, ACE inhibitors have been 
shown in landmark trials to improve survival and, when assessed, to attenuate 
remodelling in both AMI and CHF patients.
23, 66, 68, 108-113 ACE inhibitors are now the 
cornerstone of medical therapy for these conditions. Fewer clinical data are available 
on the effects of AT1-receptor blockers (ARBs) on remodelling. Limited data from 
CHF populations suggest a beneficial effect of ARBs on remodelling, while a   43 
comparable effect to that of captopril on post-infarction remodelling has recently been 
demonstrated using the ARB valsartan.
113-117  
 
‘Aldosterone escape’ and the effects of aldosterone blockade: 
Upstream inhibition of the RAAS with ACE inhibitors or ARBs leads to early 
reductions in plasma aldosterone, but over time aldosterone levels start to increase. 
This phenomenon is known as aldosterone escape.
118 It is thought to result from 
aldosterone secretion consequent to the hyperkalaemic effects of ACE 
inhibitors/ARBs together with non-ACE dependent angiotensin II/aldosterone 
synthesis; it is seen in up to 40% of CHF patients, can occur despite combined ACE 
inhibitor and ARB use, and has been documented as early as 3 days after 
commencement of an ACE inhibitor following AMI.
115, 118, 119 As aldosterone exerts a 
multitude of deleterious effects in the post-infarction phase, mineralocorticoid 
receptor antagonism represents an attractive adjunct to ACE and/or AT1-receptor 
inhibition. 
 
It is perhaps unsurprising that clinical trials of mineralocorticoid receptor antagonists 
have shown beneficial effects on cardiovascular outcomes in patients with 
hypertension, CHF and AMI. For example, the use of eplerenone in hypertensive 
patients enrolled into the 4E-LVH Study resulted in comparable reductions in blood 
pressure and LV mass to those seen with an ACE inhibitor.
120 In the Randomised 
Aldactone Evaluation Study (RALES), the addition of the aldosterone receptor 
antagonist spironolactone significantly reduced cardiovascular morbidity and 
mortality in patients with advanced CHF, most of whom were on an ACE inhibitor.
121 
In a sub-study of RALES, spironolactone evoked a reduction in PIIINP compared to   44 
placebo, suggesting an anti-remodelling effect.
122 More recently eplerenone has been 
shown to provide significant benefit on major cardiovascular outcomes in AMI 
patients with reduced LVEF and heart failure, or diabetes, again with a high baseline 
uptake of ACE inhibitors or ARBs in the eplerenone post-acute myocardial infarction 
heart failure efficacy and survival study (EPHESUS); no imaging sub-study has been 
reported.
123 
 
The striking morbidity and mortality benefits reported in RALES and EPHESUS have 
led to the inclusion of aldosterone antagonists in European and American guidelines 
for the management of CHF and AMI.
124-128 That mineralocorticoid receptor 
antagonists should exert an anti-remodelling effect in both of these conditions would 
appear logical in view of the strong pro-fibrotic effects of aldosterone. Experimental 
models have confirmed an antifibrotic effect of aldosterone blockade on reactive but 
not reparative fibrosis, alleviating fears over the safety of aldosterone antagonism 
following AMI.
106 Despite these data, the evidence for a positive effect of aldosterone 
blockers on LV remodelling from clinical trials is surprisingly weak. Neither RALES 
nor EPHESUS, the landmark aldosterone antagonist trials in CHF and AMI 
respectively, included an imaging sub-study. Evidence from small clinical trials 
suggests a beneficial effect of aldosterone blockade on LV remodelling: early (day 1) 
administration of spironolactone to a cohort of 65 patients with reperfused first 
anterior AMI, treated with ACE inhibitor, led to reductions in LV volumes, 
improvements in LVEF (measured by invasive contrast ventriculography) and 
attenuation of PIIINP rise compared to placebo, and more recently reversal of LV 
remodelling was observed in a small cardiac magnetic resonance (CMR) study (n=51) 
of patients with mild/moderate CHF and LVEF<40% with the combination of the   45 
ARB candesartan/spironolactone versus candesartan/placebo.
94, 129 Two larger recent 
CHF trials focusing on serial change in LV function have, however, failed to 
demonstrate a positive effect on LV remodelling with aldosterone blockade on top of 
baseline ACE inhibitor/ARB therapy in mild/moderate CHF patients.
130, 131 While 
theoretically attractive as a method of attenuating pathological remodelling, the role 
of aldosterone blockade is therefore not yet clear. 
 
1.5  Aldosterone synthase polymorphisms 
The final step in the biosynthetic pathway of aldosterone in the zona glomerulosa of 
the adrenal cortex is catalysed by the enzyme aldosterone synthase (Figure 1.2). 
Aldosterone synthase is a mixed-function oxidase of the cytochrome P450 family of 
haem-containing enzymes, and is encoded by CYP11B2, a 9-exon gene located in 
humans on chromosome 8q22.
132 Two common mutations in CYP11B2 have been 
identified: a single nucleotide polymorphism (SNP) involving substitution from C to 
T at position -344, and a mutation in the sequence of intron 2 of the gene, allowing 
three haplotypes to be described.
133 The -344T/C polymorphism is of particular 
interest as it lies within the binding site for a transcription factor essential in steroid 
biosynthesis: steroidogenic factor-1 (SF-1).
134 The excretion of aldosterone is 
influenced by these mutations, but with significant inter-species and inter-racial 
variability. In Caucasian populations the -344T allele has been associated with higher 
excretion rates of aldosterone, while in African American populations the -344C allele 
has not only been linked to higher aldosterone release but also to adverse prognosis in 
CHF and a tendency towards adverse ventricular remodelling.
134, 135 Polymorphic 
variations in CYP11B2 are associated with variations in LV size and mass in healthy 
populations free of cardiovascular disease, and have been shown to predict   46 
improvement in LVEF in CHF patients being commenced on medical therapy 
inclusive of ACE inhibitors.
136, 137  
 
Such variations in the synthesis, release and excretion of aldosterone, a key hormone 
in LV remodelling, understandably engendered interest in the influence of SNPs in 
CYP11B2 on post-infarction remodelling. Results from two recent studies have been 
disappointing, however. A German population-based study revealed no difference in 
allele frequency between patients who had sustained AMI 5 years previously and the 
general population; moreover, within the post-MI cohort there was no association 
between either allele and severity of LVSD, LV mass nor diastolic function.
138 In a 
separate study analysing the influence of common genetic mutations on the early 
remodelling process in 266 French patients with incident anterior AMI, no association 
between any mutation, including -344T/C, and LV remodelling out to 1 year after 
AMI was found.
139 It is noteworthy, however, that TTE was the imaging modality 
employed and that the definition of LV remodelling used was change in (∆) LV end-
diastolic volume (LVEDV) over time. LV end-systolic volume (LVESV) and the 
change therein has consistently been demonstrated to be a more powerful predictor of 
survival, and the most appropriate means of assessing LV remodelling, following 
AMI.
22 
 
Aldosterone therefore plays an important role in post-infarction LV remodelling, but 
key questions persist regarding the additional benefits of aldosterone blockade on LV 
remodelling in the context of upstream pharmacological inhibition of the RAAS, and 
the influence of CYP11B2 and its common mutations in the remodelling process; both 
of these issues were analysed in this thesis through assessing the effects of the   47 
selective MRA eplerenone on LV remodelling in a cohort of patients with LVSD 
early after AMI but without clinical or radiological evidence of heart failure.. 
 
1.6  The role of revascularisation in post-infarction LV remodelling 
Acute coronary occlusion is the index event that triggers the various mechanical, 
neurohormonal and genetic factors that drive the remodelling process. Patency of the 
infarct-related artery (IRA) is therefore an attractive and obvious target in the 
limitation of myocardial damage and prevention of remodelling. The critical 
importance of a patent IRA (the “open artery hypothesis”) has been demonstrated in 
various observational and clinical studies over the last two decades. Patients with an 
open IRA, or else an occluded IRA with adequate collateral blood supply, 30 days 
after index (non-reperfused) AMI sustained significantly less LV dilatation that 
patients with an occluded IRA and no collateral supply.
140 Comparison of patients 
treated with or without early thrombolytic revealed early improvements in LV 
function that were attributable to thrombolytic therapy, but ongoing attenuation of LV 
remodelling up to 6 weeks that was attributable to patency of the IRA.
141 Studies of 
both early and late (up to two weeks after AMI) percutaneous reperfusion have 
confirmed beneficial effects on medium- and long-term LV remodelling in those with 
a persistently patent IRA.
26, 142, 143 
 
The importance of microcirculatory dysfunction following reperfusion therapy has 
been increasingly appreciated in recent years. The role of such microvascular 
obstruction in LV remodelling is discussed separately (Chapter 1.11.4). 
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1.7  The role of neurohormonal activation in post-infarction LV remodelling 
 
1.7.1  Natriuretic peptides 
A number of natriuretic peptides are released in high quantities early after AMI.
40 
Two of these in particular have attracted considerable interest due to their potential in 
assessing prognosis and monitoring disease progression – BNP and N-terminal pro-
BNP (NTproBNP). BNP is a 32 amino acid neurohormone synthesised in ventricular 
myocardium and released in response to ventricular myocardial stretch and pressure 
overload.
144 As BNP is released, a 76 amino acid residue – the N-terminal fragment – 
is also released: NTproBNP. BNP is elevated in symptomatic and asymptomatic 
LVSD and predicts mortality across all grades of severity of CHF.
145-147  NTproBNP 
also predicts mortality in CHF.
148 
 
BNP and NTproBNP have been extensively studied in the setting of AMI. BNP is a 
powerful predictor of the development of heart failure, recurrent AMI and death in 
both ST-elevation and non-ST-elevation acute coronary syndromes.
149-151 NTproBNP 
not only predicts major adverse cardiovascular outcomes after AMI but has been 
shown to be an even stronger predictor of survival than LVEF.
151, 152 
 
The relationship between these natriuretic peptides and parameters of LV function 
after AMI is less consistent. Data from studies employing a variety of imaging 
modalities reveal associations between BNP and certain LV measurements but not 
others. In a radionuclear study, BNP correlated with size of perfusion defect but 
neither LV volumes nor LVEF.
153 Similarly, BNP showed a close relationship with 
CMR-measured infarct scar, and also with LVEF, in a stable post-AMI cohort but no   49 
consistent relationship with LV volumes.
154 Despite relatively weak correlations 
between BNP, LVEF and certain LV volumetric measurements in various studies 
there is a lack of a consistent relationship between BNP and LV parameters in the 
acute and chronic stages of myocardial infarction.
155, 156 NTproBNP is also subject to 
these inconsistencies. Despite its prognostic benefit in AMI there is no consistent 
agreement between NTproBNP levels and LV parameters after AMI; indeed, when 
NTproBNP was measured in three groups of patients with CHD – stable angina, 
unstable angina and AMI – the weakest correlation between LVEF and NTproBNP 
was seen in the AMI group.
157, 158 
 
These natriuretic peptides are of undoubted prognostic benefit in AMI. Their 
relationship with LV volumes and function after AMI is less clear; I analysed further 
this relationship in the cohort of patients studied in this thesis, in order to determine 
whether eplerenone affects BNP and/or NTproBNP after AMI. 
 
1.7.2  Noradrenaline 
NA is a catecholamine synthesised in the adrenal medulla from dopamine, under the 
influence of dopamine β-hydroxylase. It has a combined role of hormone and 
neurotransmitter and is an important effector molecule of the sympathetic nervous 
system. NA may also have an important role in LV remodelling. Direct toxic effects 
on myocytes in response to NA have been demonstrated in vitro, including β-receptor 
induced promotion of apoptosis and α-receptor induced myocyte hypertrophy.
159-161 
Prolonged infusion of the β-agonist isoproterenol caused a dose-dependent increase in 
LV volumes and reduced survival in healthy rats.
162 The sympathetic nervous system 
is activated rapidly in response to acute infarction and NA levels have been shown to   50 
remain elevated up to 90 days after AMI.
40 Not only can NA exert these toxic effects 
on surviving myocytes, it also influences other pathophysiological processes integral 
to remodelling. RAAS activation is potentiated through β1-receptor activation on JGA 
cells, excess circulating NA promotes release of ANP, BNP and inflammatory 
cytokines, and through its chronotropic and inotropic actions, NA serves to increase 
loading conditions on the infarcted LV. 
 
NA may have a role in monitoring progression of post-infarction remodelling. I 
therefore planned to characterise the influence of NA on change in LV function after 
AMI, and to assess the effects of eplerenone on this marker of sympathetic activation. 
 
1.7.3  Arginine vasopressin 
Arginine vasopressin (AVP) is a peptide hormone synthesised in the hypothalamus 
and released from the posterior pituitary. Its primary effect is to increase renal 
reabsorption of water. Marked increases in AVP have been documented within 6 
hours of infarction, which then decline irrespective of progression to heart failure.
163-
165 ACE inhibitors have no effect on AVP levels after AMI, while a specific AVP 
antagonist in an ovine AMI model failed to influence LV function or cardiac 
biomarker rise.
166, 167  
 
The role of AVP following AMI is unclear. I planned to characterise its relationship, 
if any, to change in LV function after AMI and to assess whether eplerenone has any 
effect on serial AVP measurement. 
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1.7.4  Apelin 
Apelin is an endogenous ligand for the G-protein coupled APJ receptor which was 
isolated only 10 years ago.
168 It has been shown to have potent inotropic effects in 
both normal and failing rat hearts in addition to a diuretic effect (mediated via 
suppression of AVP activity and release) and, peculiarly, a nitric oxide-dependent 
vasodilating effect.
168-170 These properties suggest a potential role for apelin in 
cardiovascular homeostasis. Results of two studies in CHF populations have been 
conflicting, showing either consistently lower or higher apelin levels than age-
matched controls.
171, 172 The natural history of apelin in the AMI setting had not yet 
been described; this was characterised this for the first time in the work in this thesis. 
 
1.8  The role of matrix metalloproteinases (MMPs) in post-infarction LV  
  remodelling 
That changes within the structure of the ECM are integral to LV remodelling has 
inevitably led to interest in the endogenous regulation of ECM components. This 
function is performed in animal and human myocardium by the MMPs, a family of 
zinc-dependent proteases essential for the physiological turnover of the ECM in not 
only myocardium but also bone growth, reproduction and wound healing. MMPs are 
synthesised as proenzymes that bind to ECM components but remain inactive; zinc-
dependent cleavage activates the MMP and promotes collagen degradation.
173, 174 
 
Each cell type found within the normal myocardium can, under physiological or 
pathological conditions, synthesise and release MMPs; cardiac fibroblasts have 
attracted the greatest attention.
175 MMPs are sub-classified according to substrate 
specificity and/or structure.     52 
 
Of particular interest in AMI, and therefore extensively studied in animal models and 
humans, are the gelatinases – MMP-2 (gelatinase A) and MMP-9 (gelatinase B). 
Results from various genetic animal models have provided strong insights into the 
relative contributions of the MMPs to LV remodelling. MMP-2-null mice experience 
less early LV rupture and less significant late LV remodelling than control wild-type 
mice after experimental infarction.
176 Similar findings of reduced early rupture and 
attenuated late remodelling have been demonstrated in MMP-9-null mice following 
AMI.
177, 178 In mice, gelatinase activity appears to relate to both early myocardial 
destabilisation and later ventricular remodelling. 
 
A number of studies examining the roles of the MMPs and their endogenous 
inhibitors - the tissue inhibitors of matrix metalloproteinase (TIMPs) – have been 
undertaken in humans. From these it is increasingly apparent that there are inter-
species differences and significant temporal variations in the activation and function 
of both MMPs and TIMPs. In the first few days following AMI in humans, MMP-2 
levels are consistently elevated and have been shown to correlate inversely with 
NTproBNP.
179, 180 The relationship between MMP-2 and LV function is variable in 
humans: a strong inverse correlation between MMP-2 levels and LV volumes in the 
first few days after AMI has been reported, but several studies have shown no 
relationship either in the immediate post-infarction or follow-up between MMP-2 and 
LV parameters.
179-181 The role of MMP-2, seemingly integral to LV remodelling in 
the mouse model, is as yet unclear in human post-infarction LV remodelling. 
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In contrast to MMP-2, evidence from human studies suggests a more significant role 
for MMP-9. The release of MMP-9 after AMI appears to be biphasic, peaking within 
the first 12 hours then falling to a plateau which remains higher than age-matched 
controls, and which persists for at least three months.
179, 181 In the early phase, peak 
MMP-9 is inversely related to baseline LVEF and strongly correlated to the change in 
LV end-diastolic volume between baseline and 3 months after AMI. Peak MMP-9 
also predicts the development of heart failure over the 2 years following the index 
infarct.
182 The relationship between MMP-9 level and LVEF is lost in the plateau 
phase, and interestingly at three months follow-up, the plateau MMP-9 level is greater 
in patients with less severe LVSD.
181 MMP-9 may therefore have a dual role in 
separate temporal periods following AMI in humans: an early collagen-lysing, pro-
remodelling action but perhaps a protective role in the first few months after the acute 
infarct period, limiting progressive LV impairment. Consistent with this theory, early 
MMP-9 correlates with baseline NTproBNP but this correlation is lost over time.
157 In 
a separate small study (n=52) in which LV function was assessed by CMR at least 4 
years after AMI, an inverse correlation was again seen between MMP-9 and LVEF 
(but not LV volumes).
157 Whether MMP-9 exacerbates progressive LV dysfunction, 
or whether this relationship to LVEF distant from the infarct represents an appropriate 
adaptive response, remains unclear. That MMP-9 exerts time-dependent actions in the 
remodelling process is, however, evident from these data. 
 
Interest has focused on the role of TIMPs in remodelling, particularly in the early 
stages of AMI when MMP activity is at its highest, in terms of the mechanism of 
remodelling and (potentially) therapeutic potential. Four TIMPs have been identified 
to date. TIMP-1 levels are increased are increased in patients presenting with acute   54 
coronary syndromes and remain high for at least 6 months thereafter.
180, 181 One study 
showed a correlation between TIMP-1 and NTproBNP at one week and one month 
after AMI but the significance of this is unclear. TIMP-1 deficiency does, however, 
amplify LV dilation after AMI in the mouse.
183 TIMP-2 levels measured in the first 
few days after AMI are modestly elevated and remain so over the next 6 months at 
least, while TIMP-4 falls immediately after AMI to levels lower than age-matched 
controls and remain low out to 6 months.
181 No relationship has been identified so far 
between TIMP-1,2 or 4 and either baseline or change in LV volumes and LVEF 
following AMI in humans. 
 
Pharmacologic suppression of MMP activity early after AMI is theoretically attractive 
as a means of limiting myocardial damage and attenuating remodelling. Animal 
studies using selective MMP inhibitors have revealed mixed results. Studies involving 
inhibition of MMP-2 and MMP-9 among others have failed to reproduce the 
beneficial effects on LV function reported by other groups.
184-186 Broad-spectrum 
MMP inhibition is not attractive due to not only musculoskeletal side-effects but also 
theoretical suppression of the appropriate reparative actions of MMPs after large AMI. 
The largest human trial of an oral MMP inhibitor, with a high affinity for MMP-
2,3,8,9,13 and 14, failed to show any benefit on LV remodelling in patients with low 
LVEF after AMI over 3 months.
187 
 
Despite the lack of success of MMP inhibition, the roles of individual MMPs in 
remodelling and the therapeutic potential of more selective MMP inhibition continues 
to drive research into the respective roles of MMPs and TIMPs in humans. MMP-3 
has recently been demonstrated to be of potential interest in post-infarction   55 
remodelling in humans and merits further study.
188 In this study of remodelling in 
patients with reduced LVEF after AMI that constitutes the focus of this thesis, I 
analysed further the roles and assessed the response to treatment of MMP-2, MMP-3, 
MMP-9 and TIMP-1, TIMP-2 and TIMP-4 in the human remodelling process. 
 
1.9  The role of cytokines in post-infarction LV remodelling 
Cytokines represent a further category of biologically-active molecules that have been 
implicated in the pathogenesis of remodelling. These are relatively low molecular 
weight (8-30kDa) protein molecules that can be synthesised in and secreted by a 
variety of cell types in different tissues. In this respect they differ from polypeptide 
neurohormones which tend to be released from specialised cells in specific tissues. 
Over 30 classes of cytokines have been recognised to date. 
 
Interest in the potential role of cytokines in LV remodelling was stimulated by the 
discovery of increased levels of the cytokine TNFα in patients with CHF.
189 
Cytokines effect a wide range of actions, some of which involve myocytes, fibroblasts 
and the ECM, hence the generation of significant interest into a potential aetiological 
role in remodelling. Most research to date in this field has focused on the “pro-
inflammatory” cytokines - TNFα, IL-1 and IL-6. 
 
In vitro studies have demonstrated myocyte hypertrophy in response to TNFα or IL-
1β, although this may be indirect and mediated via reactive oxygen species.
190-192 
Myocardial hypertrophy is also seen in mice over-expressing IL-6.
193 IL-1β and 
TNFα have also been shown to promote myocyte apoptosis and to exert negative 
inotropism in vitro and in vivo; interestingly in rats infused with TNFα, this negative   56 
inotropic effect was fully reversible as soon as the TNFα infusion was 
discontinued.
194-197 Inflammatory cytokines therefore promote changes within 
myocytes – hypertrophy, apoptosis and functional impairment – all of which are seen 
in pathological remodelling. 
 
Cytokines also adversely affect cardiac fibroblasts. In vitro, TNFα inhibits 
fibroblastic collagen gene expression and thus collagen synthesis.
198 IL-1β exerts an 
antiproliferative effect on cardiac fibroblasts, while two cytokines of the IL-6 family – 
leukaemia inhibitory factor (LIF) and cardiotrophin-1 (CT-1) – promote fibroblast cell 
growth.
199 LIF has also been shown to inhibit differentiation of cardiac fibroblasts into 
myofibroblasts, suggesting an autocrine/paracrine regulatory function in matrix 
remodelling.
200 
 
In addition to their effects on myocytes and fibroblasts, cytokines also appear to exert 
direct and indirect effects on the ECM. Infusion of TNFα not only causes progressive 
LV dilatation but also degradation of the ECM in rats.
196 Within cultured fibroblasts, 
TNFα has been shown to upregulate pro-MMP-3, and IL-1β to upregulate a number 
of MMPs including MMP-2 and MMP-9.
198 Consistent with these in vitro findings, 
over-expression of TNFα promotes enhanced MMP activity and reduced LVEF 
acutely, although over time MMP activity falls and TIMP activity rises.
196 Through 
such variations in the MMP:TIMP balance, cytokines can indirectly modulate ECM 
turnover. 
 
The pro-inflammatory cytokines therefore affect the major components of the 
remodelling process: myocytes, cardiac fibroblasts and the ECM. Several other   57 
cytokines have also shown correlation with parameters of remodelling. Monocyte 
chemoattractant protein-1 (MCP-1) appears to be protective in the short-term, 
promoting wound healing following experimental AMI in mice, but to potentiate 
adverse remodelling in the longer-term.
201, 202 Macrophage inflammatory protein-1α 
(MIP-1α), regulated on activation normally T cell-expressed and secreted (RANTES) 
and MCP-1 are all elevated in the first week after AMI in humans and remain elevated 
over the first month in those who develop heart failure; in these high risk patients, 
weak correlations have been identified between MIP-1α and LV volumes/LVEF.
203 
The recently-discovered IL-18 correlates inversely with LVEF after AMI.
204 
 
There is strong experimental evidence that cytokines play a role in remodelling. 
Further indirect evidence is provided by the marked reduction in inflammatory 
cytokines seen in CHF patients following treatment with β-blockers, which are of 
proven mortality benefit in CHF.
205, 206 Moreover, significant interplay occurs 
between the cytokines and other systems integral to pathological remodelling. TNFα 
upregulates cardiac fibroblastic expression of the AT1 receptor and also promotes 
angiotensin II release, thereby making the fibroblasts more sensitive to the effects of 
angiotensin II and promoting RAAS activation.
81 TNFα also appears to upregulate 
ACE activity, further stimulating the RAAS.
207 NA release due to sympathetic 
overactivity also activates pro-inflammatory cytokines, while the interaction between 
cytokines and the MMP:TIMP system has been discussed.
42 
 
In my study cohort I investigated further the roles of a variety of pro- and anti-
inflammatory cytokines on post-infarction LV remodelling. I also examined for the 
first time the role of a novel biomarker related to cytokine activity in the post-  58 
infarction period – serum soluble ST2 (sST2). ST2 is a member of the IL-1 receptor 
(IL-1R) family with transmembrane (ST2L) and soluble (sST2) isoforms and may be 
relevant as a biomarker of prognostic significance in AMI and in both acute and 
chronic heart failure.
208 ST2L is membrane-bound with 3 extracellular 
immunoglobulin G (IgG) domains, a single transmembrane domain, and an 
intracellular domain homologous to Toll-like receptors and other IL-1Rs.
209 sST2 
lacks the transmembrane and intracellular domains and is thought to function as a 
decoy receptor which neutralises IL-33, recently demonstrated to be the ligand for this 
receptor.
210 IL-33 exerts anti-hypertrophic effects in cultured cardiomyocytes that are 
antagonised by administration of sST2, and reduces myocardial fibrosis and 
cardiomyocyte hypertrophy after experimental pressure overload in mice, although 
interestingly these effects are not seen in mice lacking the ST2 gene.
211, 212 These data 
suggest a possible cardioprotective role for the IL-33/ST2 signalling pathway. In 
human studies, serum sST2 is elevated early after AMI and correlates with the 
myocardial-bound fraction of the enzyme creatine kinase and (inversely with) 
LVEF.
209 Serum sST2 correlates with NTproBNP in patients admitted with ST-
elevation AMI (STEMI) and predicts subsequent 30-day mortality and heart failure.
213, 
214 Additionally, serum sST2 is elevated and is of predictive value in acutely 
dyspnoeic patients with and without decompensated acute and chronic heart failure.
211, 
215, 216  
 
That sST2 predicts adverse cardiovascular outcome, and is related to LVEF after AMI, 
suggests that it may have a role in post-infarction LV remodelling but this has yet to 
be evaluated. I therefore examined for the first time the relationships between serum   59 
sST2, parameters of LV function, and a variety of circulating mediators in our trial 
cohort. 
 
1.10  The role of haemostatic markers in post-infarction LV remodelling: 
Myocardial infarction is the product of a multifactorial process culminating in the 
acute occlusion of the affected coronary artery. Substantial research has been 
undertaken into the role of the coagulation cascade in the acute stages of infarction 
and is beyond the scope of this thesis. Of relevance, however, is the evidence of a pro-
thrombotic state that not only puts the population at greater risk of developing CHD 
but also adversely affects prognosis after AMI.
217-220 
 
Tissue plasminogen activator (tPA) is a serine protease secreted from endothelial cells 
in response to vascular injury. It has a key role in the coagulation-fibrinolysis cascade, 
converting inactive plasminogen to the fibrinolytic molecule plasmin, which then 
degrades fibrin. Plasminogen activator inhibitor-1 (PAI-1) is a potent endogenous 
inhibitor of tPA (and urokinase) which is released by activated platelets and 
neutralises tPA. von Willebrand factor (vWF) is an acute phase protein stored in 
endothelial cells and platelets which is released rapidly at the site of vascular injury 
and which is crucial for platelet aggregation. 
 
Interest in the potential use of these three markers of haemostasis in risk stratification 
and prognosis in cardiovascular disease has been stimulated by epidemiological and 
clinical studies. Both tPA antigen and vWF predict the 2-year occurrence of AMI or 
sudden cardiac death in patients with angina pectoris of varying severity.
218 In 
survivors of both non-Q-wave and Q-wave AMI (including STEMI), vWF strongly   60 
predicts the 30-day major adverse cardiovascular event rate (including death and heart 
failure).
219, 220 In prolonged (10 year) follow-up of 123 survivors of AMI, both vWF 
and tPA antigen were strong independent predictors of cardiovascular mortality.
221 
 
That elevated tPA antigen predicts adverse outcome appears counter-intuitive, as it 
would be expected to promote endogenous fibrinolysis. Free, active tPA is difficult to 
measure in plasma thus tPA antigen is frequently measured instead; tPA antigen acts 
as a surrogate marker of the tPA-PAI-1 complex, however, thus elevated tPA antigen 
indirectly suggests elevated PAI-1.
217, 222 In keeping with this, strong correlation 
between tPA antigen and PAI-1 was confirmed in the European Concerted Action on 
Thrombosis and disabilities angina pectoris study group (ECAT).
218 PAI-1 is elevated 
early after STEMI, has a weak inverse correlation to baseline LVEF, and predicts 30-
day occurrence of heart failure and death.
220, 223 
 
The roles of tPA, PAI-1 and vWF in the post-infarction phase are unclear. They may 
represent the severity of the ischaemic vascular injury, endothelial dysfunction, 
success of reperfusion or platelet activation. That they have been shown to predict 
major adverse events including heart failure after AMI suggests that they may have a 
role in predicting LV remodelling or indeed its pathophysiology. Plasmin has been 
shown to activate pro-MMPs thereby promoting ECM degradation.
183 Markedly 
increased PAI-1 expression in myocytes and perivascular cardiac mast cells has been 
demonstrated following AMI in mice, contributing to replacement, reactive and 
perivascular fibrosis, key factors in LV remodelling.
224 Interestingly less fibrosis 
occurred in PAI-1 knockout mice. 
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In this thesis I analysed in greater detail the potential predictive and/or 
pathophysiological roles of tPA antigen (as a surrogate of the tPA-PAI-1 complex) 
and vWF in post-infarction LV remodelling. 
 
1.11  Non-invasive assessment of ventricular function 
European and American guidelines recommend that all patients who have suffered 
AMI should undergo a formal evaluation of LV function, ideally pre-discharge.
126-128 
The exact means of LV assessment is not stipulated in the American College of 
Cardiology/American Heart Association (ACC/AHA) guidelines, while the European 
Society of Cardiology (ESC) guidelines recommend that trans-thoracic 
echocardiography (TTE) should be performed in all patients; other modalities may be 
used if available. 
 
1.11.1  Comparison of contemporary imaging modalities 
Unenhanced 2-dimensional (2-D) TTE is the most widely-used method of assessing 
LV function following AMI.
11 More reproducible methods are favoured, however, as 
TTE carries significant inter- and intra-observer variability that limit its applicability; 
these include radionuclide ventriculography (RNVG), single photon emission 
computed tomography (SPECT), contrast-enhanced TTE, invasive contrast 
angiography, and cardiac magnetic resonance imaging (CMR). CMR affords not only 
the gold-standard means of assessment of LV volumes and ejection fraction, but also 
allows assessment of myocardial viability, perfusion, regional function and imaging 
of the thorax and upper abdominal viscera.
225-232 CMR is also superior to first pass 
RNVG and gated blood-pool SPECT, the traditional modalities of choice, in imaging 
and quantifying RV function.
226, 233, 234    62 
 
Of the various parameters of LV function that can be measured via non-invasive 
imaging, LVEF is the most relevant in clinical practice. Several important (and 
expensive) decisions rely on accurate knowledge of LVEF in patients with prior AMI, 
such as qualification for implantable cardioverter defibrillator (ICD) insertion or even 
cardiac resynchronisation therapy (CRT). Pharmacological therapy is also influenced 
by LVEF: ESC guidelines state that in patients with LVEF ≤40% following AMI, 
long-term ACE inhibitor and β-blocker therapy is indicated as is aldosterone blockade, 
if either heart failure or diabetes are present (in the absence of significant renal 
dysfunction or hyperkalaemia).
128 Such management decisions are rendered even 
more difficult by the lack of interchangeability between LVEF estimates measured by 
different modalities. This was demonstrated clearly in a study of 52 patients with CHF 
and LVSD, all of whom underwent TTE, CMR and RNVG within a 4-week period of 
clinical stability.
235 The CMR and RNVG scans were interpretable in all cases, but the 
M-mode and 2-D Simpson’s biplane TTE images were of sufficient quality for 
analysis in only 86% and 69% of patients respectively. The LVEF measured by each 
imaging modality was significantly different from all other techniques except for 
CMR and 2-D Simpson’s biplane TTE, and even between these two quantities the 
Bland-Altman limits of agreement were unacceptably wide. 
 
The ideal imaging modality should be widely-available, accurate, reproducible and 
safe for the patient. TTE remains the most widely-available imaging modality 
although the availability of CMR is increasing. The accuracy and reproducibility of 
CMR compare favourably to those of TTE, RNVG and invasive contrast 
angiography.
235-240 Moreover, CMR allows significant sample size reduction   63 
compared to TTE.
236 CMR is non-invasive, uses no radiation, and has been shown to 
be safe early after AMI, although specific safety questionnaires must be completed 
prior to consenting to the investigation and entering the designated MRI scanning 
room.
241 The limitations of CMR scanning are discussed in the Methods section. 
CMR therefore fulfils several of the criteria for the “ideal” imaging modality. 
 
In summary, CMR is now considered the gold-standard means of measurement of LV 
mass, volumes and LVEF, particularly in patients with LVSD in whom the 
geometrical assumptions on which planar imaging techniques necessarily depend, fail 
to account for the changes that occur in LV morphology. Volumetric analysis is 
performed on CMR by dividing the LV into a stack of short-axis slices, which 
removes the need for any geometric assumption. In addition, the excellent spatial and 
temporal resolution afforded by CMR allows accurate delineation of endocardial and 
epicardial borders.  
 
1.11.2  CMR in LV remodelling 
Left ventricular end-systolic volume (LVESV) is a powerful predictor of survival 
following AMI, serial change in which has been the focus of a number of clinical 
studies of LV remodelling in both AMI and CHF populations.
22, 29, 117, 242, 243 All 
patients in this study will undergo CMR imaging in which LVEF, LV volumes, mass 
and stroke volume will be measured. LV remodelling is defined as the change in 
LVESV, indexed to body surface area (BSA), over time. 
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1.11.3  Late gadolinium enhancement CMR (LGE-CMR) 
It has been known for many years that regions of acute and chronic myocardial 
necrosis, such as infarction, exhibit a higher signal intensity on T1-weighted MRI 
images following administration of gadolinium-based contrast agents.
244 Such agents 
shorten the T1 relaxation time, thereby increasing the contrast between tissues 
depending on their relative content of contrast agent. This has led to numerous studies 
of myocardial infarction models utilising a variety of pulse sequences to differentiate 
normal from abnormal myocardium. 
 
LGE-CMR allows assessment of myocardial viability in acute and chronic MI. If the 
heart is imaged 15-30 minutes after injection of a contrast agent, an increase in the T1 
signal intensity will be seen in regions of myocardium with increased extracellular 
space or abnormal wash-in/washout characteristics (such as infarcted tissue), and will 
appear bright compared to the normal myocardium. Application of an inversion-
recovery pre-pulse serves to enhance the contrast between abnormal (bright) and 
normal (dark) myocardium.
245  
 
Following AMI, therefore, the intravenous administration of a gadolinium-based 
contrast agent allows visualisation of abnormal region(s) of myocardium. Animal 
infarct models have shown a close correlation between the delayed enhanced region 
on LGE-CMR images and triphenyltetrazolium chloride-stained slices of the whole 
heart, signifying infarcted myocardium.
246 In humans with ischaemic LVSD, the 
transmural extent of the delayed enhanced region on LGE-CMR correlates inversely 
with improvement in regional contractility following revascularisation.
247 This 
technique therefore appears to allow in vivo visualisation of abnormal regions of   65 
myocardium consistent with infarction. It should be stressed, however, that delayed 
enhancement on LGE-CMR is not a specific sign of infarction – it simply indicates 
that the normal fluid homeostasis within the abnormal segment has been disrupted. 
Delayed contrast enhancement has been reported in a variety of conditions including 
myopericarditis, hypertrophic and dilated cardiomyopathies, infiltrative cardiac 
disorders, cardiac neoplasia and in the transplanted heart. 
 
In our cohort of AMI patients, the use of LGE-CMR should allow visualisation of 
abnormal regional myocardium consistent with acute infarction. We can then not only 
record the precise anatomical location of the infarcted area, but also calculate its 
transmurality and endocardial extent and relate these to LV remodelling. 
 
1.11.4  Microvascular obstruction   
Relief of the occlusive obstruction within the IRA is a key component in the acute 
management of MI and the attenuation of LV remodelling. Despite patency of the 
IRA, however, abnormal microvascular perfusion is related to worse outcome.
248, 249 
Such abnormal perfusion is termed microvascular obstruction (MVO). 
 
CMR facilitates examination of myocardial perfusion. There are two methods: 
(i)  first-pass perfusion imaging: myocardial enhancement is analysed 
immediately after contrast injection – this represents “early MVO” 
(ii)  LGE-CMR: within the hyperenhanced “bright” region as described above, 
a central hypoenhanced region is frequently seen after large AMI. From 
the initial reporting of this hypoenhanced core, a series of animal 
experiments have confirmed a precise anatomical correlation between the   66 
hypoenhanced core and markedly reduced blood flow, in addition to 
biopsy evidence of necrotic debris.
250-252 This appearance has been termed 
“late MVO”. 
 
The influence of MVO on remodelling after AMI has led to conflicting results. 
Studies using myocardial contrast echocardiography to determine presence and extent 
of MVO have consistently shown strong correlations between its presence and 
adverse remodelling.
253, 254 CMR studies have revealed strong correlations between 
early MVO and greater LV volumes at baseline, more significant remodelling, and 
increased risk of major adverse cardiovascular events post-infarct.
255, 256 
 
Results of a recent study using late MVO after reperfused AMI with confirmed 
patency of the IRA contradict many of the studies using early MVO. Although the 
presence and extent of late MVO did correlate with higher cardiac biomarkers, higher 
LVESV, larger infarct size and lower LVEF at baseline, it had no influence on 
remodelling over the ensuing 4 months.
257 The major limitation of this study was the 
small patient number (n=40). 
 
One of the technical issues in the analysis of early MVO using CMR is the need for 
ultrafast acquisition schemes, as the goal is to acquire multiple slices through the heart 
(preferably within one heart-beat) to assess the relative perfusion of the myocardium 
following bolus contrast injection. Current imaging protocols, including those used in 
our centre, allow only 3-5 slices in total from LV base to apex per heart-beat. 
Acquisition of delayed contrast-enhanced images, using fast gradient echo sequences 
with an inversion-recovery pre-pulse, allows much greater spatial resolution and   67 
coverage of the entire LV. This results in reliable quantification of not only infarct 
extent but also the presence and extent of MVO. Consequently late MVO is now 
considered to be a more precise estimate of microvascular dysfunction.  
 
The role of MVO in LV remodelling therefore remains somewhat controversial. 
Using late MVO, I planned to examine this further in the cohort of AMI patients 
studied in this thesis. 
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1.12  Aims 
On the strength of available evidence, aldosterone plays a major role in post-infarction 
LV remodelling, and indeed aldosterone blockade is now indicated in addition to ACE 
inhibitor and β-blocker therapy (both of proven benefit in attenuating adverse 
remodelling) in patients with reduced LVEF and either heart failure or established 
diabetes mellitus after AMI. Whether aldosterone blockade exerts further anti-
remodelling benefit in the presence of ACE inhibitors and β-blockers remains 
controversial, and results of several small studies are conflicting.  
 
The hypothesis that this thesis will test is whether inhibition of the effects of 
aldosterone reduces remodelling after myocardial infarction in a cohort of patients 
with LVSD early after AMI, who have been treated with standard secondary 
preventive therapy. This will be accomplished using a randomised, double-blinded 
study of the effects of the selective MRA eplerenone on LV remodelling over 24 
weeks compared to placebo. As patients with LVSD early after AMI who are diabetic 
or who develop heart failure should receive eplerenone according to current 
guidelines, such patients will be excluded from this study. This thesis will thus focus 
on ‘asymptomatic’ LVSD after AMI. 
 
CMR will be used as the imaging modality in this study, as it represents the current 
gold-standard method for measuring LV volumes, mass and LVEF.  
 
The roles of the various biomarkers discussed in LV remodelling, and the influence of 
eplerenone thereon, will also be examined. 
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The specific aims of this study are as follows: 
 
 
Effects of Eplerenone 
•  To assess the effect of eplerenone on the change in (∆) LV end-systolic volume 
index (LVESVI) over 24 weeks, compared to placebo – this is the primary end-
point 
 
•  To assess the effect of eplerenone on ∆ LV end-diastolic volume index (LVEDVI), 
∆ LV ejection fraction (LVEF), ∆ LV mass index and ∆ LV infarct volume index 
over 24 weeks, compared to placebo.  
 
•  To assess the effect of eplerenone on biomarkers related to the pathophysiology of 
LV remodelling: BNP, NTproBNP, NA, AVP, renin, aldosterone, MMPs, TIMPs, 
pro- and anti-inflammatory cytokines and markers of haemostasis 
 
Predictors of post-infarction LV remodelling 
•  To assess further the roles of biomarkers related to the molecular and cellular 
processes that underlie the macroscopic changes that occur in LV remodelling, 
using the current gold-standard means of quantifying gross changes in LV structure. 
These include: 
o  BNP and NTproBNP 
o  Noradrenaline 
o  AVP 
o  MMP-2, MMP-3 and MMP-9   70 
o  TIMP-1, TIMP-2 and TIMP-4 
o  Several families of cytokines 
o  tPA antigen 
o  vWF 
 
•  To analyse further the predictive value of late MVO in LV remodelling, measured 
using LGE-CMR. 
 
The role of aldosterone in post-infarction LV remodelling 
•  To analyse the relationships (if any) among: 
o  plasma renin and aldosterone concentrations and ceCMR  parameters 
of LV function following AMI across the entire study population, and 
by treatment group 
o  urinary steroid metabolite excretion rates and parameters of LV 
remodelling 
o  plasma aldosterone concentrations and parameters of LV remodelling 
(if any) of the -344T/C SNP in CYP11B2 
 
Novel markers 
•  The natural history of the novel peptide apelin following AMI will be characterised 
for the first time. 
•  The relationships (if any) between the novel biomarker serum soluble ST2 and 
parameters of LV remodelling, and between ST2 and a variety of circulating 
neurohormones of prognostic and/or pathophysiological significance in post-
infarction remodelling will be examined for the first time.   71 
 
Additional findings 
•  To describe the additional intra- and extra-cardiac abnormalities detected by 
performing pre-discharge CMR imaging in addition to standard TTE in a cohort of 
post-AMI patients. 
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Chapter 2 
 
Materials and Methods 
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2.1  Introduction 
The principal technique used for this thesis was contrast-enhanced cardiac magnetic 
resonance imaging (LGE-CMR). This was supplemented by transthoracic 
echocardiography, electrocardiography, and sampling and measurement of a variety 
of circulating, urinary and genetic markers. In this chapter the background, methods, 
apparatus and protocols used for these techniques will be outlined. 
 
2.2  Subjects 
2.2.1  Inclusion and exclusion criteria 
 
Inclusion criteria: 
1.  Age ≥18 years  
2.  AMI within last 1-14 days (definition in section 2.2.3) 
3.  LVEF <40% on screening 2-D TTE   
4.  Ability to give written informed consent 
 
Exclusion criteria: 
1.  Clinical and/or radiological heart failure (ie. Killip score ≥I) 
258 
2.  Established diabetes mellitus 
3.  Documented pre-existing LVSD (ie. prior to index AMI) 
4.  Serum creatinine > 220µmol/l* 
5.  Serum potassium > 5.0mmol/l* 
6.  MRI-incompatible (ferrous) prosthesis 
7.  Claustrophobia causing inability to tolerate CMR 
8.  Pregnancy   74 
9.  Addison’s disease 
10.  Concurrent use of potent inhibitors of CYP3A4: potassium-sparing 
diuretics, clarithromycin, nefazodone, itraconazole, ketoconazole, 
ritonavir, nelfinavir, tacrolimus, cyclosporin.** 
11.  Concurrent use of CYP3A4 inducers: phenytoin, carbamazepine, 
rifampicin or St. John’s Wort   
 
* upper limits of serum creatinine and potassium as used in EPHESUS 
123 
** Concurrent use of mild-to-moderate inhibitors of CYP3A4 was allowed, but in 
their presence the dose of eplerenone remained at 25mg o.d. throughout the trial 
duration. These include: amiodarone, diltiazem, verapamil, erythromycin, fluconazole 
and saquinavir. 
 
2.2.2  Recruitment 
All consecutive patients admitted directly to the Western Infirmary, Glasgow (WIG) 
with AMI, or transferred from peripheral hospitals to the WIG for further in-patient 
management following admission with AMI, were potentially eligible. During the 
study recruitment phase, all patients without obvious contraindications to enrolment 
underwent screening TTE, performed by one operator (RW), in order to estimate 
LVEF (Simpson’s biplane rule).
259 Patients with insufficient endocardial definition to 
allow accurate planimetry were excluded from recruitment. This screening process 
continued until the pre-specified target population (n=100) had been recruited. The 
TTE was performed as early as was feasible after admission and the report was made 
available immediately to the ward team; consistent with EPHESUS, patients with a 
single measurement of LVEF <40% at any time after the AMI and before enrolment   75 
were eligible (although EPHESUS was less homogeneous in its recruitment, 
employing any of three different imaging modalities – TTE, RNVG and invasive 
contrast angiography – to estimate LVEF).
123 
 
2.2.3  Definition of AMI 
AMI has been subject to significant re-definition in the last decade, as new and more 
sensitive biomarkers become available, in particular troponin T (TnT) and TnI, which 
are very sensitive markers of myocyte necrosis. The definition of AMI used in this 
study, in which recruitment commenced in 2005, was that recommended by the 
British Cardiac Society Working Group in 2004.
260 Classified as “acute coronary 
syndrome with clinical myocardial infarction”, this required either or both of a history 
of typical ischaemic cardiac chest pain and ECG changes consistent with ischaemia, 
together with a maximum TnT release of >1.0 ng/ml or TnI release of >0.5 ng/ml. In 
this study, in which the enrolled patients had necessarily sustained large infarcts, the 
peak Tn was markedly elevated in all cases. As patients initially admitted to and 
managed in hospitals other than the WIG were included, many Tn measurements were 
made in the biochemistry laboratories of these referring hospitals. Different hospital 
trusts use either TnT or TnI, with different coefficients of variation (CV) which were 
not recorded at the time, thus the Tn results for the patients enrolled in this study show 
a mixture of TnT and TnI. Troponin was therefore used as an inclusion criterion only; 
no further analysis of troponin was performed in the study. 
 
2.2.4  Acute management of patients 
The trial did not interfere with the in-patient management in any way. If percutaneous 
coronary intervention (PCI) was planned, either in the acute infarction phase or the   76 
early post-infarction period, this was given priority over, and performed prior to 
ceCMR. Patients who had undergone coronary angiography but who were to be 
referred for coronary artery bypass surgery (CABG) prior to randomisation were 
excluded. The prescription of standard secondary preventive therapies, including ACE 
inhibitors and β-blockers, was entirely at the discretion of the admitting consultant. 
Likewise, the decision to withdraw patients from the trial who developed pulmonary 
oedema after enrolment (who would therefore have qualified for eplerenone therapy 
based on the EPHESUS trial and current guidelines) was also at the discretion of the 
consultant, although it is noteworthy that eplerenone was not being used routinely at 
that time in Glasgow in these patients. 
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2.3  Trial outline 
 
 
Figure 2.1 Timeline of patient involvement in trial, from acute admission until trial 
completion. 
 
 
2.3.1  Randomisation 
After obtaining written, informed consent (Appendix I-II), enrolled patients were 
assigned an arbitrary unique identifier to be used for the duration of the trial. A form   78 
filled out by one investigator (RW) including each patient’s name, date of birth and 
unique identifier, was then sent to the WIG Pharmacy Clinical Trials Unit, where 
double-blinded randomisation was performed.  
 
Each patient underwent a series of baseline investigations, as indicated in the timeline 
(Figure 2.1). None of these investigations took place on day 1 according to protocol, 
as this was deemed a potentially unstable period. Assuming clinical stability, however, 
as early as possible after the first 24 hours of hospital admission, the following were 
performed: 
(i)  full physical examination – including measurement of height, weight 
and resting haemodynamics  
(ii)  retrieval and digital scanning of 1
st (acute admission) 12-lead ECG  
(iii)  24 hour urine collection performed 
(iv)  24 hour Holter monitor performed 
(v)  venepuncture – 50ml blood withdrawn for biomarker analysis 
(vi)  ceCMR with simultaneous digitally-acquired 12-lead ECG 
 
LGE-CMR was performed as early as possible after day 1. Once the baseline 
investigations were completed for each patient, study drug was commenced in 
addition to the secondary preventive medications prescribed by the ward team. 
Patients were discharged with a 4-week supply of study drug initially; at the 4-week 
visit, a new 8-week supply was provided, and at the 12-week visit a further 12-week 
supply was given. On receipt of each new supply of study drug, patients returned the 
remainder of the previous supply, which was immediately returned to the WIG 
Pharmacy.   79 
 
Storage, dispensing, monitoring of study drug uptake (based on counting the number 
of tablets in all returned bottles) and safe-guarding of the randomisation code were 
performed entirely by the WIG Pharmacy. The randomisation code was only released 
after the final analysis of the final LGE-CMR scan had been completed. 
 
2.3.2  12-week visit 
This comprised a 2-day visit to the WIG. On day 1 a number of the baseline 
investigations were repeated: 
  (i)  full physical examination  
(ii)  24 hour urine collection performed 
(iii)  24 hour Holter monitor performed 
(iv)  venepuncture – 50ml blood withdrawn for biomarker analysis 
 
Both the 24 hour urine sample and Holter monitor were returned on day 2, on which 
the second protocol-mandated LGE-CMR was performed, with a simultaneous digital 
12-lead ECG. 
 
2.3.3  24-week visit 
This was the final visit, and consisted of one day at the WIG. The following were 
performed: 
  (i)  full physical examination  
(ii)  venepuncture – 50ml blood withdrawn for biomarker analysis  
(iii)  digital 12-lead ECG 
(iv)  LGE-CMR   80 
 
Unused study drug was then returned, and the patient’s involvement in the trial ceased. 
 
2.3.4  Dose of study drug 
For ease of prescription, only one strength of tablet was used for the study drug. Each 
tablet contained either 25mg eplerenone or matched placebo. Consistent with the 
doses used in EPHESUS, the starting dose of eplerenone (or placebo) was 25mg o.d. 
After 4 weeks, this dose was increased to 50mg o.d. for the remainder of the trial. 
Exceptions to this rule included patients with a serum potassium >5.0 mmol/l at 4 
weeks (drug either reduced to alternate days or temporarily with-held – Table 2.1) or 
those who were simultaneously prescribed mild-to-moderate CYP3A4 inhibitors (who 
remained on 25mg o.d throughout the trial). 
 
Serum Potassium 
(mmol/l) 
Action  Dose adjustment 
< 5.0  Increase  25mg o.d. up to 50mg o.d. 
5.0 – 5.4  Maintain  No dose adjustment – remain on 25mg o.d. 
Recheck in 1 week; increase if potassium 
<5.0 mmol/l 
5.5 – 5.9  Decrease  25mg o.d. to 25mg. on alternate days 
≥ 6.0  With-hold  N/A 
 
Table 2.1  Dose adjustment of study drug at 4 weeks, according to serum biochemistry. 
 
2.3.5  Monitoring of renal function 
Although patients with significant renal impairment were excluded, all patients 
enrolled into the study had not only sustained a significant amount of myocardial 
damage, but also had been recently commenced (in the majority of cases) on at least 
one potentially nephrotoxic drug, to which eplerenone was then added in 50%. Close 
monitoring of renal function was therefore mandatory. All measurement of serum   81 
urea, creatinine and electrolytes (U&Es) was performed by the WIG routine 
biochemistry laboratory. Protocol-mandated U&Es were measured at six time-points 
over the 24-week trial period (see timeline): prior to and 2 days after commencing 
study drug, then at 4, 5, 12 and 24 weeks. Additional time-points were used if 
clinically indicated. The major dose change (25mg to 50mg o.d.) was at 4 weeks, 
hence the U&Es measurement at 5 weeks. For all time-points after 4 weeks, the drug 
dose was adjusted as in Table 2.2. All U&Es results were available on the same day 
on which venepuncture was undertaken, and were acted upon immediately if 
necessary. 
 
Serum Potassium (mmol/l) 
 
Action  Dose adjustment 
< 5.0  Increase 
Maintain 
25mg alternate days to 25mg o.d. 
If on 50mg o.d. already 
5.0 – 5.4  Maintain  No dose adjustment 
5.5 – 5.9  Decrease  50mg o.d. to 25mg o.d. 
25mg o.d. to 25mg alternate days 
25mg alternate days to with-hold 
≥ 6.0  With-hold  Recheck within 1 week and re- 
challenge at 25mg o.d. 
 
Table 2.2  Dose adjustment of study drug at any time-point after 4 weeks, according to serum 
biochemistry.      
 
2.4  TTE protocol (screening only) 
The TTE examination was performed with the patient in the left lateral decubitus 
position. Images were acquired from standard parasternal and apical views. 
Ultrasound data were acquired with an Acuson CV70 ultrasound scanner and a 3.5 
MHz transducer (Siemens). Standard LV M-mode measurements included LV end-
diastolic diameter, LV end-systolic diameter and myocardial wall thickness at end-
diastole. LVEF was estimated from the apical 4-chamber and 2-chamber views 
utilising Simpson’s biplane rule.
259 Simpson’s biplane analysis was performed by one   82 
observer (RW), and only those with LVEF less than 40% were approached regarding 
study recruitment. Manual planimetry was used to trace the endocardial contours at 
end-systole and end-diastole in both the apical 4-chamber and 2-chamber views; by 
convention the papillary muscles were included within the LV volumes (not LV mass). 
The study protocol mandated that patients with insufficient endocardial definition to 
allow accurate planimetry were excluded from recruitment, thus all 100 patients had 
endocardial definition of sufficient quality to allow accurate volumetric analysis. 
Contrast was not used.  
 
2.5  CMR protocol 
CMR was performed using a 1.5T Siemens Sonata Magnetom with a phased-array 
chest coil, during breath-hold, and gated to the ECG. Each scan was performed by one 
of two experienced operators (RW, TS), both of whom are Advanced Life Support-
qualified; RW was present throughout all scans thereby providing constant medical 
cover. Prior to entering the controlled zone, an MRI safety checklist was performed 
and signed by both patient and qualified MRI personnel (Appendix III). The 
importance of keeping as still as possible, and maintaining adequate breath-holds, was 
reinforced verbally prior to commencement of the scan. End-expiration is optimal for 
consistent breath-holding and was preferred. 
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2.5.1  Preparation of patient for scan 
 
The following steps were performed in all cases: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
•
•  Patient demographic details entered on scanner database 
•  The power injector (Medrad Spectris, Volkach, Germany) for 
administration of the contrast agent – gadolinium 
diethylenetriaminepentaacetic acid (DTPA), GE Healthcare – was 
prepared. The Medrad injector contains two quick-fit syringes connected 
by a Y-tubed delivery set. Into syringe A, gadolinium-DTPA was drawn 
at a dose of 0.1mmol/kg. Syringe B contained 50ml 0.9% NaCl 
•  Patient placed on table 
•  Siemens active Brooker ECG electrodes placed on patient’s anterior 
chest wall, and position varied to obtain an optimal R wave 
•  A 20G IV cannula was placed in a peripheral vein, and connected to the 
Medrad injector. 
•  The phased-array chest coil (Siemens CP body array flex) was applied 
and aligned 
•  Patient, wearing ear protectors or headphones, enters scanner 
•  Medrad power injector armed 
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2.5.2  LV structure and function 
All CMR scans commenced with a multi-slice breath-hold localiser. Each of the 
localisers described in this section used the same protocol: 
 
Protocol: Multislice single-shot breath-hold true fast imaging with steady-state 
precession (trueFISP) localiser with transverse, sagittal and coronal slices. Settings: 
field of view = 360mm, field of view phase = 81.3%, slice thickness = 6mm, 
repetition time (TR) = 3.41ms, echo time (TE) = 1.71ms, flip angle = 60
o, averages = 
1, phase resolution = 80%, phase oversampling = 0% 
 
From these images, the best axial image depicting the LV and septum was selected 
(Figure 2.2 A). If no suitable image was produced by the initial localiser, a second 
axial localiser was performed using the coronal images until the closest match to 
Figure 2.2 A was obtained. This was used to plan 3 vertical long axis (VLA) parallel 
localisers along the long axis of the LV from the mid-point of the mitral valve to the 
apex. 
 
From the resulting VLA scan, 3 horizontal long axis (HLA) localisers were then 
planned, using the mid-point of the mitral valve and the LV apex to prescribe the 
orientation (Figure 2.2 B). This resulted in 3 HLA slices (Figure 2.2 C). Using the 
atrioventricular groove as a landmark, 3 short axis (SA) localiser slices were planned, 
with the most basal slice positioned in the atria to depict the left ventricular outflow 
(Figure 2.2 C). From the resulting SA images, 3 long axis views can be prescribed – 
the 4-chamber, 2-chamber and left ventricular outflow tract (LVOT) views (Figure 2.2 
D).    85 
 
Cinematographic (cine) imaging: 
Having thus acquired 3 orthogonal long axis views, cine studies were acquired in each 
of these 3 orientations, as follows: 
 
Protocol: trueFISP breath-hold cine. Settings: field of view = 360mm, field of view 
phase = 81.3%, slice thickness = 8mm, TR = 47.4ms, TE = 1.58ms, flip angle = 60
o, 
averages = 1, measurements = 1, phase resolution = 65%, phase oversampling = 20%, 
segments = 15 
 
These images were used for visual analysis of structure and long axis function. 
 
Short axis cine stack: 
Quantitative volumetric assessment of ventricular function requires that the LV be 
divided into a stack of SA slices from base to apex. Measurements from each slice are 
then summed to provide overall ventricular mass and volumes, from which LVEF can 
be calculated. The SA stack was prescribed from the 4-chamber HLA cine already 
acquired. Using the end-diastolic image from this view, the cursor was positioned in 
an orientation across the mitral valve plane through the atrioventricular groove (as a 
marker of the most basal SA slice) as in Figure 2.2 E. The most basal slice that results 
is depicted in Figure 2.2 F. The slice position was then incremented by 10mm moving 
towards the apex of the LV and repeated until the LV was completely covered; inter-
slice gaps of 2 mm were used. A representation of the final SA cine stack is shown in 
Figure 2.2 G. The same protocol was used for all SA cine slices: 
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Protocol: trueFISP breath-hold cine. Settings: field of view = 340mm, field of view 
phase = 81.3%, slice thickness = 8mm, interslice gap = 2mm, TR = 47.4ms, TE = 
1.58ms, flip angle = 60
o, averages = 1, measurements = 1, phase resolution = 65%, 
phase oversampling = 20%, segments = 15 
 
 
Figure 2.2  Planning of cine CMR image acquisition. From transverse, sagittal and coronal scout 
images, the best image depicting the LV and septum is selected (A) and utilised to produce a   87 
vertical long-axis (VLA) localiser (B). Prescribing an orientation through the apex and mid-point 
of the mitral valve (B – orientation line) creates a horizontal long-axis (HLA) localiser (C). Using 
the atrioventricular grooves as landmarks (C), a perpendicular plane to this HLA localiser is 
prescribed (D), based on which three orthogonal long-axis planes can be planned (2-chamber, 4-
chamber and LV outflow tract views). Cine images are acquired for each of these three long-axis 
orientations. Finally a short-axis cine stack is planned on the 4-chamber HLA cine image (E). A 
short-axis image is acquired of the base of the LV (F), from which slice position is advanced at 
10mm intervals from base to apex, creating a short-axis cine stack (G). 
 
 
 
2.5.3  Contrast-enhanced imaging 
Both first-pass perfusion imaging and delayed contrast enhancement imaging were 
performed on all patients, to detect the presence of early and late MVO respectively 
(and to measure infarct size and characteristics in the latter). In all cases, the dose of 
gadolinium-DTPA used was 0.1mmol/kg. 
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First-pass perfusion imaging: 
The visualisation of first-pass myocardial perfusion following bolus contrast injection 
requires ultra-high speed MR imaging. A balanced single-shot turbo fast low angle-
shot (FLASH) sequence with a saturation recovery pre-pulse before each slice was 
employed. This typically allowed 4 SA slices (copied from the cine SA stack) to be 
acquired per heart-beat. No breath-hold was required. The weight-adjusted dose of 
gadolinium-DTPA was delivered into a peripheral vein via the Medrad power injector 
at a constant rate of 6ml/s, followed by 0.9% NaCl flush. The first-pass protocol was 
as follows: 
 
Protocol: first-pass single-shot turbo-FLASH sequence with saturation recovery 
preparation, 4 slices per heartbeat. Non-breath-hold, controlled respiration. Settings: 
field of view = 340mm, field of view phase = 81.3%, slice thickness = 8mm, TR = 
183ms, TE = 0.99ms, flip angle = 8
o, averages = 1, measurements = 60, time to 
inversion (TI) = 100ms 
 
Imaging of early microvascular obstruction: 
2 minutes after contrast injection, images were acquired for the determination of early 
MVO. This required a single-shot steady-state free precession sequence with a non-
selective inversion pulse. No breath-hold was required. Typically 3-5 SA slices per 
heartbeat were acquired, copied from the SA cine stack. A single-shot sequence was 
acquired at each of four time-points: 2, 3, 4 and 5 minutes after contrast injection. The 
protocol for early MVO imaging was as follows: 
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Protocol: ECG trigger, 100 lines field of view = 270 x 360, slice thickness = 8mm, 
interslice gap = 2mm, flip angle 30
o, TE 1.2ms, TR 2.7ms, TI 200-350ms, bandwidth/ 
pixel = 980 Hz, matrix 256. 
 
Late gadolinium-enhancement imaging: 
15 minutes after bolus contrast injection in all scans, LGE-CMR images were 
acquired. This utilised a contrast-sensitive segmented inversion recovery sequence to 
acquire a second stack of SA images (positions copied from the SA cine stack). 
Images were also acquired in three long axis views, with orientations copied from the 
cine 4-chamber, 2-chamber and LVOT views. Adequate breath-holding was essential 
for each acquisition. The protocol was as follows: 
 
Protocol: Breath-hold segmented re-phased Turbo-FLASH sequence with non-
selective inversion pulse with non-slice selective inversion-recovery.  
 
Constant settings: field of view = 340mm, field of view phase = 81.3%, slice 
thickness = 8mm, interslice gap = 2mm, TE = 4.3ms, flip angle = 30
o, averages = 2, 
segments = 25, phase resolution = 65%, trigger delay = 0, trigger pulse = 2 (but 
dependent to an extent on heart-rate: trigger on pulse 1 if bradycardic, or pulse >2 if 
tachycardic). 
 
Variable settings: 
The acquisition window was set greater than RR-interval and TR just under to allow 
for diastolic imaging. TI was 220ms (for initial scan) and adjusted according to image 
quality by 10ms steps within the range 200-300ms to optimise image quality. The TI   90 
was often varied between image acquisition, and if the quality of the preceding image 
was poor it was repeated until an image of adequate quality was obtained. Optimal TI 
and TR produced a diastolic image with black (nulled) myocardium and bright late 
enhancement area (Figure 2.3 A). If late MVO was present, it appeared as a dark 
hypoenhanced core within the bright hyperenhanced area (Figure 2.3 B). 
 
 
 
Figure 2.3  Mid-ventricular short-axis slices acquired using a contrast-sensitive segmented 
inversion recovery sequence 15 mintues after injection of gadolinium-DTPA, from two 
separate patients admitted with anterior STEMI. (A) Subendocardial region of 
hyperenhancement affecting the anteroseptal wall of the LV, surrounded by normal (nulled, 
dark) myocardium; there is no MVO present. (B) Full-thickness infarction of the anteroseptal 
wall of the LV reveals hyperenhancement throughout wall, from endocardium to epicardium, 
with a hypoenhanced core – this core represents (late) MVO. 
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2.6  CMR analysis methodology 
 
2.6.1  LV volumes, mass and ejection fraction 
Postprocessing was performed using commercially-available Argus software 
(Siemens, Erlangen). The number of slices required to cover the LV in end-diastole 
and end-systole varied from scan to scan dependent on the long axis diameter of the 
LV. End-systole was chosen as the point where the total LV blood pool was smallest 
and end-diastole as the point where it was largest. The most basal LV slice at both 
end-systole and end-diastole was defined as that in which the blood pool was 
surrounded by 50% or more of ventricular myocardium; papillary muscles were 
excluded from the LV volumes and included in the LV mass.
261 Manual planimetry, 
performed on all CMR scans in random order by one observer (RW) blinded to 
treatment allocation, was used to trace the epicardial and endocardial contours of each 
SA slice acquired in the cine-stack. Simple addition of the individual slice volumes in 
this stack of contiguous slices covering the entire LV then allowed calculation of 
LVESV and LVEDV (ml). LV stroke volume (LVSV) was then calculated as follows: 
LVSV = LVEDV – LVESV. LVEF was calculated: LVEF = LVSV / LVEDV (%). 
LV myocardial mass (LVM) was estimated to be the mean of the total difference 
between the inner and outer circumferences of the LV myocardium in end-diastole 
and end-systole, multiplied by the myocardial density (taken as 1.05 g/cm
3). All CMR 
measurements were adjusted for total BSA, creating the following indexed quantities: 
LVESV index (LVESVI), LVEDV index (LVEDVI), LV mass index (LVMI) and LV 
infarct volume index.
262 
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2.6.2  First-pass perfusion and early microvascular obstruction analysis 
Quantitative analysis of the size and extent of both the first-pass defect and early 
MVO tends to be imprecise as it requires multiple geometric assumptions due to the 
limited number of SA slices acquired during ultrafast imaging. Such quantitative 
analysis was not performed in this study. In purely qualitative terms, the presence or 
absence of a first-pass defect and/or early MVO was recorded for each scan, but no 
further analysis of these images was performed. 
 
2.6.3  Analysis of delayed hyper-enhanced images 
Analysis of the delayed enhancement images was also performed using Argus 
software (Siemens, Erlangen). The perimeter of the hyper-enhanced region on each 
SA slice was traced by one observer (RW); Argus software facilitated summation of 
the volume of enhanced tissue from each slice, producing a measure of infarct volume 
(ml). The mass of hyper-enhanced tissue could be calculated by multiplication of the 
volume by the myocardial density factor (1.05g/cm
3). 
 
One major issue relevant to analysis of late hyper-enhanced images pertains to partial 
volume effect.
263 The thickness of each slice is 8mm, but within this the pattern of late 
hyper-enhancement is not homogeneous. This irregularity can result in blurring of the 
infarct border. Towards the periphery of the hyper-enhanced area in some slices, 
therefore, regions are occasionally seen wherein the brightness level is intermediate 
between normal (black, nulled) myocardium and bright, hyper-enhanced myocardium. 
There is a lack of universal consensus on whether (and how) to account for this partial 
volume effect in the quantitative measurement of late hyper-enhanced tissue. In this 
study, in keeping with departmental policy and in order to maintain consistency in our   93 
results, we decided to include everything that was hyper-enhanced, taking no account 
of partial volume effects.  
 
2.6.4  Infarct characteristics 
For each patient, infarct volume and mass were calculated on all three LGE-CMR 
scans. In addition, in the initial (acute) LGE-CMR scan, the anatomical location, 
transmurality and endocardial extent of the infarct were recorded, as was the presence 
or absence of late MVO. If present, the region of hypo-enhancement representing late 
MVO was manually planimetered in identical fashion to the delayed LGE-CMR 
images. 
 
Definitions: 
Infarcted LV myocardium on LGE-CMR was defined as regional delayed hyper-
enhancement involving at least the subendocardium (Figure 2.3 A).  
 
Early MVO was defined as the appearance of at least one segment of hypo-
enhancement surrounded by hyper-enhancement on images acquired between 2 and 5 
minutes post contrast.
250 
  
Late MVO was defined as late hypo-enhancement within a hyper-enhanced region on 
the LGE-CMR images which persisted for ≥10minutes after contrast injection (Figure 
2.3 B).
264, 265  
 
The anatomical location of the infarct was based on the AHA standardised 17-
segment model (Figure 2.4).
266 Infarct location was categorised as anterior, lateral or   94 
inferior, defined as the location containing the highest percentage of infarcted 
myocardium. 
 
 
Figure 2.4  17-segment AHA model depicting anatomic segments on short-axis CMR images.
266   
 
Infarct transmurality was calculated by visually deciding the transmural extent per 
segment in quarters (1 - 1-25%, 2 – 26-50%, 3 – 51-75%, 4 – 76-100%) and 
calculating the mean. This produced a transmurality score.
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Endocardial extent of the infarct was calculated by measuring the circumferential 
extent of the infarct at each of the three SA slices used in the AHA segmentation 
model, and calculating the mean.
266     
 
LV thrombi were defined as filling defects within the LV cavity, typically adherent to 
regions of hypokinesis/akinesis, which displayed a constant (low) signal intensity 
during first-pass imaging, and which on delayed-enhancement imaging were readily 
distinguishable from scarred myocardium (Chapter 9).   95 
2.7  Coronary angiography 
Decisions regarding diagnostic coronary angiography and/or PCI were made by the 
consultant cardiologist in charge of each patient and were independent of the trial. 
When undertaken, a qualitative report of the procedure was made available 
(performed by at least one experienced observer unrelated to the trial). For descriptive 
purposes, we have defined a significant stenosis as ≥70% luminal narrowing, 
moderate disease as 50-74%, mild disease as 25-49% and normal as <25% or plaque 
disease only. Where possible, the culprit vessel was identified and whether or not PCI 
was undertaken was recorded. Successful culprit vessel PCI was defined as 
Thrombolysis In Myocardial Infarction (TIMI) 3 flow at the end of the procedure, 
with no residual stenosis >50% (TIMI Grade Flow defined in Appendix IX). 
 
2.8  Blood sampling 
Venepuncture was performed as early as was feasible after enrolment. In total 50ml of 
venous blood was withdrawn and aliquotted into a variety of collecting tubes for 
individual biomarker analysis, described below. In an ideal setting, all samples would 
have been performed in fasting patients at the same time of day (early in the morning) 
to account for the diurnal variation in certain neurohomones, particularly those of the 
RAAS. Despite the best efforts of the investigators, the very nature of the patients 
involved in this trial and the fact that it was based on an acute ward made this difficult. 
A minority of samples were therefore taken in the afternoons, and frequently the 
patients were not fasted. The investigators did ensure, however, that all neurohormone 
samples were taken after 15-20 minutes of supine rest. 
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2.8.1  Measurement of BNP and NTproBNP 
Blood for BNP and NTproBNP analysis was collected in chilled tubes containing 
potassium ethylenediamine-tetraacetic acid (EDTA) [1mg/ml blood] and aprotinin (50 
KIU/ml blood) and centrifuged immediately at 3000 rpm for 15 minutes at ambient 
temperature. Plasma was extracted and frozen in aliquots at -70
oC until batched 
analysis in a blinded fashion. BNP was measured using a radioimmunoradiometric 
assay (Shionoria kit, CIS France). The CV for this assay was <5%, with a limit of 
detection of 1pg/ml. NTproBNP was measured using a chemiluminescent assay kit 
(Roche Diagnostics) on an Elecsys 2010 autoanalyser (CV <2%, limit of detection of 
5pg/ml). 
 
2.8.2  Measurement of noradrenaline and AVP 
Blood for NA and AVP was collected in lithium heparin (20 U/ml) tubes and 
centrifuged immediately at 3000 rpm for 15 minutes at ambient temperature. Plasma 
was extracted in aliquots and frozen at -70
oC until blinded batched analysis. Plasma 
NA was assayed by high performance liquid chromatography and electrochemical 
detection; the within and between assay CV were both <10%, and the normal range in 
healthy volunteers is < 4nmol/l. AVP was measured by radioimmunoassay; the assay 
sensitivity was 0.5pg/ml. Both were previously-validated in-house assays.
267, 268 
 
2.8.3  Measurement of plasma renin concentration (PRC) and aldosterone 
After 15-20 minutes of supine rest, blood was withdrawn into tubes containing 
potassium EDTA (1mg/ml blood) for measurement of plasma renin concentration 
(PRC) and aldosterone. Both samples per patient were centrifuged at 3000 bpm for 15 
minutes at ambient temperature. Aliquots of separated plasma were then frozen at -  97 
20
oC until batched, blinded analysis.  Plasma aldosterone concentration was measured 
using a solid phase (coated tube) radioimmunoassay kit (Diagnostic Products 
Corporation UK Ltd). Intra- and inter batch precision was <10% over the sample 
concentration range.  
PRC level was measured by chemiluminescent immunoassay using the Diasorin S.p.A 
(Italy) method on the Liaison platform. Intra- and inter-batch precision was <10% 
over the sample concentration range.  
2.8.4  Measurement of MMPs and TIMPs 
Blood for MMP and TIMP analysis was collected in chilled tubes containing 
potassium EDTA (1mg/ml blood) and aprotinin (50 KIU/ml blood) and centrifuged 
immediately at 3000 rpm for 15 minutes at ambient temperature. Plasma was 
extracted and frozen in aliquots at -20
oC in the WIG until later blinded batched 
analysis. After study completion, the frozen samples from the entire cohort were 
transferred to the Department of Cardiovascular Sciences, Leicester Royal Infirmary, 
where measurement of the MMPs and TIMPs was performed by Dr. Iain Squire. 
Plasma concentrations of MMP-2, -3 and -9 and TIMP-1, -2 and -4 were measured 
using commercially-available enzyme-linked immunoabsorbent assays (ELISA), 
Amersham Ltd., Amersham, UK. Each plasma concentration listed in the results 
section represents the mean of duplicate measurements. The intra- and inter-assay CV 
was <10% for all six assays. 
 
2.8.5  Measurement of cytokines 
Blood for cytokine analysis was collected in plain tubes and allowed to clot at room 
temperature. Samples were then centrifuged at 3000 rpm for 15 minutes at ambient   98 
temperature, and the supernatant serum aliquotted into Eppendorff tubes, prior to 
being frozen and stored at -20
oC until later blinded batched analysis. 
Serum cytokines were analysed in a 20-plex human cytokine assay (Biosource, 
Invitrogen) for simultaneous quantification of eotaxin, RANTES, IL-1Ra, IL-2R, IL-4, 
IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p40), IL-15, IP-10, MIG, MIP-1α, MIP-1β, MCP-
1 and TNFα. This assay was run according to the manufacturer's procedure and read 
on the Bio-Plex suspension array system.  
2.8.6  Measurement of serum soluble ST2 
Blood for sST2 analysis was collected in plain tubes and allowed to clot at room 
temperature. Samples were then centrifuged at 3000 rpm for 15 minutes at ambient 
temperature, and the supernatant serum immediately frozen and stored at -70
oC until 
later blinded batched analysis. Serum sST2 was quantified using a human IL-1 
R4/ST2 ELISA (R&D Systems), with a lower limit of detection of 32 pg/ml.
269 
 
2.8.7  Measurement of tPA antigen and vWF 
Blood for tPA antigen and vWF was collected into potassium citrate-containing tubes 
and centrifuged within one hour at 3000 rpm for 15 minutes at ambient temperature. 
Plasma was extracted and stored at -70
oC until batched blinded analysis after 
completion of the trial. tPA antigen was measured with a commercially available 
ELISA kit manufactured by Hyphen Biomed (Neuville-sur-Oise, France); the CV for 
this assay was 9% across the entire range. vWF was measured using an in-house 
ELISA using antibodies obtained from DAKO plc. (High Wycombe, UK), for which 
the CV was 7% across the entire range. 
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2.8.8  Measurement of apelin 
Venous blood samples were collected in potassium EDTA-containing tubes (1mg/ml 
blood).  The samples were then spun at 3000 rpm for 15 mins at ambient temperature 
and plasma extracted and frozen in aliquots at -70
oC until analysis. Apelin assays 
were performed using the Apelin-12 microplate ELISA assay kit (Phoenix 
Pharmaceuticals) according to the manufacturer’s instructions. The antibody used in 
this apelin assay cross-reacts 100% with Apelin-12, 13 and 36. The assay therefore 
included each of these peptides if present in plasma. 
 
As we are the first group to characterise plasma apelin following AMI in man, we 
used a control population for comparison of plasma apelin concentration. This control 
population consisted of 32 patients with no history of cardiac events, and a normal 
ECG, TTE and NTproBNP concentration, data kindly donated by Dr. KS Chong 
(Scottish National Advanced Heart Failure Service, Glasgow Royal Infirmary). 
Although the control apelin samples were analysed in a separate batch from the study 
patients, the methodology in sample preparation and analysis was identical, and was 
performed using the same equipment in the same laboratory. 
 
As this was a first-in-man study, we not only examined the variations in plasma 
concentrations of apelin that occur after AMI but also the relationship between apelin 
and LV remodelling, and the inter-relationships between plasma apelin and other 
peptide neurohormones of interest: NTproBNP, NA and AVP. 
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2.8.9  Measurement of urinary steroid metabolites 
After completion of each 24-hour urinary collection, total volume was noted and a 
20ml aliquot withdrawn into a plain universal container which was immediately 
frozen and stored at -20
oC until blinded, batched analysis after completion of the trial. 
Extraction of urinary steroids was performed using a Sep-pak C18 cartridge (Waters, 
USA), and 24-hour excretion rates of each steroid were determined by gas 
chromatography-mass spectrometry (performed by Ms. Mary Ingram, Glasgow 
Cardiovascular Research Centre), using the method of Shackleton.
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2.8.10  Genetic analysis of aldosterone synthase (CYP11B2) 
Genomic deoxyribonucleic acid (DNA) was extracted from leucocytes using a 
variation of the method of Sambrook.
271 Samples of whole blood, withdrawn (into 
EDTA-containing tubes) at the time of recruitment into the trial and stored at -20
oC 
until batched analysis after trial completion, were gently warmed and 40 ml of cell 
lysis mix added prior to centrifugation at 1660g for 10 minutes at 4°C. The resulting 
pellet was re-suspended in nucleic lysis mix, with 10% sodium dodecyl sulphate and 
proteinase K added, and incubated overnight at 37°C. Following the addition of 1 ml 
of 6-molar sodium chloride and 5 ml of phenol:chloroform:isoamyl alcohol, the 
samples were again centrifuged at 1660g for 20 minutes at 4°C. The supernatant was 
removed and ethanol added. DNA was spooled out with a glass rod, washed in 70% 
ethanol, allowed to air dry and then suspended in buffer and stored at 4°C. Genomic 
DNA extraction was kindly performed by Dr. Gordon Inglis. 
 
DNA was quantified spectrophotometrically using a NanoDrop ND1000 (Nanodrop, 
USA). Polymerase chain reaction (PCR) was then performed, in which a fragment of   101 
the CYP11B2 promoter region was amplified using Thermo-Start DNA Polymerase 
(ABGene, UK). The quality of the extracted DNA was confirmed by electrophoresis 
on agarose gels, and PCR product clean-up performed by treating the remaining PCR 
product with AMPure (Agencourt, USA) according to the manufacturer’s published 
instructions. The resultant purified product was then transferred to a new PCR plate, 
and DNA sequencing was performed using the BigDye Terminator v3.1 (Applied 
Biosystems, USA).  A second clean-up was performed using CleanSEQ (Agencourt, 
USA) according to the manufacturer’s published instructions. 
 
In the final phase, the DNA sequencing reaction products were analysed using an 
Applied Biosystems automated DNA sequencer. The sequencing results were 
analysed using SeqScape Version 2.1.1. 
 
The above experimental work and analysis was performed entirely by Dr. Gordon 
Inglis, Dr. Eleanor Davies and Matthew Rutherford, within the British Heart 
Foundation Glasgow Cardiovascular Research Centre, under the overall supervision 
of Professor John MC Connell. I had no personal role in the laboratory-based genetic 
sequencing and analysis, but performed all analysis of results relevant to this thesis. 
 
2.9  ECGs and Holter monitors 
Digital ECGs scanned or recorded at 4 time-points (acute admission, CMR scan 1, 
CMR scan 2 and CMR scan 3) were sent to a core lab in Duke University Medical 
Centre, North Carolina, USA, as were the Holter monitors (performed pre-
randomisation and at 3 months in all patients). These data are being used in 
conjunction with other ECG-CMR studies from Europe and USA to improve the   102 
understanding of the evolution of myocardial infarction on CMR, and have provided a 
number of sub-studies which have generated several abstracts and should result in 
future publications, but are not included in this thesis. 
 
2.10  Funding of the trial 
The trial was funded by a research grant from Pfizer UK, who additionally provided 
the WIG Pharmacy Clinical Trials Unit with the study drug and matched placebo.  
 
2.11  Conduct and monitoring of the trial 
The trial was sponsored by the North Glasgow University Hospitals NHS Trust, 
which arranged quality control assessments at regular intervals throughout via 
independent auditors. Annual safety reports were additionally submitted to the 
Medicines and Healthcare Regulatory Authority (MHRA).    
 
The general practitioners (GPs) of patients involved in the trial were informed in 
writing of their inclusion (Appendix IV), and were provided with several telephone 
numbers and an e-mail address for any queries regarding the trial. Patients were 
provided with a laminated trial card and advised to keep this with them at all times. 
Adverse events – both serious and unexpected – are defined in Appendix V. All 
adverse events were reported to one investigator (RW) either directly by the patients 
or via the GP. If any adverse event was deemed to be serious and unexpected (by RW 
in collaboration with either Prof. HJ Dargie or Prof. JJV McMurray) it was reported to 
the MHRA within 7 working days. All adverse events were recorded in the case report 
form which was created for each patient and stored in a locked room in the WIG 
Cardiology Department.   103 
 
The trial protocol was approved by the local ethics committee, and is registered on 
www.clinicaltrials.gov ID: NCT00132093. The study complies with the Declaration 
of Helsinki. 
 
2.12  Pharmacovigilance 
This is covered in Appendix VI. 
 
2.13  Statistical methods 
The statistical methodology pertaining to each study in this thesis is described 
separately, within the relevant chapters. 
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Chapter 3 
 
A study of the effects of eplerenone on left ventricular 
remodelling after acute myocardial infarction 
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3.1  Introduction 
In response to AMI, through a combination of mechanical triggers and neurohormonal 
activation, morphologic changes occur within the left ventricle as part of an adaptive 
response to the acute decrease in cardiac output, but over time this process of 
remodelling becomes maladaptive, as discussed earlier. Aldosterone has been strongly 
implicated in the pathogenesis of post-infarction remodelling, in particular the 
development of both replacement and reactive fibrosis within infarcted and non-
infarct zone myocardium respectively.
54-59 Aldosterone antagonism reduces 
cardiovascular morbidity and mortality in advanced CHF, and in survivors of AMI 
with resultant LVSD and heart failure (or diabetes mellitus).
121, 123 At the time of 
writing this thesis, however, the effects of aldosterone antagonsim on post-infarction 
remodelling were uncertain, with confliciting data arising from a series of (small) 
clinical trials.
94, 129-131 Variations in the definition of remodelling, and in the 
reproducibility of the imaging modalities used to assess serial change in LV function 
have, to an extent, undermined previous trials.  
 
This study was designed to determine the effects of the selective mineralocorticoid 
receptor antagonist eplerenone on LV remodelling (defined as the change in LVESVI) 
in survivors of AMI with resultant LVSD but without heart failure (or diabetes 
mellitus) over 24 weeks, using CMR as the imaging modality. This was the primary 
end-point. The effects of eplerenone on change in LVEDVI, LVEF, LVMI and, 
through delayed, contrast-enhanced imaging, change in infarct volume were included 
as secondary end-points. 
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3.2  Methods 
 
3.2.1  Recruitment of patients 
The study cohort consisted of 100 patients admitted with AMI with no evidence of 
heart failure nor prior history of diabetes mellitus, all of whom were required to have 
LVEF <40% on screening echocardiography. Following baseline investigations 
including LGE-CMR scanning, the patients were randomised in a double-blinded 1:1 
fashion to placebo or eplerenone, and followed up over 24 weeks. LGE-CMR 
scanning was repeated at 12 and 24 weeks. Inclusion/exclusion criteria, methodology 
of screening, recruitment, randomisation to study drug, and trial protocols have been 
described in detail in Chapter 2 (2.1 – 2.3). 
 
3.2.2  Echocardiography and LGE-CMR techniques and analysis 
Screening echocardiography was performed as described in Chapter 2 (2.4). All 
recruited patients were studied using the CMR techniques described in detail in 
Chapter 2 (2.5), and CMR analysis was performed as described in Chapter 2 (2.6). 
 
3.2.3  Statistical methods 
The primary outcome of LV remodelling was defined as the between treatment 
difference in change in LVESV between baseline and 24 weeks. Within the Glasgow 
Cardiac Magnetic Resonance Unit (based in the Western Infirmary) we have a wealth 
of (non-BSA-indexed) CMR volumetric data from the follow-up of patients with AMI 
either for clinical purposes or enrolled in previous research trials, using which I 
calculated that 45 patients per treatment group would provide around 90% power to 
detect a treatment difference of 10ml in LVESV (α level 0.05). A total sample size of   107 
100 was therefore chosen to allow a 10% discontinuation rate due to deaths and drop-
outs. Only patients with both a baseline and 24-week follow-up scan were analysed 
and this was done on an intention-to-treat basis. Inter-group comparisons were made 
using paired sample t-tests for continuous variables and Chi-squared test for 
categorical variables. Paired t-tests were used to detect changes in LGE-CMR 
measurements within each treatment group over the 24 weeks of the study, and 
differences between these changes were analysed using an unpaired t test. A 
probability value of p<0.05 was considered significant. 
 
There was a pre-specified plan to adjust for covariates that were imbalanced at 
baseline, namely the use of a stepwise selection model to select baseline variables 
predictive of the primary outcome with a p value <0.10. The variables selected in this 
manner were then inserted into a linear regression analysis model to adjust the trial 
end-points for the baseline imbalances.  
 
All statistical analyses were performed using SPSS version 15.0 (SPSS Inc., Chicago, 
Illinois, USA). Professor Ian Ford was consulted prior to commencement of the 
project and acted as a statistical co-supervisor throughout. In particular, he was 
instrumental in constructing the statistical strategy employed, including verification of 
the power calculations, pre-specification of the covariate adjustment methodology and 
assistance in the post hoc analysis of results, in addition to co-authoring the primary 
results manuscript of the thesis. 
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3.3  Patient demographics 
 
3.3.1  Screening 
Commencing in April 2005, a total of 420 consecutive patients either admitted or 
transferred to the WIG with AMI were screened to obtain the target study population 
(n=100). Recruitment was completed in April 2006, and follow-up was finally 
completed in September 2006. 
 
   
Figure 3.1  Bar chart displaying the outcomes of the 420 patients screened during the trial 
recruitment phase. * LVEF ≥40% in patients with neither diabetes mellitus nor heart failure. For 
breakdown of the “Other” column, see text. [Key:  HF – heart failure; DM – diabetes mellitus] 
 
44 of the 420 patients screened (10.5%) had established diabetes mellitus and 66 
(15.7%) displayed clinical and/or radiological heart failure and were thus excluded; 
screening TTE was not performed in these patients. Of the remaining 310 patients, 
146 (47.1%) had LVEF ≥40%, 17 (5.5%) were excluded on the grounds of dementia, 
frailty or neuropsychiatric disturbance, 16 (5.2%) had a serum creatinine >220µmol/l,   109 
10 (3.2%) refused, 7 (2.3%) had MRI-incompatible ferrous prostheses, 7 (2.3%) 
required in-patient CABG, 3 (1.0%) died prior to screening and 4 (1.3%) were 
excluded due to chronic therapy with the CYP3A4 inducer carbamazepine (n=1), 
primary biliary cirrhosis (n=1), Addison’s disease (n=1) and refractory postural 
hypotension (n=1). The remaining 100 patients constituted the study cohort. The 
screening log is depicted graphically in Figure 3.1.  
 
Of relevance, a total of 256 patients underwent screening TTE with satisfactory image 
quality for analysis; of these 146 (57.0%) had LVEF ≥40% and 110 (43.0%) had 
LVEF <40%. 
 
3.3.2  Baseline characteristics   
For the entire study cohort of 100 patients, the mean age (standard deviation [SD]) 
was 58.9 (12.1) years and the majority (77%) were male, findings consistent with 
contemporary AMI studies including EPHESUS.
123 Within the study population 7 
patients (7%) had sustained a previous MI, 5 (5%) had undergone prior CABG 
surgery and 2 (2%) had undergone PCI. An echocardiogram had been performed on 
each patient with a prior cardiac event or intervention, at some point in time between 
that previous event and the index AMI that led to inclusion in this study, confirming 
unimpaired LV systolic function prior to the index AMI, ie. none of the 100 patients 
enrolled in this study were known to have pre-existing LVSD.  
 
The characteristics of the infarct are described in detail in Chapter 6; 89 patients (89%) 
sustained STEMI while 11 (11%) suffered non-STEMI (NSTEMI). On admission 12-
lead ECG criteria, the site of the AMI was anterior (± lateral) in 55% and inferior (±   110 
posterior) in 45%. Cardiovascular risk factor profile included cigarette smoking in 55 
(55%), hypertension in 35 (35%) and dyslipidaemia (defined as serum total 
cholesterol >5mmol/l and/or on lipid-lowering therapy prior to admission) in 25 
(25%). 6 patients (6%) had suffered a previous cerebrovascular event, while in 37 
(37%) patients a first-degree relative had been diagnosed with CHD at an age <60 
years. 
 
 
Baseline demographic data according to treatment group (eplerenone or placebo) are 
shown in Table 3.1. 
 
 
          Eplerenone    Placebo      p 
              (n=50)     (n=50) 
Patient characteristics 
  Age (years)      61.0 (12.0)    56.8 (12.0)  0.081 
  Male        37 (74%)      40 (80%)   0.481   
  BMI (kg/m
2)      31.2 (4.5)    30.5 (4.0)  0.364 
AMI characteristics 
Type:   STEMI /       44 (88%)      45 (90%)   
      NSTEMI          6 (12%)                5 (10%)  0.752 
Site:  Anterior (± lateral) /    27 (54%) /    28 (56%) / 
     Inferior (± posterior)       23 (46%)         22 (44%)  0.843 
Haemodynamics 
  Blood pressure (mmHg) 
    Systolic    114.5 (16.8)    111.5 (15.8)  0.363 
    Diastolic    71.2 (13.7)    68.7 (9.8)  0.295 
  Heart rate (bpm)    66.6 (14.6)    65.1 (14.0)  0.582 
Medical history 
  Previous AMI     3.0 (6.0%)    4.0 (8.0%)  0.699 
  Previous CABG    3.0 (6.0%)    2.0 (4.0%)  0.650 
  Previous PCI      1.0 (2.0%)    1.0 (2.0%)  1.000 
  Angina       16.0 (32.0%)    23.0 (46.0%)  0.154 
  Current smoker    23.0 (46.0%)    32.0 (64.0%)  0.072 
  Hypertension      22.0 (44.0%)    13.0 (26.0%)  0.060 
  Dyslipidaemia*    16.0 (32.0%)    9.0 (18.0%)  0.108 
  Diabetes mellitus    0        0         - 
  Previous stroke/TIA    2.0 (4.0%)    4.0 (8.0%)  0.405 
  Family history of CHD<60  15.0 (30.0%)    22.0 (44.0%)  0.128   111 
Time intervals relevant to admission 
  Time from symptom  
  onset to admission (hrs)  12.9 (36.7)    11.7 (33.6)  0.860 
Time from symptom 
  onset to 1
st CMR scan (hrs)  90.7 (49.6)    103.6 (65.7)  0.271 
Time from AMI to study 
  drug (days)      4.7 (2.2)    5.0 (2.2)  0.584 
Treatment 
  Thrombolysis     26.0 (52.0%)    28.0 (56.0%)  0.692 
  Primary PCI      12.0 (24.0%)    15.0 (30.0%)  0.367 
  Rescue PCI      14.0 (28.0%)    12.0 (24.0%)  0.652  
  Angiography performed  42.0 (84.0%)    43.0 (86.0%)  0.782 
  PCI performed      38.0 (76.0%)    36.0 (72.0%)  0.652 
  Glycoprotein IIbIIIa use  26.0 (52.0%)    15.0 (30.0%)  0.020 
ceCMR parameters  
  LVESVI (ml/m
2)    38.9 (10.2)    48.7 (17.7)  0.001 
  LVEDVI (ml/m
2)    79.7 (12.7)    89.0 (21.3)  0.009 
  LVEF (%)
∆      51.5 (8.2)    46.4 (8.5)  0.003 
  LVMI (g/m
2)      71.1 (11.6)    77.8 (17.1)  0.024 
  Infarct volume index (ml/m
2) 31.4 (19.4)    35.0 (22.0)  0.381 
Laboratory values 
  eGFR
†       67.1 (15.5)    73.3 (19.5)  0.084 
  Creatinine (µmol/l)    101.5 (18.4)    98.7 (24.0)  0.520 
  Urea (mmol/l)     6.7 (2.5)    6.4 (2.8)  0.583 
  Serum potassium (mmol/l)  4.1 (0.4)    4.2 (0.3)  0.383 
Admission medication 
  Aspirin      16.0 (32.0%)    7.0 (14.0%)  0.033 
  Beta blocker      14.0 (28.0%)    4.0 (8.0%)  0.009 
  ACE inhibitor or ARB  6.0 (12.0%)    6.0 (12.0%)  1.000 
  Statin        10.0 (20.0%)    5.0 (10.0%)  0.165 
Discharge medication 
  Aspirin      47.0 (94.0%)    49.0 (98.0%)  0.312 
  Clopidogrel      42.0 (84.0%)    40.0 (80.0%)  0.607 
  β-blocker      48.0 (96.0%)    45.0 (90.0%)  0.244 
  ACE inhibitor or ARB  47.0 (94.0%)    47.0 (94.0%)  1.000 
  Statin        50.0 (100%)    48.0 (96.0%)  0.156 
  Frusemide      9.0 (18.0%)    12.0 (24.0%)  0.466 
 
Table 3.1  Baseline characteristics of study population, by treatment group. Data are presented 
as mean (SD) for continuous variables and number (%) for categorical variables. Inter-group 
comparisons were made using paired sample t-tests for continuous variables and Chi-squared 
test for categorical variables. * serum cholesterol >5mmol/l and/or on lipid-lowering therapy 
prior to admission; † eGFR is estimated glomerular filtration rate, calculated using the 
Modification of Diet in Renal Disease (MDRD) formula; ∆
 normal range on CMR 58-68% .   
 
       
There were, by chance, significant differences between the treatment groups (Table 
3.1). Patients were significantly mismatched with respect to baseline LV mass and   112 
function. Patients in the eplerenone group had a significantly lower mean LVESVI 
(38.9 [10.2] v 48.7 [17.7] ml/m
2, p=0.001), LVEDVI (79.7 [12.7] v 89.0 [21.3] ml/m
2, 
p=0.009) and LVMI (71.1 [11.6] v 77.8 [17.1] g/m
2, p=0.024), and a significantly 
higher LVEF (51.5 [8.2] v 46.4 [8.5] %, p=0.003) than those in the placebo group. 
Infarct volume did not differ significantly between treatment groups.  
 
Although there were no significant inter-group differences in the proportion of 
patients undergoing PCI, there was significantly greater use of glycoprotein IIb/IIIa 
inhibitors in the eplerenone-treated patients, in whom there was additionally a 
significantly greater uptake of aspirin and β-blockers at baseline compared to the 
placebo group. The patients in both treatment groups had unimpaired baseline renal 
function in general. 
 
3.3.3  Treatment of AMI 
During the time-period over which recruitment took place (April 2005 – April 2006), 
there was no designated primary PCI service in place for the management of STEMI 
in the North Glasgow University Hospitals NHS Trust. Policy regarding acute 
reperfusion in STEMI was to use thrombolytic therapy as the first-line treatment 
unless there was an obvious contraindication or the patient had presented to hospital 
more than 12 hours after symptom onset; primary PCI was indicated in these 
circumstances. In September 2005, the thrombolytic window was shortened to 6 hours 
after symptom onset, after which primary PCI was indicated. Throughout the 
recruitment phase, the policy of immediate transfer for ‘rescue’ PCI should 
thrombolytic therapy have failed to effect satisfactory reperfusion (defined as peak 
ST-segment resolution of at least 50% with symptomatic improvement) was adopted.   113 
 
Across the entire cohort, 89 patients (89%) sustained STEMI. Thrombolytic therapy 
was used in 54 patients (54%), of whom 26 (26%) required rescue PCI. Primary PCI 
was the acute reperfusion strategy employed in 27 (27%). 8 patients (8%) were 
admitted with STEMI but received no acute reperfusion therapy: 3 patients (3%) 
presented later than 24 hours after onset of symptoms with persisting ST-segment 
elevation but, in view of resolution of symptoms together with clinical and 
haemodynamic stability, the decision against primary PCI was made by the duty 
interventional consultant cardiologist; 1 patient (1%) was transferred from a 
peripheral hospital for consideration of primary PCI but this was not performed as the 
ECG ST-segment changes had resolved by the time of transfer and the patient was 
symptom-free and stable; in 4 patients (4%) the initial ST-segment elevation had been 
missed by the general physicians under whom the patients were initially admitted thus 
no acute reperfusion was undertaken. 
 
In-patient diagnostic coronary angiography was performed in 85% of the cohort, with 
follow-on PCI being undertaken in 74% (Appendix VII). Patients requiring in-patient 
CABG were excluded. The uptake of standard secondary preventive therapies was 
exceptionally high: discharge prescription included aspirin in 96%, clopidogrel in 
82%, β-blocker in 93%, ACE inhibitor or ARB in 94% and a statin in 98%. Despite 
the protocol-mandated absence of clinical or radiological heart failure at 
randomisation, 21 patients (21%) were ultimately discharged on a loop diuretic at the 
discretion of the ward team.  
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3.3.4  Patient disposition 
The placebo and eplerenone randomisation groups each contained 50 patients. 93 
patients completed the entire 24 week follow-up. Of the 7 who failed to complete, 3 
patients died (all in the eplerenone group – Appendix VIII), 2 patients had devices 
inserted which precluded further CMR scanning (VVI pacemaker in an eplerenone 
group patient and an ICD in a placebo group patient), and 2 patients, both in the 
placebo group, voluntarily withdrew their consent. One patient, in the placebo group, 
permanently discontinued study drug due to nausea after 14 days but participated in 
all other aspects of the trial. Paired analysis was therefore performed on 46/50 in the 
eplerenone group and 47/50 in the placebo group. The mean time from AMI to 
screening TTE for all study patients was 33.6 hours, and from AMI to first CMR scan 
was 97.2 hours; study drug was commenced at a mean of 4.8 days after AMI. There 
were no between-group differences in any of these parameters. The mean daily doses 
of eplerenone and placebo achieved in the study patients were 43.7mg and 41.8mg 
respectively. 
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3.4  Effects of eplerenone on ceCMR parameters 
 
3.4.1  Effects on LVESVI 
Within the placebo group there was very little change in LVESVI over the study 
period, with a mean LVESVI at baseline of 48.6 ml/m
2 and at 24 weeks of  48.7 
ml/m
2 (p=0.97). In the eplerenone group, the mean LVESVI decreased from 38.4 
ml/m
2 to 37.4 ml/m
2 (p=0.58) over the 24-week follow-up. Although LVESVI 
decreased in the eplerenone group and increased slightly in the placebo group (Figure 
3.2), this effect was non-significant (eplerenone -1.0 ml/m
2 v placebo +0.1 ml/m
2, 
p=0.72). 
 
Figure 3.2  Mean (±SEM) changes from baseline in LVESVI (at 12 and 24 weeks from 
randomisation) according to treatment group. Unadjusted and covariate-adjusted treatment 
effect listed. 
 
The eplerenone group had significantly smaller LV volumes and higher LVEFs at 
baseline compared to the placebo group. There were also significant imbalances in 
certain other baseline variables (Table 3.1). Using the covariate adjustment strategy   116 
described in the statistical methods section, and inserting all variables listed in Table 
3.1 into the model, fifteen were selected and utilised to adjust the LGE-CMR results 
for the baseline differences (Table 3.2). Following adjustment, the treatment effect 
(SD) of eplerenone compared to placebo over 24 weeks on LVESVI was -6.1 (2.7) 
ml/m
2 (p=0.027). 
 
 
 
 
 
 Table 3.2  Baseline variables selected for covariate adjustment 
 
 
 
 
 
 
 
 
 
 
 
 
 
LVESVI  Age  Thrombolysed 
LVEDVI  Hypertension  Glycoprotein IIb/IIIa inhibitor used 
LVEF  Dyslipidaemia  eGFR 
LVMI   Previous CABG  Aspirin on admission 
LV Infarct Volume  Current smoker  β-blocker on admission   117 
3.4.2  Effects on LVEDVI 
Mean LVEDVI in the placebo group increased significantly from 88.6 ml/m
2 to 94.9 
ml/m
2 (p=0.02), while in eplerenone-treated patients it rose from 79.0 ml/m
2 to 81.2 
ml/m
2 (p=0.27) over the 24-week follow-up. There was no significant between-group 
treatment effect of eplerenone on LVEDVI (eplerenone +2.2 ml/m
2 v placebo +6.2 
ml/m
2, p=0.23), but the covariate-adjusted treatment effect was significant (-7.5 [3.4] 
ml/m
2, p=0.031) – Figure 3.3. 
 
 
Figure 3.3  Mean (±SEM) changes from baseline in LVEDVI (at 12 and 24 weeks from 
randomisation) according to treatment group. Unadjusted and covariate-adjusted treatment 
effect listed. 
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3.4.3  Effects on LVEF 
Mean LVEF increased significantly over the course of the study in both treatment 
groups (Figure 10), from 46.3% to 50.7% (p=0.01) in the placebo group and from 
51.7% to 55.3% (p=0.005) in the eplerenone group. There was no significant 
treatment effect of eplerenone on LVEF (eplerenone +3.6% v placebo +4.4%, p=0.71). 
Following covariate adjustment the treatment effect remained non-significant (+2.5 
[1.8] %, p=0.181). 
 
 
 
 
Figure 3.4  Mean (±SEM) changes from baseline in LVEF (at 12 and 24 weeks from 
randomisation) according to treatment group. Unadjusted and covariate-adjusted treatment 
effect listed. 
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3.4.4  Effects on LVMI 
Mean LVMI decreased significantly within each treatment group over 24 weeks 
(Figure 3.5). In placebo-treated patients. LVMI fell from 78.1 g/m
2 to 69.7 g/m
2 
(p<0.001) and in eplerenone-treated patients, from 70.7 g/m
2 to 64.4 g/m
2 (p<0.001). 
There was no significant between-group treatment effect (eplerenone -6.2 g/m
2 v 
placebo -8.4 g/m
2, p=0.31), and this remained non-significant after covariate 
adjustment (-1.0 [2.2] g/m
2, p=0.660). 
 
 
 
 
Figure 3.5  Mean (±SEM) changes from baseline in LVMI (at 12 and 24 weeks from 
randomisation) according to treatment group. Unadjusted and covariate-adjusted treatment 
effect listed. 
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3.4.5  Effects on LV infarct volume index 
Mean LV infarct volume index fell significantly within each treatment group (Figure 
12), from 36.4 ml/m
2 to 22.5 ml/m
2 (p<0.001) in the placebo group and from 31.5 
ml/m
2 to 19.4 ml/m
2 (p<0.001) in the eplerenone group. There was no significant 
inter-group difference in ∆ LV infarct volume index (eplerenone -12.1 ml/m
2 v 
placebo -14.0 ml/m
2, p=0.50). After covariate adjustment the treatment effect 
remained non-significant (-0.9 [1.9] ml/m
2, p=0.626). 
 
 
Figure 3.6  Mean (±SEM) changes from baseline in LV infarct volume index (at 12 and 24 
weeks from randomisation) according to treatment group. Unadjusted and covariate-adjusted 
treatment effect listed. 
 
 
3.5  Adverse events, safety and tolerability of eplerenone 
Renal function and serum potassium 
There were no significant differences in serum creatinine, potassium or eGFR 
between treatment groups at baseline. None of these changed significantly during 
follow-up in either treatment group and there were no between-treatment differences 
in any of these measures (Appendix VIII).      121 
Serious adverse events 
Three eplerenone patients died during follow-up: one from ventricular fibrillation on 
day 7, one from a stroke at 8 weeks and one after a recurrent AMI in a separate 
coronary arterial territory at 5 months, confirmed at autopsy; no placebo-treated 
patient died. A small number of patients in each treatment group were re-admitted 
with biomarker-negative chest pain, recurrent AMI, heart failure or possible 
arrhythmia (documented in only two patients, both in the placebo group: atrial 
fibrillation in one, ventricular tachycardia in another) – Appendix VIII.   
 
Other adverse events, safety and tolerability 
Three patients in each group developed transient postural hypotension in the first few 
days after starting study drug which settled in each case. At 24 weeks, mean blood 
pressure increased by 10.8/1.6mmHg in the eplerenone group and by 10.8/2.6mmHg 
in the placebo group (between-treatment difference p=0.69). Mean heart rate 
decreased by 7.4bpm in the eplerenone group and by 6.1bpm in the placebo group 
(p=0.66). Serum potassium >5.5 but <6.0 mmol/l occurred in two patients, both on 
eplerenone and both were successfully rechallenged after temporary cessation of 
study drug. Serum potassium <3.5 mmol/l occurred in two placebo-treated patients. 
No patient required cessation of study drug due to worsening renal function or 
developed gynaecomastia. One placebo-treated patient permanently discontinued 
study drug due to non-specific symptoms. 
 
 
 
   122 
3.6  Discussion 
 
3.6.1  Study population 
In any study designed to examine the serial change in a particular biophysiological 
variable it is important to examine the substrate on which the research is based. The 
demography, acute management and chronic treatment of this study population need 
to be placed in context by comparison with contemporary trials of LV remodelling 
after AMI in humans. The mean age of patients in this study was just under 60 and the 
overwhelming majority were male, findings consistent with several contemporary 
AMI and remodelling studies.
272-278 The pre-specified recruitment strategy excluded 
patients with known LVSD; in the small number who had suffered a prior MI or who 
had undergone prior PCI or CABG (total 12%), we stipulated that a LVEF >40% had 
to have been confirmed on a cardiac imaging study performed at some point in time 
between the prior cardiac event and the index AMI that led to recruitment in this study. 
In comparison to the trial populations in recent post-infarction LV remodelling studies, 
we therefore obtained a ‘clean’ cohort of patients without known pre-existing LVSD. 
In contrast to our cohort, the CAPRICORN investigators reported a 25% incidence of 
prior MI (but no note of any previous LV functional assessment) in the 127 patients 
enrolled in an echo sub-study examining the effects of carvedilol on LV remodelling 
after AMI, with similar incidences of prior known CHD in imaging sub-studies of the 
Carvedilol Heart Attack Pilot Study (CHAPS) and the Healing and Early Afterload 
Reducing Therapy (HEART) study.
273-276 
 
89 of the 100 patients in our study cohort suffered STEMI which was acutely 
reperfused in 81 (91%) via thrombolytic or primary PCI. Overall coronary   123 
angiography was undertaken in 85% and PCI in 74%. In comparison, while the early 
β blocker studies of LV remodelling employed a high uptake of thrombolytic therapy 
(97%) prior to commencement of carvedilol, in the CAPRICORN echo sub-study, 
published in 2004, there was only a 41% rate of thrombolytic and/or PCI, while in the 
HEART echo sub-study only 72% were thrombolysed prior to assessing the effects of 
the ACE inhibitor ramipril on LV remodelling after AMI.
273-276    
 
Historically, remodelling studies examining the effects of ACE inhibitors or β 
blockers in AMI have necessarily been placebo-controlled thus only half of the 
patients receive the active drug. Although the uptake of ACE inhibitor therapy was 
very high at 93% in the CAPRICORN echo sub-study, only 50% received 
carvedilol.
273 Earlier remodelling studies employed significantly lower prescriptions 
of known anti-remodelling medications.
272, 274 The discharge prescription of β 
blockers was 93% and of ACE inhibitors or ARBs 94% within our study cohort. 
There was also a very high uptake of statins, which have been shown in experimental 
AMI in rats to attenuate LV remodelling, although there are no such data in 
humans.
279 
 
The study population under investigation in this thesis therefore represents a very 
well-treated cohort with a very high acute revascularisation rate, almost universal 
uptake of current evidence-based anti-remodelling therapies, and, as each patient had 
5 post-discharge trial visits to the Western Infirmary during their 24-week 
participation in the study, a very closely monitored group of patients. These factors 
must be kept in mind when attempting to assess the additional benefits on LV 
remodelling of the study drug.   124 
 
3.6.2  The effects of eplerenone on LV remodelling 
The study was designed to determine the effect of eplerenone on LV remodelling in a 
cohort of patients with AMI and resultant LVSD, but neither heart failure nor diabetes 
mellitus, over 24 weeks. Not only were there, by chance, significant baseline 
imbalances between treatment groups, there was also little evidence of remodelling 
(defined as ∆LVESVI) in this population of AMI patients treated aggressively with 
contemporary therapies. Across the entire cohort of 93 patients who completed the 24-
week follow-up, mean (SD) LVESVI did not vary significantly over time: 43.6 (15.2) 
ml/m
2 at baseline vs. 43.1 (20.7) ml/m
2 at 24 weeks, p = 0.77. Eplerenone did not 
significantly affect the pre-specified primary end-point and was only noted to exert an 
anti-remodelling effect after adjustment for 15 baseline covariates. While these were 
selected using an appropriate statistical strategy, the results of a 100-patient study 
corrected for multiple covariates must be treated with caution. That the primary end-
point was not met implies that eplerenone did not exert a significant anti-remodelling 
effect in the srudy population. Nonetheless there was a slight divergence between 
treatment groups in the primary end-point (∆LVESVI) occurring despite the superior 
baseline LV function in the eplerenone group. 
 
Despite the greater predictive accuracy in determining survival after AMI of LVESV 
over LVEDV (and even LVEF), a number of studies have defined remodelling as 
serial change in LVEDV rather than LVESV.
22, 130, 131 LVEDVI increased 
significantly over time in our study cohort as a whole, from 83.9 (18.0) ml/m
2 at 
baseline to 88.1 (23.0) ml/m
2 at 24 weeks, p = 0.011. When analysed by treatment 
allocation, although LVEDVI increased significantly in the placebo group but not in   125 
the eplerenone group, the between-treatment difference, again, was only significant 
after covariate adjustment. 
 
An increase in LVESVI after AMI is a powerful predictor of poor clinical outcomes, 
and attenuation of this change is associated with improved prognosis.
22 The magnitude 
of the adjusted between-treatment differences in LV volumes in this study (6.1 and 
7.5 ml/m
2 for LVESVI and LVEDVI respectively) compares favourably with prior 
remodelling trials despite differences in AMI management and LV assessment. Early 
studies using captopril <48 hours after Q-wave AMI (72% thrombolysed, baseline 
LVEF 40.7%) showed significant reductions of 8.0 and 10.4 ml/m
2 in LVESVI and 
LVEDVI respectively over 3 months compared to placebo.
280 A meta-analysis of 
three studies from the early 1990s showed small, non-significant changes of 0.5 ml/m
2 
in both LVESVI and LVEDVI with ACE inhibitor use over 3 months after 
thrombolysed AMI, although ACE inhibitors did significantly attenuate remodelling 
in the non-reperfused sub-group.
281 A further meta-analysis of 8 studies from the 
1980s and 1990s revealed small but significant reductions of 3.3 and 4.2 ml in 
LVESV and LVEDV respectively over 6-12 months in patients with LVEF ≤45% 
after AMI.
282 More recently, the Perindopril and Remodeling in Elderly with Acute 
Myocardial Infarction (PREAMI) study showed a significant attenuation of 3.3 ml in 
LVEDV in 631 elderly patients with LVEF ≥40% treated with perindopril compared 
to placebo.
283  In a well-treated cohort of patients with a high uptake of anti-
remodelling therapies, I have shown comparable, significant effects on covariate-
adjusted LV volumes over 6 months using eplerenone. However, while the magnitude 
and direction of this covariate-adjusted treatment effect is similar to the effect of ACE 
inhibitors in such prior remodelling studies, the unadjusted data do not support a   126 
significant treatment effect of aldosterone antagonism on top of ACE inhibitor/β 
blocker therapy in this setting. 
 
The use of LGE-CMR in this study afforded in vivo visualisation of abnormal regions 
of myocardium consistent with infarction.
245-247 TTE, the imaging modality employed 
in the majority of AMI remodelling studies, can only indirectly estimate infarcted 
myocardium via wall motion scoring and regional wall thickening indices.
275, 276 
While infarct volume fell significantly over time in each treatment group, there was 
no significant between-treatment difference in ∆ infarct volume even after covariate-
adjustment. This may appear counter-intuitive given the covariate-adjusted effect of 
eplerenone on serial change in LV volumes. However, early administration of 
eplerenone has been shown to reduce reactive fibrosis in viable myocardium distant 
from the infarct site but to have no effect on reparative fibrosis, which is necessary for 
the structural integrity of the healing scar, in experimental AMI in rats.
106 That 
eplerenone does not reduce infarct volume more than placebo over time may represent 
the lack of drug effect on the reparative fibrosis within the infarct site. 
 
Reactive fibrosis in non-infarct zone myocardium should be detectable on delayed 
LGE-CMR imaging, as this technique simply indicates that the normal fluid 
homeostasis within the abnormal region has been disrupted (section 1.11.3). 
Anecdotally, no evidence of non-infarct fibrosis was observed during the 24-week 
follow-up of our study patients, in whom LGE-CMR images were obtained at all 3 
time-points. Reactive fibrosis is a phenomenon frequently seen within the first few 
months after experimental AMI in rodent models and is attenuated by ACE inhibitors, 
presumably via reduction in angiotensin II (and thus aldosterone) and possibly via   127 
down-regulation of mineralocorticoid receptor expression in the heart and kidney.
106, 
284, 285 In humans, indirect evidence of such fibrosis has been provided by, for example, 
attenuation of increases in markers of collagen matrix turnover (eg. PIIINP in the 
RALES study, suggesting an anti-fibrotic effect of spironolactone in patients with 
advanced CHF).
121 That no macroscopic evidence of such reactive fibrosis in non-
infarct sites was seen in our study population may reflect the high uptake of 
antagonists of the RAAS. Alternatively, the process of non-infarct zone fibrosis may 
be more chronic in humans and may have been missed by the relatively short 24-week 
follow-up. 
 
3.6.3  Safety profile of eplerenone in patients presenting with AMI and LVSD 
The study was not powered to examine major clinical end-points thus the events listed 
in Appendix VIII are purely descriptive. In an appropriately-powered study 
(EPHESUS), eplerenone clearly reduced cardiovascular death and hospitalisation in 
patients with LVSD and heart failure, or diabetes mellitus, following AMI.
123, 286 That 
the 3 strokes recorded during follow-up all occurred in eplerenone-treated patients in 
our study must be treated with caution, however, as a non-significant excess of stroke 
was seen in the EPHESUS study despite the significant morbidity and mortality 
reductions.
123 
 
Eplerenone was well-tolerated biochemically in this study, with no significant change 
in serum creatinine, eGFR or serum potassium in either treatment group, although it is 
noteworthy that renal function was normal at baseline across the cohort. In contrast, 
small but significant increases in creatinine and potassium were seen with the use of 
spironolactone in RALES (serum creatinine increased by 4-9 µmol/l and potassium by   128 
0.30 mmol/l relative to placebo, p<0.001) and eplerenone in EPHESUS (serum 
creatinine increased by 3.5 µmol/l and potassium by 0.10 mmol/l relative to placebo, 
p<0.001).
121, 123 Both studies used the same renal function cut-off for patient inclusion 
as in this study (serum creatinine ≤220 µmol/l) 
 
In our study cohort, although the absolute number of patients randomised to 
eplerenone was small (n=50), the use of the drug in conjunction with an ACE 
inhibitor and β blocker early after AMI in patients with LVSD was safe and well-
tolerated. 
 
3.6.4  Limitations 
The major limitation of this study is the dependence of the primary results on 
covariate adjustment, which calls into question the validity of these results. Such 
adjustment was necessary, however, due to the significant imbalances in LV volumes, 
mass and function between the treatment groups at baseline. The plan to adjust for any 
baseline imbalance was pre-specified. We did not pre-specify stratification of 
randomisation on LGE-CMR outcomes; retrospective analysis of the randomisation 
process (performed in conjunction with Professor Ian Ford), in chronological order of 
index event, failed to reveal any aberrant patterns in treatment allocation. 
 
The pre-specified statistical strategy excluded those with an incomplete dataset. Had 
the worst outcome been assigned to those who died, all 3 of whom were in the 
eplerenone group, such a strategy may have eliminated an effect of active therapy on 
remodelling (even after covariate adjustment). 
   129 
The marked baseline imbalance in LV function is unfortunate, and suggests a 
potentially important biologic imbalance: placebo-treated patients were perhaps 
pathophysiologically more likely to remodel to a greater extent than eplerenone-
treated patients due to poorer baseline LV function. That there is a divergence in 
∆LVESVI between treatment groups in favour of eplerenone despite the superior LV 
function in patients randomised to eplerenone at baseline, is nonetheless encouraging 
and does suggest an anti-remodelling effect of eplerenone. 
 
3.6.5  Conclusions 
Aggressive management of this cohort of AMI patients with reduced LVEF using 
contemporary therapies (exclusive of aldosterone antagonists) resulted in very little 
adverse ventricular remodelling over 24 weeks. Eplerenone had no significant effect 
on remodelling prior to covariate adjustment. While such statistical adjustment was 
necessary due to significant baseline imbalances, the potential anti-remodelling 
effects of eplerenone must be interpreted with caution. Nevertheless, there was a 
divergence in ∆LVESVI in favour of a beneficial anti-remodelling effect of 
eplerenone compared to placebo. These results suggest that larger studies powered to 
detect an improvement in clinical outcomes in a broader patient population than that 
enrolled in EPHESUS may be worthwhile, ie. patients with ‘asymptomatic’ LVSD, 
irrespective of heart failure status or diabetes mellitus. 
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Chapter 4 
 
A study of the use of biomarkers in the prediction of left 
ventricular functional recovery after acute myocardial 
infarction 
 
 
 
 
 
 
 
 
 
 
   131 
4.1  Introduction 
Patients with limited functional recovery early after AMI resulting in a persistently 
reduced LVEF constitute a population at high risk of malignant arrhythmias, adverse 
remodelling, progressive LV dilatation and dysfunction, and premature death as 
previously described. The use of predictive biomarkers to identify such high-risk 
patients is gaining popularity as these patients require stringent monitoring, and may 
qualify for device therapies such as implanted cardioverter defibrillators. Additionally, 
certain management decisions depend on an adequate knowledge of the LVEF, but as 
discussed earlier the estimates of LVEF provided by various commonly-used imaging 
modalities are by no means interchangeable, particularly in patients with LVSD 
(Chapter 1.11.1). CMR imaging is now recognised as the gold standard means of LV 
structural and functional assessment; that this technique does not depend on geometric 
assumptions makes it particularly reproducible in those with LVSD (Chapter 1.11.1). 
 
The patients enrolled in the clinical trial on which this thesis is based constitute an 
ideal population in which to analyse the relationships of a variety of biomarkers with 
serial change in LV volumes and function, as each patient had been admitted with 
AMI, was required to have LVSD, and underwent serial LGE-CMR imaging over 24 
weeks. 
 
The aim of this study was to attempt to enhance the risk stratification process of 
survivors of AMI with resultant LVSD by examining the relationships between a 
variety of biomarkers measured early after AMI and post-infarction remodelling 
(measured using serial LGE-CMR), the effects of eplerenone on each biomarker, and 
whether these biomarkers could be used to predict adverse remodelling.     132 
4.2  Methods 
 
4.2.1  Study patients and trial protocol 
The study cohort consisted of 100 patients admitted with AMI, with LVEF <40% on 
screening TTE but without heart failure or diabetes mellitus. Patients were 
randomised in a double-blinded 1:1 fashion to placebo or eplerenone, and followed up 
serially over 24 weeks. The screening, recruitment, randomisation process and trial 
outline are described in detail in Chapter 2 (2.1 – 2.3), and baseline demographic data 
of the study cohort are shown in Table 3.1. 
 
ceCMR imaging was performed at baseline (pre-randomisation), 12 and 24 weeks; the 
methods of imaging and analysis are described in detail in Chapter 2 (2.5 – 2.6). 
Venepuncture for measurement of circulating biomarkers was also performed at 
baseline (pre-randomisation) and again at 12 and 24 weeks. Individual methods of 
sample collection, storage and analysis are described in Chapter 2 (2.8). 
 
4.2.2  Statistical methods 
Non-normally distributed biomarkers were log-transformed prior to analysis. The 
change in each biomarker over time was analysed by treatment group, and the effects 
of eplerenone on the change in each biomarker assessed. Inter-group comparisons 
were made using paired sample t-tests or Mann-Whitney-U tests as appropriate for 
continuous variables and Chi-squared test for categorical variables. Paired t-tests were 
used to detect changes in ceCMR measurements and biomarkers within each 
treatment group over the 24 weeks of the study, and differences between these   133 
changes were analysed using an unpaired t test. A probability value of p<0.05 was 
considered significant. 
 
As the randomisation groups were, by chance, significantly imbalanced in terms of 
baseline LV function (Table 3.1), the treatment effect of eplerenone on each 
biomarker was assessed before and after the pre-specified covariate-adjustment 
strategy described in Chapter 3 (3.2.3). In brief, variables predictive (p < 0.10) of the 
primary outcome of the study (i.e. remodelling, defined as change in LVESVI), 
identified via stepwise selection, were inserted into a linear regression analysis model 
in order to adjust the treatment effect of eplerenone on each biomarker for the 
baseline imbalance in LV function. 
 
Biomarkers exhibiting logarithmic-normal distribution were log-transformed prior to 
parametric correlation and multivariable analysis. Pearson’s correlation co-efficients 
were then computed for baseline biomarker concentrations with changes in three LV 
parameters – LVESVI, LVEDVI and LVEF – from 0 to 24 weeks. Clinical variables 
predictive of LV remodelling (∆LVESVI) were selected by inserting all baseline 
clinical variables into stepwise linear regression analysis. Multivariable regression 
models were then constructed using the forward selection of the baseline biomarkers 
selected as significant (p < 0.05) univariable predictors of LVESVI at 24 weeks, and 
adjusted for these clinical predictors. 
 
All statistical analyses were performed using SPSS version 15.0 (SPSS Inc., Chicago, 
Illinois, USA) under the guidance of Professor Ian Ford. 
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4.3  Biomarker concentrations after AMI, and the effects of treatment with 
eplerenone 
 
Venepuncture for measurement of cardiac biomarkers was performed at a mean 3.7 
days (SD 1.8 days; range 1-12 days) after AMI. 
 
4.3.1  The effects of eplerenone on peptide neurohormones 
Baseline values of the neurohormones BNP, NTproBNP, NA and AVP according to 
treatment group are shown in Table 4.1. Due to the wide range of NTproBNP values, 
a logarithmic transformation was undertaken.   
 
 
Table 4.1   Plasma concentrations of peptide neurohormones at baseline (mean 3.7 days after 
AMI) according to randomisation group. Data are expressed as mean (SD). Normal reference 
ranges provided within relevant sub-sections below. 
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BNP 
BNP was elevated at baseline in both treatment groups (Table 4.1; normal range <100 
pg/ml). There was no significant inter-group difference in baseline BNP. Within each 
treatment group, BNP levels fell significantly over the 24-week follow-up (Figure 4.1). 
Using data from only those patients who completed follow-up, mean BNP fell from 
236.5 pg/ml to 139.8 pg/ml (p=0.003) in the placebo group and from 248.6 pg/ml to 
100.4 pg/ml (p<0.001) in the eplerenone group. The unadjusted treatment effect of 
eplerenone on BNP compared to placebo was non-significant (eplerenone -148.1 
pg/ml v placebo -96.7 pg/ml, p=0.155), although there was a trend towards a 
continuing reduction in BNP in the eplerenone group from three to six months (Figure 
4.1). Following adjustment for the covariates listed in Table 3.2, the treatment effect 
of eplerenone remained non-significant: the adjusted treatment effect (SD) on BNP 
was -35.0 (39.6) pg/ml (p=0.380). 
 
 
Figure 4.1  Mean (±SEM) changes from baseline in BNP (at 12 and 24 weeks from 
randomisation) according to treatment group. Unadjusted and covariate-adjusted treatment 
effect listed. 
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NTproBNP 
NTproBNP was elevated in both treatment groups at baseline but with no significant 
inter-group differences (Table 4.1; normal range <125 pg/ml). Within each treatment 
group, NTproBNP levels decreased significantly during follow-up. In the placebo 
group, mean NTproBNP fell from 2526.1 pg/ml to 909.7 pg/ml over 24 weeks 
(p<0.001), while in the eplerenone group, the mean NTproBNP fell from 2649.2 
pg/ml to 773.1 pg/ml over the same time period (p<0.001). Following logarithmic 
transformation, mean log10(NTproBNP) decreased from 3.24 to 2.55 units (p<0.001) 
in the placebo group and from 3.28 to 2.59 units (p<0.001) in the eplerenone group 
over the 24-week follow-up (Figure 4.2).     
    
 
 
Figure 4.2  Mean (±SEM) changes from baseline in log10NTproBNP (at 12 and 24 weeks 
from randomisation) according to treatment group. Unadjusted and covariate-adjusted 
treatment effect listed. 
 
The unadjusted treatment effect of eplerenone on NTproBNP compared to placebo 
was non-significant, and remained non-significant after adjustment for the covariates   137 
listed in Table 3.2: unadjusted treatment effect (eplerenone  -1876.1 pg/ml v placebo -
1616.3 pg/ml, p=0.512); adjusted treatment effect (SD) -124.9 (317.5) pg/ml, p=0.695. 
Similarly, using the logarithmic scale, the unadjusted treatment effect of eplerenone 
on log10(NTproBNP) was non-significant and remained so after covariate adjustment: 
unadjusted treatment effect (eplerenone -0.69 units v placebo -0.68 units, p=0.930); 
adjusted treatment effect (SD) -0.24 (0.190), p=0.209 (Figure 4.2).        
 
 
Figure 4.3  Mean (±SEM) changes from baseline in (A) noradrenaline and (B) AVP at 12 and 
24 weeks from randomisation according to treatment group.  
 
Noradrenaline (NA) 
NA levels were at the upper limit of normal at baseline; there was no significant 
baseline imbalance between treatment groups (Table 4.1; normal range <4nmol/l). 
Within both groups, NA levels fell over time (Figure 4.3 A). In the placebo group, 
mean NA decreased significantly from 3.18 nmol/l to 2.74 nmol/l (p=0.013), while in 
the eplerenone group it fell from 3.03 nmol/l to 2.82 nmol/l (p=0.348). Eplerenone did 
not exert a significant treatment effect on unadjusted NA levels over the 24 week 
follow-up (eplerenone -0.21 [1.49] nmol/l v placebo -0.44 [1.86] nmol/l, p=0.174). 
Following covariate adjustment, this treatment effect remained non-significant (+0.24 
[0.23] nmol/l, p=0.309).    138 
AVP 
Serum AVP levels were within normal limits at baseline and were well-matched 
between treatment groups (Table 4.1; normal range 0.2-2.2pg/ml). AVP decreased 
significantly over the 24 week follow-up in both groups (Figure 15B). Within the 
placebo group mean AVP decreased from 0.87 pg/ml to 0.65 pg/ml (p=0.001), and 
from 0.88 pg/ml at baseline to 0.62 pg/ml at 24 weeks in the eplerenone group 
(p=0.004). Eplerenone had no significant treatment effect on serum AVP levels either 
before or after adjustment: unadjusted (eplerenone -0.26 [0.55] pg/ml v placebo -0.21 
[0.72] pg/ml, p=0.789); adjusted treatment effect (SD): +0.14 (0.13) pg/ml, p=0.294 
 
4.3.2  The effects of eplerenone on hormones of the RAAS: 
 
 
Table 4.2  Plasma concentrations of plasma renin concentration, aldosterone and 
aldosterone:renin ratio at baseline (mean 3.7 days after AMI) according to randomisation 
group. Data are expressed as mean (SD), and represent the results of all participants in the 
study pre-randomisation (n=100).   
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PRC and aldosterone 
At baseline there were no significant differences in PRC or plasma aldosterone 
between treatment groups (Table 4.2). PRC increased in both treatment groups over 
the study period (Figure 4.4 A); the change within each group approached 
significance. In the placebo group, mean PRC increased from 117.7 uIU/ml to 215.2 
uIU/ml (p=0.064) over 24 weeks; in the eplerenone group PRC increased from 156.7 
uIU/ml to 305.8 uIU/ml (p=0.071). The unadjusted treatment effect of eplerenone on 
PRC was non-significant (eplerenone +149.2 [547.0] uIU/ml v placebo +97.5 [352.6] 
uIU/ml, p=0.589) and failed to achieve significance after covariate adjustment (+98.2 
[121.7] uIU/ml, p=0.423).  
 
 
Figure 4.4  Mean (±SEM) changes from baseline in (A) plasma renin concentration (PRC) 
and (B) plasma aldosterone at 12 and 24 weeks from randomisation according to treatment 
group.  
 
 
Conversely, plasma aldosterone did not change significantly within the placebo group 
although there was a trend towards a decrease over time (from 235.3 pmol/l to 186.5 
pmol/l, p=0.238) but rose significantly within the eplerenone group, from 180.0 
pmol/l to 287.9 pmol/l (p=0.006) over the study period (Figure 4.4 B). There was a   140 
significant treatment effect of eplerenone on serum aldosterone (eplerenone +107.9 
[248.3] pmol/l v placebo -48.8 [279.4] pmol/l, p=0.006) which remained significant 
after covariate adjustment (+130.0 [52.2] pmol/l, p=0.015).  
 
Aldosterone to renin ratio (ARR) 
ARR was significantly lower in patients in the eplerenone group compared to the 
placebo group at baseline (Table 4.2). There were no significant changes in ARR over 
time within each group. In the placebo group, mean ARR was 4.85 at baseline and 
5.89 at 24 weeks (p=0.523), and in the eplerenone group it was 2.89 at baseline and 
rose to 5.74 at 24 weeks (p=0.103). Eplerenone had no significant treatment effect 
either before (eplerenone +2.85 [11.3] v placebo +1.04 [11.1], p=0.445) or after 
(+0.43 [3.0], p=0.888) covariate adjustment. 
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4.3.3  The effects of eplerenone on MMPs / TIMPs: 
Each of the sampled MMPs and TIMPs was elevated at baseline compared to a 
reference control population (data kindly provided by Professor LL Ng, Leicester 
Royal Infirmary, who performed the MMP and TIMP assays); changes in each 
biomarker over time are shown in Figure 4.5. 
 
 
 
   
 
 
Plasma MMP-2, MMP-3, MMP-9 and TIMP-1, TIMP-2 and TIMP-4 levels were 
well-matched between treatment groups at baseline (Table 4.3).    
 
 
Figure  4.5  Plasma  concentrations  of  the 
sampled  MMPs  and  TIMPs  at  baseline,  12 
and 24 weeks after AMI. Data expressed as 
means (SEM). *p<0.05  **p<0.001 compared 
to baseline value.   142 
 
 
Normal  Eplerenone group   Placebo group 
Biomarker    Range  *           mean (SD)           mean (SD)                 p 
MMP-2  10-20      24.0 (11.4)      24.2 (11.7)    0.745 
MMP-3  2.0-5.0     6.07 (2.80)      6.32 (3.40)    0.669 
MMP-9  30-60      243.2 (247.1)     271.6 (295.9)   0.782 
TIMP-1  3-10      132.8 (88.4)      118.5 (108.8)   0.532 
TIMP-2  20-60      72.4 (22.1)      73.8 (93.0)    0.821 
TIMP-4  1.0-3.0     3.38 (3.72)      11.3 (58.7)    0.352 
Table 4.3  Plasma concentrations of each MMP and TIMP at baseline, by randomisation group. Values 
are expressed as mean (SD) and represent the results of all participants in the study pre-randomisation 
(n=100). All units are ng/mL. Reference (control) population values kindly donated by Professor LL 
Ng, Leicester Royal Infirmary. 
 
 
MMP-2 and MMP-3 levels were modestly elevated at baseline and remained high at 
24 weeks (Table 4.3, Figure 4.5). MMP-9 concentration was highly elevated at 
baseline, and although it fell significantly over time, remained high at 24 weeks. 
TIMP-1 concentration was elevated at baseline and decreased significantly over time; 
TIMP-2 concentration was modestly elevated and increased significantly, while 
TIMP-4 remained elevated throughout with no significant change over time (Table 
4.3, Figure 4.5). Correlations between MMPs, TIMPs and LV parameters are shown 
in Table 4.4.   143 
 
Table 4.4  Pearson correlation co-efficients for each MMP/TIMP (baseline sample only) and 
parameters of LV function / infarct volume at baseline and 24 weeks, following Bonferroni correction. 
Correlation co-efficients are also listed for the relationship between each biomarker at baseline and 
change in each measured ceCMR parameter.   *p<0.05   **p<0.01 
 
 
Eplerenone was associated with a fall in MMP-2 in addition to a greater increase in 
MMP-3 and a lesser reduction in MMP-9 compared to placebo-treated patients, but 
these effects were non-significant (Table 4.5). Following covariate adjustment, 
however, the effects of eplerenone on MMP-2 (-6.22 [3.00] ng/ml, p=0.039) and 
MMP-9 (+72.6 [37.1] ng/ml, p=0.046) were significant (Table 4.5). There was no   144 
significant treatment effect of eplerenone on TIMP-1, TIMP-2 or TIMP-4 over the 24 
weeks follow-up either before or after covariate adjustment (Table 4.5). 
 
                    Adjusted 
    Eplerenone group  Placebo group      treatment 
Biomarker    ∆ marker (SD)  ∆ marker (SD)       p         effect         p* 
 
MMP-2     -0.35 (14.8)              +2.82 (13.0)     0.275    -6.22 (3.00)      0.039 
MMP-3     +0.67 (3.21)   +0.07 (2.83)     0.342    +0.04 (0.64)       0.947 
MMP-9     -83.2 (304.5)  -143.7 (301.1)    0.338    +72.6 (37.1)       0.046 
TIMP-1     -32.0 (94.4)    -21.6 (122.1)     0.648     +10.1 (17.1)    0.555 
TIMP-2     +17.2 (22.3)   +19.2 (33.0)     0.739    -5.1 (7.0)       0.464 
TIMP-4     +1.47 (2.91)   +4.25 (21.00)     0.381     +0.36 (1.25)    0.771 
Table 4.5  Change between baseline and 24 weeks in sampled MMPs/TIMPs. All measurements in 
ng/ml. [∆ marker (SD) – change over 24 weeks in each marker; p* - p value for covariate-adjusted 
treatment effect of eplerenone on each biomarker] 
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4.3.4  The effects of eplerenone on cytokines:  
 
 
 
 
Baseline value 
mean (SEM) 
 
 
Change between 
baseline and 24 weeks 
mean (SEM) 
 
 
 
Cytokines 
Eplerenone  Placebo 
 
 
 
p 
Eplerenone  Placebo 
 
 
 
p 
Covariate-
adjusted 
treatment 
effect 
mean 
(SEM) 
 
 
 
p 
Eotaxin  134.5 
(8.8) 
159.0 
(10.5) 
0.078  55.0 
(9.7) 
46.8 
(9.0) 
0.538  -0.33 
(15.73) 
0.983 
RANTES  178904 
(44107) 
178441 
(144152) 
0.994  -24536 
(44220) 
48673 
(67474) 
0.367  -15876 
(92651) 
0.864 
IL-1Ra  157.6 
(55.9) 
798.0 
(380.6) 
0.099  -35.0 
(15.0) 
-167.3 
(72.1) 
0.076  -3.4 
(38.3) 
0.930 
IL-2R  62.2 
(4.6) 
113.0 
(47.3) 
0.288  -4.4 
(2.5) 
-24.1 
(21.2) 
0.358  -0.32 
(3.90) 
0.934 
IL-4  15.2 
(0.3) 
16.9 
(0.3) 
0.306  -0.02 
(0.30) 
-0.96 
(0.79) 
0.280  0.21 
(0.29) 
0.461 
IL-5  1.09 
(0.05) 
6.57 
(5.10) 
0.286  -0.11 
(0.0.05) 
-0.20 
(0.14) 
0.522  -0.006 
(0.056) 
0.918 
IL-6  33.9 
(4.3) 
61.1 
(18.1) 
0.148  -26.8 
(4.3) 
-30.6 
(7.1) 
0.647  -7.3 
(6.2) 
0.243 
IL-7  55.1 
(2.4) 
59.8 
(5.3) 
0.419  6.4 
(3.5) 
3.5 
(3.9) 
0.585  7.78 
(4.93) 
0.119 
IL-8  40.5 
(9.6) 
40.6 
(7.4) 
0.992  -7.5 
(10.5) 
-7.7 
(7.9) 
0.988  2.32 
(2.47) 
0.349 
IL-10  26.6 
(10.8) 
29.4 
(10.4) 
0.851  -11.6 
(10.6) 
-0.2 
(5.2) 
0.335  -18.3 
(8.6) 
0.036 
IL-12p40  152.0 
(12.8) 
324.2 
(107.8) 
0.116  45.2 
(18.3) 
-9.7 
(57.5) 
0.365  -15.4 
(29.5) 
0.603 
IL-15  14.1 
(1.6) 
70.3 
(36.3) 
0.126  -2.8 
(1.1) 
-31.0 
(18.8) 
0.138  -0.37 
(1.57) 
0.814 
IP-10  37.7 
(7.6) 
37.4 
(9.2) 
0.977  11.6 
(13.1) 
-1.8 
(6.5) 
0.363  15.1 
(14.0) 
0.287 
MIG  52.5 
(6.9) 
81.5 
(21.0) 
0.194  -7.0 
(8.1) 
-8.5 
(10.4) 
0.908  -6.3 
(11.3) 
0.576 
MIP-1α  39.5 
(1.8) 
81.6 
(27.0) 
0.123  -2.8 
(1.6) 
-19.1 
(11.6) 
0.167  -0.65 
(1.54) 
0.676 
MIP-1β  119.7 
(14.4) 
226.4 
(73.9) 
0.160  -13.1 
(7.7) 
-47.6 
(23.9) 
0.177  -4.1 
(10.0) 
0.685 
MCP  695.7 
(43.3) 
893.8 
(101.4) 
0.075  197.1  
(53.5) 
187.2 
(65.9) 
0.907  -127.0 
(80.0) 
0.117 
TNFα  1.61 
(0.43) 
17.60 
(10.92) 
0.147  -0.54 
(0.37) 
-9.38 
(6.59) 
0.184  -0.51 
(1.50) 
0.733 
 
Table 4.6  Comparison of serum cytokines at baseline, and change in each cytokine between 0 
and 24 weeks, according to randomisation group. The treatment effect of eplerenone, adjusted 
for the covariates listed in Table 4 using the statistical model described in the Methods 
Section (Chapter 3.2.3), is also shown. All data are expressed as mean (SEM). 
. 
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Baseline levels of serum cytokines were well-matched between treatment groups 
(Table 4.6). Eplerenone had no significant effect on the change in any of the measured 
cytokines over 24 weeks, compared to placebo. The only significant effect of 
eplerenone after covariate adjustment was on the anti-inflammatory chemokine IL-10, 
in which it attenuated the reduction over 24 weeks relative to placebo (p=0.036). 
 
Of note, a number of cytokines sampled at the same time-points (baseline: 3.7 ± 1.8 
days, 12 weeks, 24 weeks) were consistently below the lower limits of detection of 
the assays in both groups, including IL-13, IL-17, interferon γ, interferon α and GM-
CSF. 
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4.3.5  The effects of eplerenone on markers of haemostasis:  
 
              Eplerenone group  Placebo group 
Biomarker  Normal range             mean (SD)       mean (SD)        p 
 
vWF (iu/dl)        50-200            222.7 (55.9)      212.0 (54.8)     0.18  
 
tPA Ag (ng/ml)       1-20    7.19 (3.38)       7.52 (4.43)     0.77  
 
Table 4.7  Comparison of plasma haemostatic biomarkers at baseline according to 
randomisation group. Data are expressed as mean (SD)   
 
Initial vWF and tPA antigen (Ag) were well-matched between both groups (Table 4.7). 
vWF was elevated in both treatment groups at baseline and decreased significantly 
within each group over the 24 weeks follow-up (Figure 4.6 A). Within the placebo 
group, mean vWF fell from 212.0 iu/dl to 144.2 iu/dl (p<0.001); in the eplerenone 
group mean vWF fell from 222.7 iu/dl to 160.5 iu/dl (p<0.001). The unadjusted 
treatment effect of eplerenone on vWF was non-significant (eplerenone -62.2 [42.7] 
iu/dl v placebo -67.8 [51.8] iu/dl, p=0.597) as was the covariate-adjusted effect (+4.1 
[11.2] iu/dl, p=0.718) 
 
 
Figure 4.6  Mean (±SEM) changes from baseline in (A) plasma vWF and (B) tPA antigen at 
12 and 24 weeks from randomisation according to treatment group.   148 
tPA Ag was within normal limits in both groups at baseline and fell significantly 
within each group over the course of the 24 weeks follow-up (Figure 4.6 B). In the 
placebo group mean tPA Ag fell from 7.52 ng/ml to 5.95 ng/ml (p<0.001) and in the 
eplerenone group it fell from 7.19 ng/ml to 5.46 ng/ml (p<0.001). Eplerenone had no 
significant treatment effect on tPA Ag (eplerenone -1.72 [2.14] ng/ml v placebo -1.57 
[3.02] ng/ml, p=0.781), even after covariate adjustment (-0.36 [0.66] ng/ml, p=0.584). 
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4.4  Biomarker predictors of LV remodelling  
 
Baseline biomarker          ∆LVESVI        ∆LVEDVI        ∆LVEF 
Peptide neurohormones 
  NTproBNP†      +0.30**  +0.29**  -0.16 
  BNP†        +0.22**  +0.15    -0.21* 
  Noradrenaline      +0.05    +0.02    -0.09 
  AVP        +0.12    +0.14    -0.08 
  PRC        +0.23*    +0.15    -0.19 
  Aldosterone†      +0.21*    +0.19    -0.21* 
 
Collagen matrix markers 
  MMP-2       +0.03    +0.05    -0.08 
  MMP-3       +0.18    +0.19    -0.12 
  MMP-9       -0.09    -0.06    +0.09 
  TIMP-1       -0.06    -0.04    +0.06 
  TIMP-2       +0.26*    +0.22*    -0.13 
  TIMP-4       +0.34**  +0.36**  -0.09 
 
Haemostatic markers 
  tPA antigen      +0.38**  +0.32**  -0.23* 
  vWF        +0.27**  +0.19    -0.28** 
 
Cytokines 
  Eotaxin       -0.26*    -0.12    +0.27** 
  RANTES      -0.13    -0.18    +0.09 
  IL-1Ra       -0.03    -0.01    +0.08 
  IL-2R        -0.08    -0.09    +0.05 
  IL-4        -0.04    -0.05    +0.02 
  IL-5        -0.09    -0.09    +0.05 
  IL-6        +0.09    +0.12    +0.05 
  IL-7        -0.23*    -0.17    +0.23* 
  IL-8        +0.05    +0.09    -0.03 
  IL-10        +0.06    +0.04    -0.08 
  IL-12p40      -0.06    -0.06    +0.05 
  IL-15        -0.03    -0.02    +0.03 
  IP-10        -0.08    -0.08    +0.06 
  MIG        -0.10    -0.11    +0.11 
  MIP-1α        -0.07    -0.07    +0.05 
  MIP-1β       -0.09    -0.09    +0.06 
  MCP        -0.17    -0.12    +0.15 
  TNFα        -0.04    -0.05    +0.02 
Table 4.8  Pearson’s correlation co-efficients for each sampled biomarker at baseline with 
change in (∆) LV volumes and LVEF from baseline to 24 weeks across the entire study cohort 
(n=100). *p<0.05    **p<0.01     † log transformed  
 
   
Correlation co-efficients were computed for all biomarkers sampled at baseline with 
serial change in LV volumes and LVEF from baseline to 24 weeks, and are shown in   150 
Table 4.8. Non-normally distributed biomarker concentrations including BNP and 
NTproBNP were log-transformed prior to parametric correlation. 
 
Increased baseline concentrations of NTproBNP, BNP, PRC, aldosterone, TIMP-2, 
TIMP-4, tPA antigen and vWF, and decreased concentrations of eotaxin and IL-7, 
were significantly associated with increasing LVESVI over time. Increased BNP, 
aldosterone, tPA antigen and vWF, and decreased eotaxin and IL-7 at baseline, 
correlated with worsening LVEF over time. 
 
Multivariable analysis of biomarkers in LV remodelling 
A multivariable model adjusted for clinical predictors of LVESVI at 24 weeks, and 
fitted with those baseline biomarkers selected as univariate predictors of ∆LVESVI, 
was constructed. Significant clinical predictors of LVESVI at 24 weeks were chosen 
by inserting all baseline clinical variables listed in Table 3.1 into a stepwise selection 
model; this selected the following baseline variables as independent predictors of 
LVESVI at 24 weeks: baseline LVESVI and infarct volume, prior MI, age, smoking 
status, thrombolysis, dyslipidaemia, serum urea, and ACE inhibitor/ARB prescription 
on discharge.  
 
The multivariable analysis of a model fitted with these clinical variables and the 
baseline biomarkers selected as univariate predictors of LV remodelling revealed that 
age, baseline LVESVI, infarct volume (all p<0.001), thrombolysis (p=0.007) and 
dyslipidaemia (p=0.009) were all independent predictors of LVESVI at 24 weeks. Of 
the selected biomarkers, only TIMP-4 and tPA antigen remained in the model as   151 
significant independent predictors of LVESVI at 24 weeks, and thus LV remodelling 
(Table 4.9). 
 
 
 
 
 Variable        Multivariable β                    p   
             co-efficient 
    
Clinical 
   
  Age           0.34                  <0.001     
  Smoker                  -0.003        0.96 
  LVESVI        0.69                  <0.001 
  Infarct Volume       0.39                  <0.001 
  Thrombolysed                 -6.2        0.007 
  Prior MI       0.09        0.08 
  ACE inhibitor/ARB               -0.07        0.24 
  Hypercholesterolaemia    -6.8        0.009 
  Urea          0.09        0.14   
 
Serological 
 
  Log10 NTproBNP    -0.02        0.80 
  Log10 BNP      -0.02        0.81 
  PRC         0.05        0.44 
  Log10 aldosterone     0.03        0.64 
  TIMP-2       -0.09        0.21 
  TIMP-4        0.07        0.028 
  tPA antigen       0.78        0.019 
  vWF         0.006        0.92 
  Eotaxin       -0.09        0.11 
  IL-7        -0.1        0.075   
Table 4.9  Multivariable predictors of LVESVI at 24 weeks, separated into clinical and 
serological categories.   
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4.5  Discussion 
 
4.5.1  Prediction of LV function after AMI 
LVEF is a powerful predictor of survival after AMI. Even a single measurement of 
LVEF in patients who have sustained AMI predicts major cardiovascular outcomes 
including development of CHF, recurrent AMI and death.
22-27 Moreover, persistence 
of a depressed LVEF for >40 days following AMI is now an indication for 
consideration of implantable cardioverter defibrillator therapy (ICD).
124, 125 Selection 
of patients who would potentially qualify for ICD insertion due to persistent LVSD 
after AMI is difficult in practice, due to a number of factors. These include the lack of 
robust schemes for serial cardiac imaging after AMI to re-quantify LV function, 
marked inter-modality differences in LVEF measurement, difficulties in predicting at 
baseline the patients in whom LVEF will improve and those in whom it will fail to 
improve and/or progressively deteriorate and the lack of biomarkers that closely track 
serial change in LV function over time. Our study design provided serial follow-up 
data regarding LV function following AMI, but additionally a number of circulating 
biomarkers of relevance to the pathophysiology of post-infarction LV remodelling 
were sampled. In addition to analysing the effects of eplerenone on serial change in 
each biomarker, I also examined the significance and potential use of a single 
measurement of each biomarker early after AMI in the prediction of medium-term LV 
function. 
 
BNP and NTproBNP 
BNP and NTproBNP are powerful prognostic markers after AMI.
40, 152 Plasma 
concentrations of both natriuretic peptides were highly elevated at baseline across the   153 
entire study population and fell significantly over time (although the mean 
concentration of each remained above the normal range even at 24 weeks). 
NTproBNP had weak correlations with baseline and 24-week LVESVI and infarct 
volumes and inverse correlations with LVEF at these time-points; it also correlated 
with 24-week LVEDVI and ∆LVESVI. BNP displayed a weak inverse correlation 
with 24-week LVEF and ∆LVEF but not with any measure of LV volume; it did 
correlate weakly with baseline and 24-week infarct volume. Neither BNP nor 
NTproBNP were independent predictors of ∆LVESVI in a model fitted with clinical 
variables of statistical importance to LV remodelling. 
 
These findings agree with previous studies of natriuretic peptides and remodelling. 
While both BNP and NTproBNP are strong independent predictors of mortality in 
acute coronary syndromes (NTproBNP more so than even LVEF), their relationship 
with LV function and serial change therein after AMI is very inconsistent.
152 This 
may relate in part to the timing of neurohormone sampling. In a long-term follow-up 
CMR study, serial NTproBNP levels sampled at a mean 3.3 days after AMI (similar 
to our sampling interval) then again at 1 month, 1 year and >4 years were correlated 
with LV volumes and LVEF at least 4 years remote from the infarct.
157 Plasma 
NTproBNP at 3.3 days showed a weak correlation with chronic LVEF only (not with 
LV volumes), although much stronger correlations were noted between the 
NTproBNP samples at the 3 later sampling time-points and chronic LV volumes and 
LVEF. Similarly, serial measurements of plasma BNP over the first 30 days after 
AMI in a small study (n=30) revealed modest correlations only between day 2 BNP 
and ∆LVESVI, ∆LVEDVI and ∆LVEF over one month but much stronger 
correlations between BNP measurements sampled at later time-points in the first   154 
month (strongest at day 7) and these parameters.
156 Significant correlations between 
BNP and infarct size but not with LV volumes or LVEF were seen in a nuclear 
imaging study of 54 patients with either recent (<2 month) or remote (>6 month) 
AMI.
153 
 
It is conceivable that the strength of the relationship between natriuretic peptides and 
LV structure and function is somewhat reduced in the first few days after AMI, and 
that delaying the timing of sampling to at least day 7 might increase the accuracy of 
the natriuretic peptides in predicting remodelling, although this hypothesis is 
speculative. It is noteworthy, however, that NTproBNP correlates more powerfully 
with LVEF in patients with stable or unstable angina than in those with AMI, with the 
suggestion that the process of infarction blunts the relationship between LVEF and 
NTproBNP by influencing the production and release of natriuretic peptides.
158 
 
Eplerenone had no significant effect on BNP or NTproBNP over time in our study 
despite covariate adjustment. Interestingly, despite the significant difference in 
baseline LVEF between treatment groups, baseline natriuretic peptides were well-
matched which again suggests a dissociation between these peptides and LV function 
early after AMI. Infarct volume was well-matched between treatment groups and both 
natriuretic peptides correlated with this parameter at baseline and 24 weeks. That the 
effect of eplerenone on remodelling was at best modest overall, and that the 
relationships between the natriuretic peptides and parameters of LV function were 
weak, it is perhaps unsurprising that we did not demonstrate a treatment effect of 
eplerenone on either BNP or NTproBNP. Consistent with these findings, ramipril   155 
significantly attenuated LV remodelling after AMI in the HEART trial but in the 
neurohormonal sub-study it had no effect on BNP.
40 
 
Noradrenaline 
Plasma concentrations of NA at baseline were within the upper limits of normal, and 
fell significantly over the 24-week study period. Inverse correlations were observed 
between baseline NA and baseline and 24 week LVEF but no relationship with LV 
volumes or change in any LV functional parameter over time was seen. 
 
NA is an important effector molecule of the sympathetic nervous system, and 
circulating levels act as a marker of sympathetic activation. Experimental evidence 
suggests that NA may play an important role in triggering and potentiating 
remodelling after AMI through direct toxic effects on myocytes, activation of the 
RAAS and stimulation of pro-inflammatory cytokines and natriuretic peptides.
40, 41, 43, 
159 We sampled circulating NA only, and only at one time-point in the early post-
infarction period, thus we have no data on local tissue NA nor on any fluctuations in 
circulating NA that may have occurred prior to the first sample (mean day 3.7). 
Nonetheless, that NA was shown to correlate with lower LVEF both acutely and 
remote from the infarct does provide a weak link between circulating NA and LV 
function, although there was no association between NA and change in any parameter 
of LV function, and it had no predictive effect on remodelling on multivariable 
analysis. 
 
Eplerenone had no effect on plasma NA. As NA was not significantly elevated at 
baseline sampling, and as it does not track serial change in LV volumes or LVEF, we   156 
would not expect to observe a treatment effect of eplerenone on plasma 
concentrations of this neurohormone. Similarly, ramipril failed to influence 
circulating NA despite attenuating remodelling in the HEART neurohormonal sub-
study.
40 
 
AVP 
AVP levels remained within the normal range but declined over the course of the 
study. In keeping with prior studies I found no association between AVP and LV 
function.
166, 167 Eplerenone had no effect on plasma AVP concentration. 
 
Marked increases in plasma AVP have been documented within 6 hours of AMI 
which then decrease over time (irrespective of progression to heart failure).
163-165 The 
timecourse of activation of AVP appears to be very variable following AMI, however, 
with no relationship to activation of any other neurohormonal system (including NA, 
renin and atrial natriuretic peptide [ANP]) when sampled pre-discharge in patients 
with post-infarction LVSD.
20 Suggestions that persistent activation of AVP in such 
patients who do not display clinical heart failure following AMI (akin to our study 
cohort) may indicate those at higher risk of developing clinical complications 
including heart failure have never been supported by any robust evidence and remain 
speculative. The novel biomarker copeptin (the C-terminal component of the AVP 
pre-cursor) is believed to be more stable than AVP ex vivo, and this surrogate marker 
of AVP release may well supersede AVP assay in time, but on the strength of our data 
using AVP I found no relationship between AVP and LV remodelling.
287 
 
   157 
MMPs and TIMPs 
Each MMP and TIMP was only measured at one time-point (mean 3.7 days) in the 
early post-infarction period. I observed a number of temporal trends in MMP and 
TIMP activation which will be discussed separately. Each biomarker was well-
matched at baseline between treatment groups and was unaffected by eplerenone over 
time. Following covariate-adjustment, however, eplerenone was found to attenuate 
significantly the increase in MMP-2 and to limit the decrease in MMP-9 seen in the 
placebo group. 
 
In the study cohort, MMP-2 concentration was elevated throughout the 24 weeks, 
with no significant change over time. Baseline MMP-2 did not have any correlation 
with any LV parameter or change in LV volumes/LVEF and did not predict 
∆LVESVI. A number of studies of ventricular function and MMP:TIMP balance after 
AMI have provided variable results regarding the prognostic and functional 
significance of MMP-2 in the early post-infarction phase. Consistent with our findings, 
elevated MMP-2 concentrations out to 96 hours after AMI, bearing no relationship to 
LV volumes or LVEF, were reported in 91 patients admitted with STEMI (59% 
thrombolysed) with resultant LVSD.
181 Smaller studies, however, have reported 
inverse correlations between very early MMP-2 and LV volumes, while MMP-2 
measured 14 days after infarction has been shown to predict progressive ventricular 
dilatation.
179, 288, 289 MMP-2 may therefore have a biphasic role, protective in the first 
few days, during early remodelling, but detrimental if it remains high over the ensuing 
weeks and months. Consistent with this MMP-2 correlated inversely in a previous 
study with NTproBNP in the first few days after AMI but this relationship was lost by 
30 days.
180 Persistent MMP-2 activation therefore appears to have adverse   158 
consequences for ventricular function following AMI; although I found no 
relationships between MMP-2 and LV volumes/LVEF, I have shown that eplerenone 
reduces this biomarker over 24 weeks, albeit after covariate-adjustment. 
 
MMP-9 concentrations were highly elevated throughout the study although they 
decreased significantly over time. Baseline MMP-9 correlated with baseline and 24-
week infarct volume but not with any other LV parameter and did not predict 
remodelling. MMP-9 has been extensively investigated in man and has a very 
interesting early activation temporal profile following AMI. Peak circulating MMP-9 
occurs within 12 hours of infarction but then falls rapidly to a plateau phase, which 
persists for several months, during which MMP-9 concentration remains higher than 
normal controls.
181 A secondary peak at c.96 hours was reported by one group but this 
has not been consistently demonstrated.
179 Peak MMP-9 correlates with lower LVEF 
at baseline and greater remodelling over a mean 6 month period, but interestingly 
higher plateau MMP-9 concentrations appear protective, predicting higher LVEF and 
less change in LV volumes over time.
181 In keeping with this, peak but not plateau 
MMP-9 correlates with NTproBNP and predicts the occurrence of late-onset CHF 
after AMI.
180, 182 
 
The timing of our baseline MMP-9 sample most likely coincides with the plateau 
phase. I found that this relates to higher infarct volumes at baseline and 24 weeks, 
findings that are novel. I postulate that increased MMP-9 activity at a mean 3.7 days 
after AMI is related to wound healing. In view of the lack of correlation with LV 
volumes/LVEF it is difficult to determine whether this elevated MMP-9 activity 
represents a reparative response to a large infarct or a proteolytic consequence of   159 
extensive myocardial damage leading to destabilisation. MMP-9 null mice experience 
less early LV rupture and late remodelling after experimental AMI but many findings 
from rodent models of MMP:TIMP activation have failed to find parallels in human 
studies.
177, 178 That eplerenone, which exerted an albeit modest anti-remodelling effect 
on this population, reduced the fall in MMP-9 over time relative to placebo suggests 
that elevated MMP-9 in this (prolonged) plateau phase is beneficial, although in the 
absence of any relationship with serial LV volume/LVEF change this view is 
speculative.  
 
MMP-3 was modestly elevated at each time-point but did not vary significantly over 
time. Baseline MMP-3 correlated inversely with LVEF and positively with infarct 
volume at baseline and 24 weeks, and additionally correlated with LVESVI and 
LVEDVI at the latter time-point although it did not predict ∆LVESVI or change in 
any other LV parameter. MMP-3 specifically targets a number of key ECM proteins 
including aggrecan, fibronectin and several fibrillar collagens (mainly type III), and 
has also been demonstrated to activate several pro-MMPs (including pro-MMP-1) in 
experimental in vitro studies, yet it has been less extensively studied in humans than 
the gelatinases.
174, 290, 291 A recent TTE study of 382 patients admitted with AMI with 
resultant low LVEF, followed up over a mean of 5 months, has revealed several 
insights into the activity profile of MMP-3.
188 MMP-3 concentrations progressively 
increase between AMI and hospital discharge but fall to normal levels by 5 months. 
The authors found that the peak pre-discharge MMP-3 concentration had no 
relationship with baseline LV volumes or LVEF, but did have weak but significant 
correlations with increasing LV volumes and decreasing LVEF at follow-up. They 
also reported a predictive effect of peak pre-discharge MMP-3 on LV remodelling.   160 
Complementary to these data, and using a much more reproducible and accurate 
imaging modality, I have found that elevated MMP-3 concentration on a single 
sample measured at a mean 3.7 days after AMI does have a significant relationship to 
lower baseline LVEF and, as our imaging technique allows measurement of infarct 
volumes, I have for the first time shown a relationship between increased MMP-3 and 
higher infarct volume both acutely and at 24 weeks. In keeping with prior data, I again 
found that baseline MMP-3 predicts greater LV volumes and lower LVEF at 24 weeks. 
That MMP-3 did not have any effect on serial change in LV parameters (including 
∆LVESVI) might reflect the aggressive invasive and pharmacologic management of 
this study population (which effectively abolished remodelling across the cohort), the 
smaller number of patients in this study, or the fact that I used a solitary pre-discharge 
MMP-3 measurement rather than peak pre-discharge MMP-3; these may also explain 
the lack of treatment effect of eplerenone. Nevertheless I have shown that a single 
pre-discharge MMP-3 measurement does have a predictive effect on medium-term 
LV volumes, LVEF and infarct volume, but not remodelling per se.  
 
The role of TIMPs in humans after AMI has been less thoroughly investigated than 
that of the MMPs. I found that, in comparison to a reference control population, 
plasma TIMP-1 concentration was elevated throughout but fell significantly over time, 
TIMP-2 concentration was elevated throughout and increased significantly over time, 
while TIMP-4 concentration was elevated throughout and increased non-significantly 
between baseline and 24 weeks. TIMP-1 had no relationship with LV volumes or 
LVEF and did not predict remodelling. In contrast, baseline measures of TIMP-2 and 
TIMP-4 correlated with several LV parameters. Increased baseline TIMP-2 correlated 
with greater baseline LVEDVI, greater 24-week LVESVI and LVEDVI, and higher   161 
∆LVESVI and ∆LVEDVI. Baseline TIMP-4 correlated with baseline LVESVI, 24-
week LVESVI, LVEDVI and (inversely) LVEF in addition to greater ∆LVESVI and 
∆LVEDVI. In the multivariable model fitted with clinical variables of importance to 
remodelling, TIMP-4 but not TIMP-2 remained as an independent predictor of 
∆LVESVI. Eplerenone had no effect on any TIMP. 
 
Our findings of a persistently elevated TIMP-1 over 24 weeks with no relationship to 
LV volumes or LVEF are consistent with prior human studies.
288, 292 TIMP-1 
deficiency amplifies adverse remodelling following experimental MI in mice.
183 Its 
precise role in human ventricular remodelling remains unclear, although a correlation 
between TIMP-1 and NTproBNP has previously been reported when both biomarkers 
were simultaneously sampled 30 days after AMI.
180 
 
I observed that TIMP-2 levels increased over time. A smaller study of 32 patients with 
AMI found identical temporal trends in circulating TIMP-2 concentrations but no 
relationship with any parameter of LV function.
292 TIMP-4 levels were found to be 
reduced in that study throughout the first 6 months and to have no relationship to LV 
structure or function. In contrast I found that TIMP-4 was mildly increased throughout 
our study. No groups have found any relationship between either TIMP-2 or TIMP-4 
and LV volumes, LVEF or remodelling after AMI in humans. I present for the first 
time data that suggest that a single measure of TIMP-2 or TIMP-4 early after AMI can 
predict LV volumes and, in the case of TIMP-4, LVEF at 24 weeks, and moreover 
that a single measure of TIMP-4 early after AMI independently predicts LV 
remodelling. 
   162 
The mechanism of this predictive effect is unclear. That MMPs and TIMPs have very 
variable temporal profiles of release and activity particularly in the first few days after 
AMI is well documented. I cannot comment on circulating concentrations of any of 
the biomarkers in our study during the interval between infarction and first sampling 
which was at a mean 3.7 days after AMI. However, I propose that elevated 
concentrations of TIMP-2 and TIMP-4 at the time of first sampling may inactivate 
certain MMPs which have protective properties towards the integrity of the ECM at 
that time-period, rather than switching off aggressively proteolytic MMPs, hence the 
associations with adverse ventricular function over time. 
 
Cytokines 
Several families of cytokines were analysed in this study. Only two of the sampled 
cytokines had any relationship to remodelling. Eotaxin and IL-7, when measured at 
baseline, correlated with ∆LVEF and inversely with ∆LVESVI suggesting an 
association between these two cytokines and improved LV function over time after 
AMI. Eplerenone had no effect on either cytokine. 
 
Eotaxin (CCL11) is an eosinophil-specific chemokine produced by a variety of cell 
types and acts as a potent eosinophil chemoattractant.
293 The eotaxin receptor (CCR3) 
has been identified on a number of cell types other than eosinophils including 
macrophages, mast cells and neutrophils, ie. cells that are involved to varying extents 
in post-infarction remodelling.
294 The observation that circulating eotaxin 
concentrations were higher in patients with chronic stable angina admitted for elective 
PCI compared to control patients, and  increased transiently after PCI, led to further 
studies to investigate the potential significance of eotaxin as a vascular risk factor.
295   163 
The results of such studies have been inconsistent to date. No difference in circulating 
eotaxin was found between patients with or without atherosclerosis or prior MI, and 
eotaxin had no relationship to severity of coronary artery disease at angiography.
296, 
297 However, a large population study (n=1014) of patients with known CHD showed 
that a low level of circulating eotaxin is an independent predictor of future 
cardiovascular events.
298 Our findings complement this last study, as lower eotaxin 
concentrations early after AMI related to greater remodelling and lower LVEF over 
time in our patients, although the predictive efficacy of the chemokine was lost on 
multivariable analysis. 
 
IL-7 is predominantly a haemopoetic factor necessary for the production and release 
of various cells of the immune response, including B- and T-cells and natural killer 
cells. There are very few published data on IL-7 concentrations after AMI in man. A 
study of patients with angina (stable or unstable) showed higher plasma IL-7 levels in 
both angina sub-groups compared to normal controls, and further reported on 
associations between IL-7 and other pro-inflammatory cytokines suggesting that 
elevated IL-7 levels were deleterious and promoted atherosclerotic plaque (and thus 
clinical) instability.
299 Our findings are at odds with this, as high IL-7 levels predicted 
better functional recovery of the LV (albeit we measured this cytokine in a different 
patient population), although this predictive value was lost on multivariable analysis. 
 
The significance of our findings regarding IL-7, and indeed eotaxin, is unclear, 
particularly when the following are taken into consideration. I sampled plasma 
cytokines, and thus have no information on local (tissue) effects of each cytokine 
class. Also, venepuncture was performed once only in the early post-infarction period,   164 
and by the mean time of sampling (3.7 days), the early phase of cytokine stimulation 
(which occurs mainly in the first 24-48 hours after infarction) would have passed. 
This may explain our rather disappointing yield from the analysis of multiple classes 
of pro- and anti-inflammatory cytokines. Further study in the field of cytokine 
activation after AMI should focus on very early initial measurement and serial 
sampling in the first few post-infarction days. 
 
Haemostatic biomarkers 
Across the study population, vWF was elevated at baseline tPA antigen (a surrogate 
for the tPA-PAI-1 complex) just within the normal range; both decreased significantly 
over time. Baseline concentrations of both biomarkers correlated with serial change in 
LV structure and function. vWF correlated with ∆LVESVI and inversely with ∆LVEF 
while tPA antigen had significant correlations with both of these parameters and with 
∆LVEDVI. Moreover, on multivariable analysis tPA antigen remained in the model as 
an independent predictor of ∆LVESVI. 
 
tPA is produced predominantly by vascular endothelial cells and promotes fibrinolysis 
via the conversion of plasminogen to plasmin, but as described in Chapter 1 (1.10), 
several studies have confirmed that tPA antigen acts mainly as a marker of the tPA-
PAI-1 complex in vivo, and therefore acts as a surrogate marker of plasma PAI-1 
activity (and thus reduced fibrinolytic activity) rather than free tPA.
217, 218, 222    
 
I have shown that tPA antigen concentration is associated with increasing LV volume 
after AMI in this study. A number of studies have shown strong associations between 
tPA antigen levels and adverse cardiovascular outcomes across the spectrum of   165 
atherosclerosis.
217, 218, 221 Epidemiologic data suggest a link between plasma tPA 
antigen concentrations and the development of CHD.
217 In patients with 
angiographically-confirmed CHD and established angina pectoris, tPA antigen 
concentrations predict the 2-year occurrence of acute coronary syndromes.
218 
Following STEMI, tPA antigen predicts 10-year cardiovascular mortality; PAI-1 is a 
strong independent predictor of 30-day mortality in this setting.
220, 221 Plasma PAI-1 
concentrations also predict 30-day occurrence of heart failure after STEMI, correlate 
(weakly) with decreasing LVEF, and PAI-1 knockout mice display less myocardial 
fibrosis (a key component of remodelling) after experimental AMI.
220, 224 To the best 
of my knowledge, no associations have been published previously between tPA 
antigen concentrations and serial LV volume change after AMI in man. 
 
Circulating vWF is recognised as a plasma index of endothelial damage and 
dysfunction.
300 Consistent with this I found that circulating vWF concentrations were 
elevated at baseline but fell back to within the normal range over time. vWF has 
previously been shown to predict development of CHD, and the occurrence of heart 
failure 30 days after STEMI (although less strongly than tPA antigen), and 
independently predicts 30-day death, re-infarction and revascularisation following 
non-ST-elevation ACS.
217, 219, 220 I found a relationship between baseline vWF 
concentration and LVESVI at 24 weeks on univariate but not multivariate analysis; 
previous groups have also failed to demonstrate a consistent relationship between 
vWF and LV structure and function after AMI.
220 
 
An association has recently been found between mineralocorticoid receptor activation 
by aldosterone and production of a variety of haemostatic factors in cultured human   166 
vascular endothelial cells, suggesting a possible link between the RAAS and the 
coagulation-fibrinolysis system.
301 My findings did not provide any further evidence 
towards such a link as eplerenone had no effect on either haemostatic biomarker over 
time. 
 
In summary, I have shown for the first time that tPA antigen, as a surrogate marker of 
plasma PAI-1 activity, predicts LV volumes and LVEF 24 weeks after AMI in 
patients with LVSD but neither heart failure nor diabetes mellitus. Further studies 
should focus on mechanistic links between the coagulation-fibrinolysis cascade and 
systems of pathophysiological importance to the process of LV remodelling, in 
particular MMP:TIMP balance as plasmin has been shown to activate pro-MMPs; 
these two systems may therefore be linked following AMI.  
 
4.5.2  Limitations 
As outlined in Chapter 3 (3.6.4), the major limitation of this study is the dependence 
of the results on covariate adjustment, made necessary by the significant baseline 
imbalances in LV volumes, mass and function between the treatment groups. 
 
I designed the study to analyse the effects of eplerenone on structural and functional 
LV change, assessed by serial LGE-CMR, and on serial change in a number of plasma 
biomarkers. However, each biomarker was sampled at only one time-point at baseline; 
during the interval from infarct to venepuncture (mean 3.7 days), the process of 
‘early’ remodelling (which occupies the first 72 hours after infarction) would have 
ceased and ‘late’ remodelling would have begun. Plasma concentrations of several of 
the sampled biomarkers fluctuate, particularly in the first few days after AMI. I cannot   167 
comment on such fluctuations, nor indeed on plasma concentrations of each 
biomarker in the very early post-infarction phase. 
 
Regarding the biomarker sub-studies, it is also relevant that I measured plasma 
concentrations of each biomarker only, and thus have no data on local tissue activity. 
However, one of our aims was to determine, for potential use on a practical (ward-
based) level, whether a single measure of any of the plasma biomarkers could predict 
LV functional recovery post-MI thus local tissue activity was beyond the scope of this 
thesis. 
 
It is noteworthy that very little adverse remodelling occurred over the course of the 
study in this well-treated cohort (LVESVI did not change significantly over 24 weeks 
across the cohort as a whole), thereby reducing the likelihood of detecting strong 
correlations between biomarkers and change in LV volumes. In the primary study 
(Chapter 3) eplerenone had no effect on LV remodelling prior to covariate adjustment, 
hence it is perhaps unsurprising that it failed to influence any of the biomarkers (other 
than plasma aldosterone) prior to covariate-adjustment in this study.  
 
Finally, I have reported correlations between measured biomarkers and LGE-CMR 
parameters; such correlations do not imply any definite biologic interaction but are 
hypothesis-generating. This must be borne in mind when interpreting the results of 
this study. 
 
 
   168 
4.5.3  Conclusions 
Eplerenone had no effect on any measured biomarker other than plasma aldosterone 
prior to statistical adjustment. A covariate-adjusted treatment effect of eplerenone was 
demonstrated on two of the MMPs known as the gelatinases, which have gained 
popularity as key enzymes in ECM turnover and matrix remodelling. Specifically, 
eplerenone decreased MMP-2 and attenuated the drop in MMP-9 that occurred in the 
placebo group. Both of these treatment effects are theoretically beneficial and provide 
support for an anti-remodelling effect of eplerenone. 
 
In the prediction of LV functional recovery following AMI, I found that, based on a 
single sample taken on (mean) day 3 after AMI, an elevated plasma BNP, NTproBNP, 
TIMP-2, TIMP-4, tPA antigen and vWF, and a reduced plasma eotaxin and IL-7, 
correlated with poorer LV function over time. Furthermore, I found that TIMP-4 and 
tPA antigen were independent predictors of LV remodelling, findings that are novel 
and may provide further pathophysiological insights into the mechanisms that 
underlie this process. 
 
 
 
 
 
 
   169 
 
 
 
Chapter 5 
 
A study of the role of aldosterone in post-infarction 
remodelling 
 
 
 
 
 
 
 
 
 
 
 
   170 
5.1  Introduction 
The mineralocorticoid hormone aldosterone, synthesised in the zona glomerulosa of 
the adrenal cortex, exerts a number of adverse effects on the cardiovascular system as 
described in Chapter 1. Aldosterone also possesses pro-fibrotic properties, and is 
strongly implicated in the development of myocardial fibrosis, a key component of the 
pathophysiological process of post-infarction remodelling. Such pro-fibrotic effects 
occur only in the presence of a high-salt environment in animal studies, although 
equivalent data from human studies are lacking.
103  
 
Through a variety of mechanisms aldosterone production is upregulated early after 
AMI, and aldosterone levels correlate directly with mortality in heart failure.
95 
Significant reductions in cardiovascular morbidity and mortality have been confirmed 
with the use of aldosterone antagonists in patients with advanced CHF (RALES), and 
in survivors of AMI with LVEF <40% and heart failure or diabetes mellitus 
(EPHESUS).
121, 123 These data might suggest that aldosterone antagonism should have 
an anti-remodelling effect, but this had not been demonstrated convincingly when I 
began my research project.    
 
The aim of this study was to describe in detail the role of aldosterone in post-
infarction remodelling. This was performed by examining not just circulating 
aldosterone concentrations following AMI, but additionally using urinary steroid 
metabolite excretion rates, and genetic markers. As described in Chapter 1.5, 
mutations in the gene that encodes aldosterone synthase significantly influence 
aldosterone excretion rates – I therefore assessed the influence of a common mutation 
in aldosterone synthase on plasma aldosterone concentrations and remodelling   171 
outcomes following AMI. I also examined the potential interactions between 
circulating aldosterone, urinary sodium excretion (a marker of total body sodium state) 
and remodelling in order to determine whether the pro-fibrotic/pro-remodelling 
effects of aldosterone were influenced by salt-status in humans. 
 
 
5.2  Methods 
 
5.2.1  Study patients and trial protocol 
All 100 patients enrolled in the primary study of this thesis (Chapter 3) were included 
in this study examining the role of aldosterone in post-infarction remodelling. The 
screening, recruitment, randomisation process and trial outline are described in detail 
in Chapter 2 (2.1 – 2.3), and baseline demographic data of the study cohort are shown 
in Table 3.1. 
 
Plasma aldosterone and renin concentrations were measured at baseline (mean 3.7 
[SD 1.8] days after AMI) and again at 12 and 24 weeks. Detailed methods of 
collection, storage and analysis are described in Chapter 2.8.3.  
 
24-hour urinary collections were performed at baseline (prior to randomisation to 
placebo or eplerenone) and again at 12 weeks; urinary sodium concentration was 
multiplied by total volume of urine produced over 24 hours to provide a measurement 
of 24-hour urinary sodium excretion; a 20ml aliquot was withdrawn from each 24-
hour urine collection and stored for later measurement of urinary steroid metabolite 
excretion rates, as described in Chapter 2.8.9.   172 
 
A whole blood sample taken at trial recruitment was used for genetic analysis, as 
described in Chapter 2.8.10.  
 
LGE-CMR imaging was performed at baseline (pre-randomisation), 12 and 24 weeks; 
the methods of imaging and analysis are described in detail in Chapter 2 (2.5 – 2.6). 
 
5.2.2  Statistical methods 
Biomarkers exhibiting logarithmic-normal distribution were log-transformed prior to 
parametric correlation. Bivariate correlations between aldosterone and LGE-CMR 
parameters were examined across the entire study cohort, and then by treatment group. 
Inter-group comparisons were made using paired sample t-tests or Mann-Whitney-U 
tests as appropriate for continuous variables and Chi-squared test for categorical 
variables. Paired t-tests were used to detect changes in LGE-CMR measurements and 
biomarkers within each treatment group over the 24 weeks of the study, and 
differences between these changes were analysed using an unpaired t test. A 
probability value of p<0.05 was considered significant. 
 
Urinary steroid analysis: 
Prior to analysing the predictive effect of urinary steroid sub-groups on serial change 
in LV parameters, bivariate correlation was undertaken with all sub-groups inserted 
into the model, producing Pearson correlation co-efficients. Paired sub-groups that 
were highly correlated were analysed in separate regression equations. 
Multicollinearity was assessed using variance inflation factors (VIF) for each 
independent variable in each regression equation; if two variables had VIF >10 it was   173 
deemed that the variance of each of the two variables had been inappropriately 
increased by the other due to collinearity, and such variables were analysed separately. 
 
The treatment effect of eplerenone on urinary steroid sub-groups, and the influence of 
this effect on serial change in LV parameters and infarct volume, was examined using 
interaction quotients. For each steroid sub-group the baseline and 12 week values 
were multiplied by either ‘0’ if on placebo or ‘1’ if on eplerenone. In this way 
interaction quotients were created for each steroid sub-group at baseline and 12 weeks, 
and were then used in linear regression analysis equations to examine their influence 
on serial change in LVESVI, LVEDVI, LVEF, LVMI and infarct volume. Interaction 
quotients were also created in this manner to investigate the influence of urinary 
sodium excretion on the effects of eplerenone on LV parameters.   
 
Genetic analysis of SNPs in aldosterone synthase gene: 
The distribution of allelic frequencies within the study population was analysed for 
Hardy-Weinberg equilibrium using an online Hardy-Weinberg calculator 
(www.oege.org/software/hardy-weinberg.shtml). Inter-genotypic comparison of LV 
parameters, infarct volume and plasma aldosterone was performed using one-way 
ANOVA. The effect of the -344T/C allele status on LVESVI, LVEDVI, LVEF, 
LVMI and infarct volume was examined with multiple linear regression analysis after 
adjustment for the following common clinical variables: age, sex, hypertension 
history, smoking status and previous MI. 
 
All statistical analyses were performed using SPSS version 15.0 (SPSS Inc., Chicago, 
Illinois, USA) under the guidance of Professor Ian Ford.   174 
5.3  Aldosterone in post-infarction LV remodelling 
 
Aldosterone and its potential role in LV remodelling was examined using three 
separate indices: plasma concentration, urinary metabolite excretion rates and genetic 
markers. Each will be described separately.  
 
5.3.1  Plasma studies 
Across the entire study cohort (n=100), PRC and aldosterone were sampled at 
baseline, 12 and 24 weeks. PRC was elevated at baseline and plasma concentrations 
rose significantly over time (Figure 5.1 A). Plasma aldosterone concentration was 
within normal (supine) limits at baseline and although it did not change significantly, 
there was a trend towards an increase over time (Figure 5.1 B).  
 
 
Figure 5.1  Mean plasma renin concentration (A) and aldosterone (B) at baseline, 12 and 24 
weeks for the entire study cohort. Data are expressed as mean (SEM). * p=0.011 for 
difference between baseline and 24 week PRC; there was no significant change in plasma 
aldosterone over the 24 week follow-up. 
 
 
Baseline aldosterone concentrations were non-normally distributed and were thus log 
transformed. Correlations between logarithmic baseline aldosterone concentration and 
LV parameters at baseline, 24 weeks and change in these parameters between baseline   175 
and 24 weeks are shown in Table 5.1. Baseline aldosterone concentration had weak 
but significant correlations with parameters of deteriorating LV function over time. 
Baseline log-aldosterone correlated with greater LVESVI, larger infarct volume and 
lower LVEF at baseline and 24 weeks, and also with greater LVEDVI at 24 weeks 
although not at baseline. Baseline log-aldosterone also correlated with a greater 
increase in LVESVI (ie. greater degree of LV remodelling) and a greater decrease in 
infarct volume between baseline and 24 weeks.  The change in plasma aldosterone (∆ 
aldosterone) from baseline to 24 weeks, however, had a weak inverse correlation with 
∆LVEDVI over the same time period (r= -0.23, p = 0.02) and a positive correlation 
with ∆ infarct volume (r = 0.23, p = 0.03) but had no significant correlations with 
∆LVESVI, ∆LVEF or ∆LVMI. 
 
_____________________________________________________________________ 
                Baseline                    24 weeks    ∆ 0-24 weeks 
 
LVESVI      0.26**             0.32**              0.21* 
LVEDVI      0.15             0.24*         0.20 
LVEF                 -0.31**           -0.31**       -0.10 
LVMI        0.24*             0.16       -0.15 
Infarct Volume     0.39**             0.37**       -0.43** 
 
Table 5.1  Pearson correlation co-efficients for (logarithmic) baseline plasma aldosterone 
concentration with LGE-CMR parameters at baseline and 24 weeks across the entire study 
cohort. ∆ 0-24 weeks represents the correlation between aldosterone and change in each 
ceCMR parameter between baseline and 24 weeks. *p<0.05   **p<0.01 
 
 
Plasma aldosterone by treatment group 
Mean (SD) baseline aldosterone concentration was not significantly different in the 
placebo group (in which baseline LV function was significantly poorer) than in the 
eplerenone group: placebo 242.7 (235.8) pmol/l vs. eplerenone 184.7 (149.0) pmol/l; 
p = 0.15.    176 
 
Placebo group: 
In placebo-treated patients, there was a trend towards a decrease in mean plasma 
aldosterone over time from 242.7 (235.8) pmol/l to 186.5 (168.2) pmol/l at 24 weeks, 
but this was not significant (p = 0.24) – Figure 4.4. Correlations between logarithmic 
baseline aldosterone and LV parameters by treatment group are shown in Table 5.2. 
Baseline aldosterone in the placebo group correlated significantly with baseline 
infarct volume but not with any baseline LV functional parameter. There was however 
significant positive correlation between baseline aldosterone and ∆LVESVI (ie. 
remodelling) and ∆LVEDVI. 
 
In the placebo group ∆aldosterone (baseline to 24 weeks) correlated inversely with 
∆LVEDVI (r = -0.38, p = 0.008) but not with ∆LVESVI, ∆LVEF, ∆LVMI or ∆infarct 
volume.  
 
Eplerenone group: 
Eplerenone-treated patients experienced a significant increase in plasma aldosterone 
concentration over time, from 184.7 (149.0) pmol/l to 306.6 (266.0) pmol/l at 24 
weeks, p = 0.006 (Figure 4.4). Although there was significant correlation between 
logarithmic baseline aldosterone and baseline LVESVI, LVEDVI, infarct volume and 
(inversely with) LVEF, there was no correlation between logarithmic baseline 
aldosterone and change in any LV functional parameter over time including 
∆LVESVI (Table 5.2). 
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In the eplerenone group ∆aldosterone (baseline to 24 weeks) did not correlate with 
change in any parameter (∆LVESVI, ∆LVEDVI, ∆LVEF, ∆LVMI or ∆infarct volume) 
over time.  
 
   
 
Table 5.2  Pearson correlation co-efficients for (logarithmic) baseline plasma aldosterone 
concentration with ceCMR parameters at baseline and 24 weeks by treatment group. 
Correlation co-efficients are also displayed for (logarithmic) baseline plasma aldosterone and 
change in (∆) each ceCMR parameter between 0 and 24 weeks. *p<0.05   **p<0.01 
 
 
 
5.3.2  Urinary sodium excretion 
24-hour urinary sodium excretion (expressed as median, interquartile range) was 61.8 
(36.0 – 105.7) mmol at baseline and 127.9 (91.4 – 182.2) mmol at 12 weeks, p<0.001. 
There was no interaction between eplerenone therapy, urinary sodium excretion rate 
(baseline or 12 weeks) and any parameter of LV function. For the entire study cohort, 
division of baseline and 12 week 24-hour urinary sodium excretion rates into tertiles, 
and comparison of highest versus lowest 24-hour urinary sodium excretion rate 
revealed no significant inter-tertile difference in any parameter of LV function. 
Similarly, comparison of highest versus lowest 24-hour urinary sodium excretion rates 
within each treatment group revealed no significant inter-tertile difference in change   178 
in any LV functional parameter. These analyses were limited, however, by very small 
patient numbers within each tertile. 
 
Interaction between baseline plasma aldosterone, baseline 24-hour urinary sodium 
excretion and remodelling (∆LVESVI) was assessed by creating an interaction 
coefficient, defined as the product of baseline plasma aldosterone and baseline 24-
hour urinary sodium excretion. This interaction coefficient was then used in a linear 
regression analysis model for each treatment group, and also for the study cohort as a 
whole. No significant interactions were observed between these two quantities and 
∆LVESVI in either treatment group, or in the entire study population. 
 
5.3.3  Urinary steroid metabolites 
At baseline (pre-randomisation) and at 12 weeks, 24-hour urinary collections were 
undertaken in all patients. The excretion rates of the following steroid metabolites 
were measured: tetrahydrodeoxycorticosterone (THDOC), tetrahydroaldosterone 
(THAldo), tetrahydrodeoxycortisol (THS) and total cortisol metabolites (Figure 1.2: 
biosynthetic pathway). 
 
Across the entire study cohort, urinary excretion of THDOC did not vary significantly 
between baseline and 12 weeks (p = 0.80) but urinary excretion of THAldo, THS and 
total cortisol metabolites fell significantly over time (all p<0.001). There were no 
significant differences in any of these urinary steroids between treatment groups at 
either sampling time-point (Table 5.3). Of note, total cortisol metabolites were very 
highly elevated at baseline.   
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Table 5.3  Urinary steroid metabolites according to treatment group, at baseline (ie. pre-
randomisation) and after 12 weeks of therapy with either placebo or eplerenone. Data are 
presented as mean (SD). Inter-group comparisons were made using paired sample t-tests. 
12-week urinary collections were available in 94 of the 100 patients at baseline. 
 
In order to determine whether either (or both) aldosterone or cortisol are implicated in 
LV remodelling following AMI, the urinary steroids were divided into those produced 
predominantly during the biosynthesis of aldosterone (THAldo) and those produced 
during cortisol biosynthesis (THS and total cortisol metabolites). THDOC is not only 
an intermediate in aldosterone biosynthesis but also in cortisol biosynthesis thus its 
usefulness as a marker of remodelling in this analysis is ambiguous. 
 
Baseline urinary steroids and serial change in LV function 
Many of the baseline urinary steroids were highly correlated (Figure 5.2), particularly 
THS and THDOC (r = 0.93, p<0.001). Due to this high inter-correlation, inclusion of   180 
all four groups of urinary steroids in a single regression equation (to determine their 
influence on serial change in LV volumes, mass and function) led to excessively high 
VIFs (>>10) as described in Chapter 5.2.2, which would reduce the accuracy of the 
regression analysis. As THS and THDOC were the most powerfully correlated, two 
separate regression equations were constructed for each LV parameter: THS, total 
cortisol metabolites and THAldo were analysed in one; THDOC, total cortisol 
metabolites and THAldo in the other (ie. THS and THDOC were analysed separately). 
 
 
Figure 5.2  Inter-correlations between the urinary steroids at baseline. Pearson correlation co-
efficients are displayed for each interaction. ** p<0.01 
 
The results of multiple paired linear regression analysis equations, constructed to 
determine the predictive value of baseline urinary steroids on 24-week LVESVI, 
LVEDVI, LVEF, LVMI and infarct volume are shown in Table 5.4. Although the 
value of the data is limited by the relatively small sample numbers involved (n=100),   181 
certain trends are evident. None of the baseline urinary steroids had any predictive 
effect on 24-week LVESVI, LVEF or LVMI. However, decreased urinary THDOC 
and increased THAldo at baseline predicted increased 24-week LVEDVI, while 
increased THAldo also predicted greater 24-week infarct volume (irrespective of 
whether THS or THDOC was excluded from the model). These data provide some 
support for the plasma aldosterone findings, in which baseline plasma aldosterone 
also correlated significantly with 24-week LVEDVI and infarct volume (Table 5.1). 
The data additionally suggest that it is the aldosterone limb of the cholesterol 
metabolic pathway (Figure 1.2) rather than the cortisol limb that is related to serial 
change in LV structure (and infarct volume), as the only significant predictors of such 
change were THDOC and THAldo; THS and total cortisol metabolites had no 
predictive value.    182 
 
Table 5.4  Multivariable predictors of LV parameters and infarct volume at 24 weeks 
performed using linear regression analysis. Baseline urinary steroid metabolites were used as 
independent variables. Due to collinearity between THS and THDOC, these two steroid sub-
groups could not be inserted into the same regression equation. Each regression equation was 
therefore computed separately using either THS or THDOC. The multiple correlation co-
efficient for each regression equation is shown; all metabolites log10-transformed prior to 
analysis. 
 
Effects of eplerenone on urinary steroid sub-groups 
Eplerenone had no effect on serial change in any urinary steroid sub-group compared 
to placebo (Table 5.3). The treatment effect of eplerenone on urinary steroid sub-  183 
groups was analysed using interaction quotients as described in the Statistical 
Methods section (5.2.2) There were no relationships between eplerenone therapy, 
urinary steroid sub-groups and serial change in LVESVI, LVEDVI, LVEF, LVMI or 
infarct volume. It is noteworthy that such analysis involved <50 patients per sub-
group and was thus vastly under-powered to detect any significant treatment effect. 
 
5.3.4  Genetic studies: influence of aldosterone synthase polymorphisms on 
plasma aldosterone and LV function: 
Seven of the 100 whole blood samples obtained for genetic analysis at randomisation 
were destroyed due to storage issues outwith the control of the principal investigator. 
Thus stored whole blood samples were available for 93 patients in the study, from 
which DNA was successfully extracted. The allelic frequencies of the aldosterone 
synthase -344T/C SNP for these patients are shown in Box 5.1, and were in Hardy-
Weinberg equilibrium (χ
2 0.14, p = 0.71). 
 
 
 
 
              Box 5.1 Allelic frequencies of -344T/C SNP 
 
Baseline and 24-week LV parameters, infarct volume and plasma aldosterone sub-
divided by genotype are displayed in Table 5.5. Although the absolute number of 
patients involved in this genetic sub-study was very small, some significant inter-
genotypic differences in certain LV functional parameters were observed. Baseline 
LVEF was significantly higher in the presence of the TT genotype compared to the 
CC genotype (p = 0.040). At 24 weeks, LVESVI was significantly lower (p = 0.018) 
 
    All patients (n = 93): 
TT genotype    26 (28.0%) 
CT genotype    48 (51.6%) 
CC genotype    19 (20.4%)   184 
and LVEF significantly higher (p = 0.007) in TT than CT or CC genotypes. There 
were no significant differences between CT and CC genotypes in any parameter listed 
in Table 5.5. No significant inter-genotypic difference in plasma aldosterone was 
observed at either time-point. 
 
 
Table 5.5  Comparison of inter-genotypic variations in ceCMR parameters and plasma 
aldosterone at baseline and after 24 weeks. Data are presented as mean (SD). Continuous data 
compared with the use of ANOVA. TT, CT and CC represent single nucleotide 
polymorphisms in the aldosterone synthase gene at a site 344 base pairs upstream of the 
transcription initiation site.  
[Key:  † p<0.05 TT v CC only; †† p<0.05 TT v CC, TT v CT (but not CT v CC); *over 24 
week period 2 patients with CC genotype and one with TT genotype died, and one patient of 
each of the three genotypes withdrew from follow-up] 
 
 
Baseline and 24-week LVESVI, LVEDVI, LVEF and plasma aldosterone data and 
change in each of these parameters by treatment group are shown graphically in 
Figure 5.3.   185 
 
Figure 5.3  Baseline and 24-week LVESVI (A), LVEDVI (B), LVEF (C) and plasma 
aldosterone (D) by genotype for the 93 patients included in the genetic sub-analysis. Data are 
presented as mean (SEM). Significance values for comparison of baseline and 24-week value 
for each parameter within each genotype are shown. 
 
There were no significant changes over time in ∆LVESVI, ∆LVEDVI or ∆aldosterone 
within any of the three genotype sub-groups (Figure 5.3 A,B,D) although there was a 
trend towards a reduction in LVESVI and an increase in plasma aldosterone, in TT 
patients compared to the two other genotype sub-groups. LVEF increased 
significantly in both TT (∆LVEF +7.9 [11.3] %, p = 0.003) and CT (∆LVEF +3.9 
[8.1]%, p = 0.004) sub-groups but not significantly in the CC sub-group (∆LVEF +1.7 
[12.4] %, p = 0.39). 
 
The influence of genotype on serial change in LV structure, function and infarct 
volume was then analysed using multiple linear regression analysis following 
adjustment for age, sex, hypertension history, smoking status and prior MI as 
described in the statistical methods section (Chapter 5.2.2) – Table 5.6. There did   186 
appear to be a weak association between the TT genotype and greater final LVEF 
although the small patient numbers and the low multiple correlation co-efficient of the 
model (R
2 = 0.32) limit the significance of this finding. A significant association was 
also noted between the TT genotype and final infarct volume. No significant 
relationships were observed between the CT or CC genotype and any ceCMR 
parameter. 
 
 
Table 5.6  Multiple linear regression analysis assessing the predictive value of -344T/C SNPs 
on serial change in LV parameters and infarct volume, adjusted for age, sex, prior MI, 
hypertension history and smoking status. The multiple correlation co-efficient (R
2) for each 
model is shown. 
 
 
 
 
 
 
 
   187 
5.4  Discussion 
 
5.4.1  The role of aldosterone in post-infarction remodelling 
Aldosterone has a number of detrimental effects on the cardiovascular system, 
including promotion of myocardial interstitial and perivascular fibrosis, stimulation of 
myocyte apoptosis, mediation of baroreceptor dysfunction, prevention of myocardial 
neuronal re-uptake of norepinephrine, increase in sympathetic drive, and potentiation 
of fluid overload and electrolyte imbalance.
84-89, 302 Furthermore, elevated aldosterone 
levels correlate directly with mortality following (ST-elevation) AMI and in CHF.
95, 
303 Robust clinical trial evidence supports beneficial effects on cardiovascular 
morbidity and mortality of aldosterone antagonists in both CHF and AMI.
121, 123 There 
has been debate recently, however, as to whether the effects of aldosterone 
antagonists on the heart are due to mineralocorticoid receptor blockade independently 
of aldosterone effects, ie. that circulating aldosterone is a “bystander”.
304 
 
I have shown, taking our cohort as a whole, that aldosterone was within normal supine 
limits at baseline with a trend towards increase over time, in keeping with the well-
documented phenomenon of aldosterone escape.
118 I found a direct correlation 
between baseline aldosterone and measures of adverse LV remodelling over 24 weeks, 
and also found a significant relationship between aldosterone and infarct volume. 
Analysis of the treatment groups revealed that plasma aldosterone did not change over 
time in the placebo group but increased significantly in the eplerenone group. 
Baseline plasma aldosterone correlated with 24-week LVESVI, ∆LVESVI and 
∆LVEDVI in the placebo group, and ∆aldosterone correlated inversely with 
∆LVEDVI. Thus a high baseline aldosterone in the placebo group correlated with   188 
adverse remodelling, but surprisingly a fall in aldosterone over time correlated with 
progressive ventricular dilatation. In the eplerenone group baseline aldosterone 
correlated with baseline and 24-week LVESVI, baseline and 24-week LVEF 
(inversely) and baseline LVEDVI but not with change in any of these parameters over 
time, unlike in the placebo group. The association between ∆aldosterone and 
∆LVEDVI, seen in the placebo group, was lost in eplerenone-treated patients. 
 
Before discussing the possible interpretation of these results, it is important to re-
affirm that the absolute number of patients in this study was small as the study was 
powered for CMR end-points, not fluctuations in plasma RAAS hormones. 
 
In eplerenone-treated patients, in whom we can hypothesise that a significant 
percentage of mineralocorticoid receptors were occupied by the study drug, although 
a high baseline aldosterone did correlate with some parameters of poorer LV function 
at 24 weeks, it did not specifically predict remodelling, ie. change over time in 
LVESVI (or indeed change over time in LVEDVI or LVEF). Moreover, even though 
plasma aldosterone rose over time, this had no bearing on LV remodelling either. In 
contrast to this, in placebo-treated patients, in whom mineralocorticoid receptors 
would not be occupied by the study drug, the LV continued to dilate even though 
plasma aldosterone tended to decrease over time. These data may suggest that in the 
early stages of AMI, circulating aldosterone acts to select a particular remodelling 
pathway for each patient but that over time it is the mineralocorticoid receptor 
blockade that is key to modifying the remodelling pathway. Although plasma 
aldosterone had a tendency to decrease in the placebo group, the mineralocorticoid 
receptors were not occupied by study drug, thus circulating cortisol (the concentration   189 
of which was highly elevated) could activate these receptors, thereby potentiating 
adverse LV remodelling independently of circulating aldosterone. Conversely in the 
eplerenone group, although plasma aldosterone rose over time, the mineralocorticoid 
receptors were occupied by eplerenone thus neither aldosterone nor cortisol could 
bind to and activate these receptors. Thus aldosterone may have an adverse effect in 
the acute post-infarction phase but then takes more of a ‘bystander’ role in the sub-
acute phase: our data suggest that it is mineralocorticoid receptor activation that 
drives remodelling rather than circulating aldosterone. 
 
The predictive value of metabolites of corticosteroid catabolism, measured in urine, 
was assessed in an attempt to analyse further the relative roles of aldosterone and 
cortisol in LV remodelling. Of the urinary steroids produced predominantly during the 
aldosterone limb of the pathway (Figure 1.2), THAldo excretion rate fell significantly 
over the 12 weeks between urinary collections. Total cortisol metabolite and THS 
excretion rates, both predominantly metabolites of cortisol biosynthesis, fell 
significantly over time. Total cortisol metabolites were very highly elevated at 
baseline, presumably reflecting the acute stress response following large AMI across 
the patient population. Multiple linear regression analysis was complicated by 
multiple correlations between excretion rates of the steroid groups. Removing those 
with the strongest inter-correlation revealed trends towards a relationship between a 
lower baseline THDOC and a higher baseline THAldo with greater 24-week LVEDVI. 
THAldo also predicted 24-week infarct volume. 
 
Although the study is insufficiently powered to detect significant differences between 
urinary steroid sub-groups, these results show that, although the cortisol pathway is   190 
highly activated early after infarction, the only significant correlation with LV 
function occurred in the aldosterone pathway. This suggests that aldosterone rather 
than cortisol is linked with the pathophysiology of LV dilatation and dysfunction 
early after AMI. The speculated relationship of THAldo, the principal metabolite of 
aldosterone, with ∆LVEDVI and infarct volume supports the baseline plasma 
aldosterone findings and again suggests that aldosterone in the early post-infarction 
period is a key factor in determining subsequent LV remodelling.  
 
Given the power of the study it is unsurprising that no interaction was observed 
between eplerenone therapy, steroid sub-group excretion rates and LV function. 
Adequately-powered future studies in the field of urinary steroids and their predictive 
effect on LV function after AMI in the presence of potential anti-remodelling 
medication would shed more light in this area. Nevertheless, the urinary steroid 
findings do support some of the plasma aldosterone results and again suggest that 
aldosterone in the first few days after AMI is a key determinant of subsequent 
remodelling. 
 
Following AMI, fibrotic change occurs at the site of acute myocardial injury over 
time, and reactive fibrosis develops in non-infarct myocardium in a number of animal 
models.
37, 104, 105 Fibrosis can be induced in the rat heart experimentally by infusing 
aldosterone in salt-loaded conditions (although aldosterone had no pro-fibrotic effect 
in salt-deplete conditions).
103, 106 Our sub-groups are too small to allow any major 
insights into the association between aldosterone and fibrosis, but the correlations 
between baseline plasma aldosterone and infarct volumes in both treatment groups 
and between THAldo and infarct volume suggests a relationship between aldosterone   191 
and infarct zone fibrosis that is independent of mineralocorticoid receptor occupation. 
Contrary to the rat model, I found no interaction between urinary sodium excretion (a 
marker of total body sodium), eplerenone therapy and LV function/infarct volume 
over time although again the study was not powered to detect such a relationship. 
 
The genetic sub-study into the relationships of the -344T/C SNP in aldosterone 
synthase and LV function was limited to 93 patients, thus any results should be treated 
as hypothesis-generating only. I observed that LVEF at baseline was higher in patients 
with TT genotype (n=26) than in those with either CT or CC. This probably 
represents the play of chance given the small numbers involved. At 24 weeks, 
LVESVI was significantly lower and LVEF significantly higher in TT patients than in 
CT or CC. Although neither ∆LVESVI nor ∆LVEDVI differed significantly between 
genotype sub-groups, there was a trend towards reduction in both in TT patients 
compared to CT or CC. That the TT sub-group had superior baseline LV function 
suggests that these patients would be more likely to improve/reverse remodel in 
comparison to those with poorer LV function in the CT and CC sub-groups, thus these 
results may also be spurious and related to the chance baseline difference in LV 
function. However, LVEF increased significantly in not only TT but also CT patients, 
while there was no significant change in LVEF in CC patients. Moreover, in a 
multivariable model adjusted for clinical variables, the TT genotype remained a weak 
predictor of superior 24-week LV function, and also of infarct volume. Despite the 
small numbers, the -344T allele in our population did appear to be associated with 
improved LV function. 
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Aldosterone excretion is influenced by this SNP in aldosterone synthase, although 
there appears to be significant inter-racial variability, with higher excretion rates of 
aldosterone seen with the -344T allele in Caucasian populations and with the -344C 
allele in African American populations.
134, 305 In this small study I found no 
significant differences in plasma aldosterone concentrations between the genotypes at 
baseline or 24 weeks, although 24-week plasma aldosterone and ∆aldosterone were 
non-significantly higher in TT patients than CT or CC. As 99% of the study cohort 
was Caucasian, these trends would support the previously-reported association 
between the -344T SNP and higher circulating aldosterone in such a population.
134, 305 
It is noteworthy, however, that a study of 216 European hypertensive patients found 
higher aldosterone excretion rates in those with the -344C allele, while a separate 
European epidemiologic study of 562 patients found no association between -344T/C 
allele status and plasma aldosterone.
306, 307 
 
I found a relationship between the -344T allele and improved LV function, occurring 
despite a trend towards increase over time in plasma aldosterone in this sub-group. I 
also observed an association between the -344T allele and greater infarct volume. The 
significance of these findings is unclear. I hypothesised earlier that circulating 
aldosterone in the first few days after AMI is detrimental and may select a particular 
remodelling pathway, but that over the ensuing weeks and months circulating 
aldosterone is no longer integral to ongoing remodelling, but rather mineralocorticoid 
receptor activation (by aldosterone or cortisol) is the main driving force behind 
progressive remodelling. That LV function improved in the TT sub-group despite a 
trend towards increasing aldosterone is consistent with the latter hypothesis, that of 
the “bystander” role for aldosterone in the subacute phase. However, in view of the   193 
small number of patients in each of the genotype sub-group, further speculation on the 
relative importance of the -344T/C SNP in this population is unwarranted. A more 
appropriately-powered study showed no difference in allele frequency in patients 5 
years after AMI than in the general population, while in a separate study of 226 
patients with incident anterior AMI, no association was found between -344T/C and 
LV remodelling out to 1 year after AMI.
138, 139 
 
5.4.2  Limitations 
That each plasma biomarker was sampled at only one time-point at baseline (mean 3.7 
days), by which time the process of ‘early’ remodelling (which occupies the first 72 
hours after infarction) would have ceased and ‘late’ remodelling would have begun, 
and that plasma concentrations of several of the sampled biomarkers fluctuate, 
particularly in the first few days after AMI and thus cannot be commented upon in 
this study, have been discussed earlier (Chapter 4.5.2). Additionally, plasma 
concentrations of each biomarker were measured only; no data on local tissue activity 
of each biomarker (which was beyond the scope of this thesis) are available.  
 
Finally, the primary study on which this sub-study was based was powered for LGE-
CMR end-points only. Results of the genetic, plasma and urinary aldosterone analysis 
must be interpreted in this light and as such are hypothesis-generating only. Where 
appropriate, results of adequately-powered studies in the literature have been cited. 
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5.4.3  Conclusions 
The role of aldosterone in LV remodelling was examined in detail. Combining results 
from genetic analysis, plasma aldosterone and urinary steroid metabolite excretion 
rates, I hypothesise that there exists a temporal variation in the cardiac effects of 
aldosterone after AMI, specifically that circulating aldosterone in the first few days 
after infarction is key in selecting a remodelling pathway but that over the following 
weeks and months circulating aldosterone is less influential in the pathogenesis of 
ongoing remodelling – mineralocorticoid receptor activation (by aldosterone or 
cortisol) potentiates remodelling over time.  
 
I also demonstrated a relationship between plasma aldosterone and greater infarct 
volume that was unaffected by eplerenone therapy, which provides support for the 
theory that aldosterone antagonists do not influence reparative fibrosis after AMI; no 
evidence of reactive fibrosis was found in our optimally-treated population.  
 
Finally, analysis of the -344T/C SNP in aldosterone synthase in the study population 
revealed an association between the -344T allele and superior LV function, contrary 
to published studies in this field. I acknowledge however that this study was 
significantly under-powered to detect any definite relationships in any of the 
neurohormonal or genetic data, and that the hypotheses above are purely speculative. 
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Chapter 6 
 
A study of the predictive value of infarct characteristics 
determined by contrast-enhanced cardiac magnetic 
resonance imaging in post-infarction left ventricular 
remodelling 
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6.1  Introduction 
Prognosis after AMI is directly related to the extent of myocardial injury that occurs 
during coronary occlusion.
308 CMR, through delayed contrast-enhanced imaging 
techniques as described in Chapter 1, allows in vivo visualisation of infarcted 
myocardium. A number of infarct characteristics can then be described and/or 
quantified. Previous studies have confirmed that total infarct size, endocardial extent 
and transmurality predict adverse cardiovascular outcomes.
255, 309 MVO has also been 
shown to confer an adverse prognosis, although this has been questioned in a recent 
study.
257 
 
The cohort examined in the primary study (Chapter 3) represents a population of 
patients who underwent LGE-CMR imaging serially over 24 weeks after AMI. The 
aims of this study were to examine the infarct characteristics on delayed enhancement 
imaging in the study cohort at baseline, and to assess the utility of these characteristics 
in the prediction of LV remodelling over 24 weeks after AMI. 
 
6.2  Methods 
 
6.2.1  Study patients and trial protocol 
All 100 patients enrolled in the primary study of this thesis (Chapter 3) were included 
in this study examining infarct characteristics and their potential role in the prediction 
of post-infarction remodelling. The screening, recruitment, randomisation process and 
trial outline are described in detail in Chapter 2 (2.1 – 2.3), and baseline demographic 
data of the study cohort are shown in Table 3.1. 
   197 
LGE-CMR imaging was performed at baseline, 12 and 24 weeks. Detailed 
descriptions of imaging techniques and methods of analysis (including definitions of 
the various infarct characteristics measured in this study) are provided in Chapter 2 
(2.5 – 2.6).  
  
6.2.2  Statistical methods  
All data are expressed as mean (SD) for continuous variables and number (%) for 
categorical variables unless otherwise stated. Comparisons between sites of infarction 
were made using paired sample t-tests or Mann-Whitney-U tests as appropriate for 
continuous variables and Chi-squared test for categorical variables. Pearson’s and 
Spearman’s correlation co-efficients were used for parametric and non-parametric 
data respectively.A probability value of p<0.05 was considered significant. 
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6.3  Results 
 
6.3.1  Site of infarction 
The site of the acute infarct on baseline ceCMR, defined using the 17-segment AHA 
model, was anterior in 53 (53.0%), inferior in 24 (24.0%) and lateral in 4 (4.0%). 
Infarcted myocardium was equally distributed between anterior and lateral segments 
in 2 (2.0%) and between inferior and lateral segments in 17 (17.0%) – such infarcts 
were classified as anterolateral and inferolateral respectively. Baseline infarct 
characteristics according to site are shown in Table 6.1. 
 
         Total     Anterior ± lateral       Inferior ± lateral     Lateral     p† 
                     (n=100)          (n=55)                       (n=41)         (n=4) 
Infarct vol (ml/m
2)  33.2 (20.7)    36.1 (22.1)                30.2 (18.8)     23.7 (16.2)          0.17 
Endocardial extent (%)  36.8 (11.5)    40.2 (11.0)               33.1 (11.1)   27.4 (5.8)           0.003 
Transmurality Score    3.3 (0.6)         3.2 (0.6)                   3.5 (0.5)       3.1 (0.6)           0.031 
Early MVO       69 (69%)       35 (35%)                  32 (32%)                  2 (2%)            0.13 
Late MVO       56 (56%)       29 (29%)     26 (26%)                  1 (1%)            0.30 
 
Table 6.1  Baseline infarct characteristics on LGE-CMR. Infarcts classified according to the 17-
segment AHA model.  Anterior and anterolateral  infarcts were combined as “anterior ± lateral” 
while inferior and inferolateral were combined as “inferior ± lateral”. 4 infarcts involved only 
lateral segments with no anterior or inferior extension and are hence classified as lateral only. 
Data are presented as mean (SD) for continuous variables and number (%) for categorical 
variables unless otherwise stated. Two sample t-test used to compare continuous variables and 
chi-square test for categorical variables. †Comparison made between “anterior ± lateral” and 
“inferior ± lateral” only due to small numbers (n=4) in “lateral” group. 
 
 
There was no significant difference in infarct volume between combined 
anterior/anterolateral, inferior/inferolateral and lateral infarct sites. Anterior and 
anterolateral infarction was of greater endocardial extent than inferior and 
inferolateral infarction, while the latter group had mildly but significantly higher 
transmurality scores. Of note, there was no significant difference in the extent of LV 
remodelling between anterior/anterolateral and inferior/inferolateral infarcts   199 
(∆LVESVI was +0.06 [15.4] ml/m
2 in anterior vs. -0.9 [12.1] ml/m
2 in inferior AMI, 
p=0.76) 
 
6.3.2  Transmurality score and endocardial extent 
Across the entire study cohort, there were significant correlations between 
transmurality score, endocardial extent and LV volumes/LVEF at baseline and 24 
weeks (Table 6.2). Both infarct parameters, particularly transmurality score, 
correlated with ∆LVESVI (Figure 6.1). 
 
 
        Transmurality     Endocardial 
              Score          extent  
                      (%) 
   
Baseline 
  LVESVI              0.21*             0.45** 
  LVEDVI             0.20*             0.28** 
  LVEF             -0.15                       -0.55** 
 
24 weeks 
  LVESVI             0.43**             0.50** 
  LVEDVI             0.37**             0.37** 
  LVEF             -0.46**            -0.55**   
 
∆LVESVI (0-24 weeks)           0.47**             0.26*   
 
 
Table 6.2  Spearman correlation coefficients for baseline infarct transmurality score, 
endocardial extent and LGE-CMR parameters of LV function and remodelling. Units: 
LVESVI, LVEDVI: ml/m
2; LVEF: %  
         Key: *p<0.05    **p<0.01   200 
 
Figure 6.1  Plot of change in LVESVI from baseline to 24 weeks against mean transmurality 
score at baseline. A statistically significant correlation exists between the measured quantities. 
 
 
6.3.3  Microvascular obstruction 
MVO was present in 69% of the study cohort and persisted on delayed contrast-
enhanced images (ie. late MVO) in 56% (Table 6.1). A representative example is 
shown in Figure 6.2. The presence of late MVO was significantly correlated with 
adverse LV remodelling whereas the absence of late MVO was associated with 
reverse remodelling (∆LVESVI +4.0 [13.4] ml/m
2 in patients with late MVO vs. -6.4 
[12.7] ml/m
2 without late MVO, p<0.001); Figure 6.3. 
 
 
Figure 6.2  Short-axis LGE-CMR images (at mid-ventricular level) of a 48 year-old male 
patient admitted with an anteroseptal STEMI, performed 3.5 days after AMI. (A) First-pass   201 
perfusion image depicting an extensive hypoperfused segment occupying the septum and 
anterior wall (black area); note the bright appearance of the blood pool in the LV cavity, and 
less so in the RV cavity, as these images were acquired within seconds of IV injection of 
gadolinium-DTPA. (B) Single-shot steady-state free precession sequence with a non-selective 
inversion pulse acquired 2 minutes after contrast injection (non-breath-hold) confirms lack of 
penetrance of contrast into infarcted segment (black area) – this represents “early MVO”. (C) 
Contrast-sensitive segmented inversion recovery sequence (with breath-hold) acquired 15 
minutes after contrast injection. Infarcted tissue appears bright as contrast ultimately 
penetrates slowly into the hypoenhanced segment seen in (A) and (B), but the hypoenhanced 
core within the bright anteroseptal infarct depicts “late MVO”. 
 
 
The absolute volume of late MVO significantly correlated with total infarct volume 
(r=0.65, p<0.001). Although there were weak correlations between late MVO volume 
and 24 week LVESVI (r=0.30, p=0.029) and LVEDVI (r=0.32, p=0.023), there was 
no significant relationship between MVO volume and ∆LVESVI (r=0.25, p=0.07). 
 
 
 
Figure 6.3  Mean change in LVESVI from baseline to 24 weeks in patients grouped according 
to presence or absence of late MVO on baseline LGE-CMR scan. Error bars represent SEM. 
A statistically significant difference in ∆LVESVI exists between the patient groups (p < 
0.001). 
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Coronary angiography was performed in 48/56 (85.7%) patients with late MVO on 
baseline LGE-CMR and in 37/44 (84.1%) with no evidence of late MVO. TIMI flow 
rates within the IRA at the end of angiography (with or without PCI) are shown in 
Table 6.3. 
 
 
TIMI flow within IRA       
  
                                                Angio 
                                  n         performed     
 
3 
 
2 
 
1 
 
0 
MVO present  56  48 
(85.7%) 
42 
(75.0%) 
2 
(3.6%) 
0  4 
(7.1%) 
MVO absent  44  37 
(84.1%) 
32 
(72.7%) 
3 
(6.8%) 
0  2 
(4.5%) 
 
Table 6.3  Final TIMI flow rates within the IRA at completion of angiography +/- PCI 
according to presence or absence of late MVO on baseline (pre-discharge) LGE-CMR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
   203 
6.4  Discussion 
 
6.4.1  Infarct characteristics and the prediction of LV function after AMI  
Using LGE-CMR images, I analysed the predictive value of a number of 
characteristics of the acute infarct in LV remodelling. Unsurprisingly total infarct 
volume, endocardial extent and transmurality score predicted adverse remodelling in 
keeping with previous studies, as all three quantities indicate more substantial 
infarction.
255, 309 One of the aims of this thesis, however, was to examine the 
phenomenon of late MVO and its predictive value as recent trial data have been 
contradictory. I found that late MVO occurred in 56% of the population and was 
evenly distributed between (predominantly) anterior and (predominantly) inferior 
anatomical location. Importantly, the presence or absence of late MVO divided 
patients into two distinct groups: those with late MVO adverse remodelled while 
those without late MVO reverse remodelled, with a strongly significant difference in 
mean ∆LVESVI of around 10 ml/m
2 between these two groups. 
 
MVO represents abnormal microvascular perfusion within an infarcted segment thus 
it is predictable that it is associated with deteriorating LV function. Several prior 
CMR studies have produced similar results, with incidences of MVO of 45-55% 
amongst patients admitted with AMI, the majority of whom had low LVEF, and 
associations between MVO and adverse remodelling.
255, 257, 265 One recent study in 
which 57.5% of infarcts displayed late MVO reported that, although those with MVO 
had larger infarct volumes, greater elevation in cardiac biomarkers and lower LVEF at 
baseline than their counterparts without late MVO there was no difference between 
these two groups in LV remodelling over 4 months.
257 This appears counterintuitive,   204 
and the authors argue that the aggressive treatment of their patients abolished the 
deleterious effect of late MVO on serial LV function (all patients underwent primary 
PCI and the discharge prescription of β blockers and ACE inhibitors/ARBs was 100% 
and 80% respectively), but it is more likely to relate to the small patient numbers 
involved (total population n = 40, 23 of whom had late MVO). In comparison with 
recent CMR studies, we have shown that not only is late MVO common despite a 
very high uptake of acute reperfusion therapies, but also it remains ominous in terms 
of LV functional recovery despite a higher uptake of contemporary anti-remodelling 
pharmacotherapy than in any other post-infarction remodelling trial to date.  
 
A key aspect of post-MI care is the prediction of those patients in whom LV function 
may progressively deteriorate, as such patients warrant more stringent follow-up and 
may be candidates for ICD therapy. Many studies (and guidelines) use LVEF as the 
criterion upon which such decisions are made. However, early post-infarction LVEF 
measurement is not as powerful a predictor of adverse remodelling and major adverse 
cardiac events as might be anticipated.
8 Significant myocardial stunning may lead to 
under-estimation of LVEF, while compensatory hyperkinesis of non-infarcted 
myocardium may ‘falsely’ suggest a higher LVEF despite significant myocardial 
damage; variations in afterload may also influence LVEF acutely. It has been 
suggested that LVEF not be used as an end-point in early post-infarction studies.
310  
 
The data provided in this thesis suggest that the presence or absence of MVO may be 
of use in predicting remodelling outcomes. Previous criticisms of the use of MVO as a 
predictor of adverse outcome were based on the theory that MVO simply related to 
larger infarction, and that it was infarct size that determined outcome rather than   205 
presence of MVO. While there is undoubtedly a relationship between MVO and larger 
infarct size (as demonstrated in this thesis and previous studies), presence of MVO 
has been shown to remain an indicator of adverse prognosis even after controlling for 
infarct size.
255, 257, 311 Likewise, MVO predicts development of a fibrous, transmural 
scar after AMI even when adjusted for infarct size.
255 It therefore appears that 
although MVO is related to infarct size, it also provides independent prognostic 
information rather than simply acting as a marker of the magnitude of infarcted 
myocardium. 
 
A number of angiography-based trials have used patency of and TIMI flow rates 
within the IRA as end-points (Appendix IX). In such trials, TIMI 3 flow is generally 
accepted as the optimal result following AMI, irrespective of the means of reperfusion. 
It is therefore of considerable interest that MVO has been shown to be a stronger 
predictor of post-infarction death, re-infarction, CHF and stroke than patency of the 
IRA.
255 Moreover, MVO is frequently present despite TIMI 3 flow within the IRA; in 
the cohort on which this sub-study is based, (late) MVO was present in 56/100 
patients (56%), of whom 48 underwent coronary angiography and 42 (i.e. 75% of 
those with late MVO) ultimately had TIMI 3 flow restored within the IRA despite 
subsequent detection of MVO on pre-discharge ceCMR imaging. This finding is of 
considerable significance, as it implies that TIMI 3 flow alone does not equate to 
normal microcirculatory perfusion, and further suggests that ceCMR-measured infarct 
characteristics, particularly MVO, might be a more appropriate end-point in clinical 
studies assessing the “success” of reperfusion therapies. MVO may indeed be the 
missing pathophysiological link between reperfusion, remodelling and cardiovascular 
outcome after AMI.   206 
6.4.2  Limitations 
The measurement of baseline infarct size in the study cohort was undoubtedly an 
over-estimation of the amount of myocardium genuinely infarcted. I included all 
abnormal myocardium (using standardised contrast and brightness settings) during the 
post hoc analysis of the delayed enhancement images: this will have included the 
infarct plus the surrounding peri-infarct zone, consisting of oedema, haemorrhagic 
change (particularly as the majority of infarcts were acutely reperfused) and acutely 
inflamed tissue within and around the fresh infarct. This is an almost inevitable 
limitation in LGE-CMR imaging of large acute infarcts, and although trials using 
“oedema imaging” are ongoing, this process is not used in clinical practice at the time 
of writing this thesis. 
 
In comparison to previous studies examining infarct characteristics following AMI, 
there are a number of methodological issues that lead to marked inter-study variability. 
These include partial volume effects, variability in gadolinium-DTPA dose and time 
to delayed enhancement imaging between studies, variations in the wash in/wash out 
profiles of different gadolinium-DTPA preparations and in the definition of the 
boundary zones of the infarct.
246, 263, 312, 313 Such methodological issues provide 
compelling evidence for the need for a universal consensus on infarct size 
measurement on LGE-CMR. 
 
Finally, it must be acknowledged that the patients in this study were required to have 
LVSD, thus the findings cannot be applied to all AMI patients. MVO is less likely to 
occur in association with smaller infarcts, and the predictive potential of MVO in 
small-to-medium infarcts cannot be commented upon from the data in this thesis.   207 
6.4.3  Conclusions 
The findings of this study suggest that the presence or absence of late MVO on pre-
discharge LGE-CMR imaging divides patients presenting with AMI into two groups 
with very different remodelling outcomes and may assist in the risk stratification 
process. The detection of (late) MVO, with its adverse effects on prognosis, in 
patients in whom angiography (with or without follow-on PCI) had ultimately 
confirmed TIMI 3 flow in the IRA, suggests that patency of and flow within the IRA 
are not necessarily markers of optimal outcome after AMI. Infarct characteristics on 
LGE-CMR, and in particular MVO, may be more appropriate end-points in future 
studies assessing the success of reperfusion therapies. 
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Chapter 7 
 
A study characterising plasma apelin concentrations after 
acute myocardial infarction in man 
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7.1  Introduction  
Apelin, the endogenous ligand for the APJ receptor (a G-protein coupled receptor 
found in many organs including heart, kidney, lung, vasculature and adipose tissue) 
has a putative role in cardiovascular physiology and homeostasis, as discussed in 
Chapter 1.7.4. The demonstration in both animal and human studies of potent 
inotropic, diuretic and (nitric-oxide dependent) vasodilator properties, in addition to 
antagonistic effects on angiotensin II, have stimulated interest in the role of apelin as 
an endogenous mediator, which would be of particular relevance in the failing 
heart.
169, 314-316 
  
Data regarding blood apelin concentrations in patients with heart failure are 
inconsistent. Plasma apelin concentrations were similar in patients with and without 
acute heart failure in one study evaluating the predictive value of biomarkers in this 
condition.
317 Studies in CHF, generally limited by small numbers of patients, showed 
a lower concentration of apelin in patients with both ischaemic and non-ischaemic 
CHF compared to controls, across a wide range of disease severity.
171, 318, 319 
Interventions such as cardiac resynchronisation therapy and left ventricular assist 
device implantation increase LVEF, which is associated with a rise in plasma apelin 
concentrations over time in small studies of patients with advanced CHF.
172, 320 
 
That apelin has been demonstrated to possess such inotropism suggests a potential 
role for this peptide in LV remodelling following AMI. At the time of my research 
project, there were no published data on plasma apelin concentrations following AMI 
in man. The aim of this study was therefore to characterise for the first time the 
temporal profile of plasma apelin that occurs following AMI in man, and to determine   210 
whether apelin had any relationships with parameters of LV function/remodelling or 
with a selection of established biomarkers thought to be of pathophysiological 
significance in post-infarction remodelling. 
 
 
7.2  Methods 
 
7.2.1  Study patients 
All 100 patients enrolled in the primary study of this thesis (Chapter 3) were included 
in this study examining the role of apelin in post-infarction remodelling. The 
screening, recruitment, randomisation process and trial outline are described in detail 
in Chapter 2 (2.1 – 2.3). Separate from the AMI cohort, 38 patients on no regular 
prescribed medications, with no history of cardiac events, and with a normal ECG and 
TTE, acted as controls (data on controls kindly donated by Dr. KS Chong, Scottish 
National Advanced Heart Failure Service, Glasgow Royal Infirmary).  
 
7.2.2  Trial outline 
LGE-CMR imaging was performed at baseline (pre-randomisation), 12 and 24 weeks; 
the methods of imaging and analysis are described in detail in Chapter 2 (2.5 – 2.6). 
 
Plasma apelin was measured twice in patients in the AMI cohort: at baseline (pre-
randomisation to placebo or eplerenone) and again at 24 weeks. In the 38 normal 
controls, plasma apelin was measured only once. Details of apelin collection, storage 
and analysis are described in Chapter 2.8.8.  
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In order to elucidate further the role (if any) of apelin in LV remodelling after AMI, I 
also assessed its relationships with NTproBNP (a prognostic marker after AMI), NA 
(a marker of sympathetic activation and of potential pathophysiological significance 
in post-infarction remodelling) and AVP (which has been shown to antagonise apelin 
in animal models).
321 For the purposes of this study, only the baseline and 24 week 
measurements of each of these three biomarkers were included; detailed methods of 
collection, storage and analysis are described in Chapter 2.8. 
 
7.2.3  Statistical methods 
Plasma apelin concentrations were analysed across the entire study population (n=100) 
and compared to control plasma apelin concentrations (n=38). Plasma apelin 
concentrations within the study cohort were also analysed by treatment group. Inter-
group comparisons were made using paired sample t-tests or Mann-Whitney-U tests 
as appropriate for continuous variables and Chi-squared test for categorical variables. 
Paired t-tests were used to detect changes in ceCMR measurements and biomarkers 
within each treatment group over the 24 weeks of the study, and differences between 
these changes were analysed using an unpaired t test. 
 
Pearson’s and Spearman’s correlation coefficients were used for parametric and non-
parametric variables respectively. Comparison of median plasma apelin 
concentrations within quartiles of LVESVI and LVEF was then performed using 
separate Kruskal-Wallis tests. A probability value of p<0.05 was considered 
significant. All statistical analyses were performed using SPSS version 15.0 (SPSS 
Inc., Chicago, Illinois, USA). 
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7.3   Apelin following AMI in man 
 
7.3.1  Demographic data of AMI cohort patients and controls 
Comparison of demographic data between the study cohort and the control population 
is shown in Table 7.1. The mean age of patients admitted with AMI (n = 100) was 
58.9 ± 12 years and that of controls (n = 38) was 56.4 ± 11.4 years (p = 0.24). 
Significantly more patients were of male gender in the AMI cohort (77%) than in the 
control population (59.4%); p = 0.03. 
 
 
 
Table 7.1  Baseline characteristics of AMI patients (n=100) and controls (n=38). Unless 
otherwise stated, continuous data are expressed as mean (SD), while categorical data are 
expressed as percentages of the relevant treatment group.  eGFR was calculated using the 
MDRD formula. 
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7.3.2  Serial change in plasma apelin concentrations after AMI 
Baseline plasma apelin concentrations, sampled on average 2 days after AMI, were 
significantly lower than in the control population: mean ± SD apelin was 0.54 ± 0.25 
ng/ml in AMI patients v. 3.22 ± 3.01 ng/ml in controls (p<0.001). Plasma apelin 
concentration was lower in smokers at baseline (0.50 ± 0.18 ng/ml v. 0.64 ± 0.36 
ng/ml in non-smokers, p=0.014) but had no relationship with age, sex, prior MI, 
history of hypertension, dyslipidaemia or stroke.  
 
 
 
Figure 25. Mean (SD) plasma apelin concentration at baseline and 24 weeks in study cohort. 
The increase in plasma apelin concentration from baseline to 24 weeks is statistically 
significant. 
 
Plasma apelin concentrations rose significantly over time (0.54 ± 0.25 ng/ml at 
baseline v. 0.62 ± 0.36 ng/ml at 24 weeks, p=0.030) – Figure 7.1, Table 7.2 – but even 
at 24 weeks remained significantly lower than the control apelin concentrations 
(p<0.001).   214 
  
Peptide hormone  Baseline  24 weeks  p 
Apelin (ng/ml)  0.54 (0.25)  0.62 (0.36)  0.030 
NTproBNP (pg/ml)  2588 (2732)  841 (1983)  <0.001 
Noradrenaline (nmol/l)  3.19 (1.81)  2.74 (1.23)  0.013 
AVP (pg/ml)  0.87 (0.83)  0.65 (0.72)  0.001 
 
Table 7.2  Baseline and 24 week comparative plasma concentrations of peptide hormones for 
entire study (post-MI) cohort (n = 100). 
 
 
7.3.3  Relationships between apelin and parameters of LV function 
Baseline plasma apelin had no significant relationship with initial LVESVI (r = 0.01, 
p = 0.92), nor did it correlate with baseline LVEDVI, LVMI, LVEF or infarct volume 
index (Table 7.3). There was no relationship between baseline apelin and ∆LVESVI 
(r=0.06, p=0.55). Similarly there were no associations between baseline apelin and 
∆LVEDVI, ∆LVEF, ∆LVMI or ∆infarct volume. 
 
I divided study patients into quartiles of baseline LVESVI (Figure 7.2 A) and LVEF 
(Figure 7.2 B); no interquartile differences in baseline apelin concentrations were 
demonstrated. Similarly, baseline apelin bore no relationship to ∆LVESVI or ∆LVEF 
over 24 weeks within each quartile.   215 
 
 
Figure 7.2  
(A) Boxplot graph depicting plasma apelin concentrations in the AMI cohort (n = 100) 
according to quartiles of baseline LVESVI: q(i) ≤33.5 ml/m
2; q(ii) 33.6 – 42.4 ml/m
2; q(iii) 
42.5 – 50.1 ml/m
2; q(iv) ≥50.2 ml/m
2. There were no significant inter-quartile differences in 
apelin concentrations. 
 
(B) Boxplot graph depicting plasma apelin concentrations according to quartiles of baseline 
LVEF: q(i) ≤43.4%; q(ii) 43.5 – 49.2%; q(iii) 49.3 – 54.2%; q(iv) ≥54.3%. There were no 
significant inter-quartile differences in apelin concentrations. 
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          Apelin              NT-proBNP          Noradrenaline                AVP 
      Baseline  24 weeks  Baseline  24 weeks  Baseline  24 weeks  Baseline  24 weeks 
   
Baseline 
  LVESVI    0.010    -0.116   0.325**  0.338**    0.172     0.048     0.066       0.004 
  LVEDVI    0.089    -0.089   0.191    0.235**    0.100    -0.004     0.028     -0.039 
  LVEF      0.064     0.050            -0.393**         -0.368**   -0.223*   -0.129    -0.143     -0.105 
  LVMI     0.003    -0.064   0.055    0.163      0.228*    0.208*   -0.036         0.075 
  Inf Volume   -0.071    -0.115   0.262**  0.359**    0.167     0.111     0.115     -0.023 
 
24 weeks 
  LVESVI    0.104     0.018   0.431**  0.577**    0.227*    0.169     0.137     -0.042 
  LVEDVI    0.114    -0.077   0.301**  0.476**    0.087    -0.037     0.091      -0.066 
  LVEF     -0.077    -0.102            -0.448**         -0.549**   -0.312**   -0.317**   -0.155     -0.028 
  LVMI     0.069    -0.059   0.024    0.247*     0.162     0.069    -0.139     -0.184 
  Inf Volume   -0.117    -0.126   0.335**  0.447**    0.174     0.090     0.094     -0.032 
 
∆ceCMR parameter (0 – 24 weeks) 
  ∆LVESVI    0.063        -    0.265*       -         0.101        -      0.156          - 
  ∆LVEDVI   -0.002           -    0.191        -      0.001        -      0.156          -   
  ∆LVEF   -0.137        -             -0.191        -     -0.147        -     -0.103          - 
  ∆LVMI    0.004        -             -0.056        -     -0.194        -     -0.140          -   
  ∆Inf Volume    0.006        -             -0.079        -     -0.139        -     -0.146         _ 
______________________________________________________________________________________________________________
___
Table 7.3  Spearman correlation coefficients for neurohormones (sampled at baseline and 24 weeks) and LGE-CMR parameters of LV remodelling. 
Units: LVESVI, LVEDVI, Infarct Volume: ml/m
2; LVEF: %; LVMI g/m
2         Key: *p<0.05    **p<0.01   217 
7.3.4  Relationships between apelin and sampled biomarkers 
The relationships between baseline plasma apelin and NTproBNP, NA and AVP are 
shown in Figure 7.3 A-C. Baseline apelin correlated weakly but significantly with 
baseline NA (r = 0.26, p = 0.008). There were no significant correlations between 
baseline apelin and baseline NT-proBNP or AVP. Baseline apelin had no association 
with ∆NA (r = -0.04, p = 0.70), ∆NT-proBNP (r = 0.01, p = 0.98) or ∆AVP (r = -0.03, 
p = 0.81) over the 24 week follow-up.  
 
 
Figure 7.3  Scatter plots showing the relationships between apelin and baseline NT-proBNP 
(A), NA (B) and AVP (C). Spearman correlation coefficients are shown for each group. 
Normal reference ranges are depicted by dotted lines. 
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7.3.5  Treatment effect of eplerenone on plasma apelin concentration 
Baseline plasma apelin concentration was similar within both treatment groups (0.58 
± 0.33 ng/ml in the placebo group vs. 0.54 ± 0.21 ng/ml in the eplerenone group, 
p=0.45). Over 24 weeks, plasma apelin concentrations were significantly higher in the 
eplerenone group than in the placebo group: the change in plasma apelin 
concentration was -0.01 ± 0.28 ng/ml in the placebo group and +0.17 ± 0.38 ng/ml in 
the eplerenone group (p=0.016). 
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7.4  Discussion 
 
7.4.1  Plasma apelin and post-infarction LV remodelling   
There are no published data on plasma apelin concentrations early after AMI in 
humans. This study has shown for the first time that plasma apelin concentration is 
reduced compared to healthy controls following AMI, and remains low out to 24 
weeks. A small but significant increase over time in apelin concentration was 
observed, although there was no association between apelin and LV remodelling, 
quantified using ceCMR. The lack of any relationship between apelin and LV 
function, either acutely or remote from the infarct, is perhaps counter-intuitive. It is 
relevant, however, that very little adverse ventricular remodelling occurred in this 
well-treated group of patients: LVESVI remained virtually unchanged although LVEF 
improved significantly, by 4.1%, over the course of the study.  
 
The source of circulating apelin in humans is unclear. While APJ receptor-like 
immunoreactivity (IR) and apelin-like IR have been demonstrated in endothelial and 
smooth muscle cells from major conduit vessels, the predominant source of plasma 
apelin is thought to be myocardial tissue, in particular the atria; plasma and atrial 
apelin levels are positively correlated.
319, 322 Changes in LV shape after large AMI and 
consequent elevated filling pressures may therefore be partly responsible for the 
reduced plasma apelin concentrations noted in this study. Rat myocytes, when 
subjected to mechanical stretch in culture, or chronic pressure overload in vivo, 
significantly down-regulate apelin mRNA synthesis.
316 In order to meet the criteria 
for recruitment, each patient in this study was required to have LVSD and thus had 
necessarily suffered an acute change in LV geometry. Such changes in LV geometry   220 
may well suppress apelin synthesis via apelin mRNA down-regulation. Also, 
stretching and expansion of the infarcted segment and consequent morphological 
change in the non-infarcted ventricle is an ongoing process, and may contribute to the 
persisting depression in plasma apelin concentration at 24 weeks. In addition, animal 
models of CHF have shown that activation of RAAS hormones may promote the 
down-regulation of myocardial apelin levels seen in this syndrome.
323 Activation of 
the RAAS early after AMI may have contributed to the reduced plasma apelin levels 
in our patients, while powerful pharmacologic inhibition of the RAAS, which was 
undertaken in almost all of our study patients, may be partly responsible for the 
significant increase in apelin over time, although as the effects of such 
pharmacological interventions on the apelin-APJ system in humans are currently 
unknown, these views are purely speculative. It is noteworthy that measurement of 
plasma apelin provides no information on local activity of the peptide at tissue level; 
indeed the lower plasma concentrations seen in the AMI group may reflect an 
atherosclerosis-related effect not applicable to the control group. Additionally, there 
are no published data on apelin levels following AMI in patients with preserved 
LVEF. If my theory that change in LV geometry promotes down-regulation of cardiac 
apelin synthesis is correct, we might anticipate higher plasma apelin levels in patients 
with preserved LVEF compared to our cohort, although this view is speculative. 
 
Evidence from a number of animal and human studies suggests that apelin possesses a 
range of properties that would be beneficial early after AMI. Apelin directly increases 
sarcomeric shortening and promotes enhanced contractility in cultured normal and 
failing rat myocytes.
314-316 Apelin knockout mice develop progressive LVSD over 
time.
324 Infusions of apelin into rats following experimental AMI promote   221 
improvements in stroke volume in the context of unchanged LVEDV, suggesting an 
antiremodelling effect; similar inotropic effects are seen in healthy mice in response 
to apelin infusion.
170, 325 In humans with CHF, plasma apelin levels are reduced across 
the spectrum of disease severity, with weak but significant correlations to LVEF, right 
ventricular ejection fraction (RVEF) and peak VO2, and interventions such as cardiac 
resynchronisation therapy and left ventricular assist device implantation promote 
improvements in LV function and increases in plasma apelin levels.
171, 172, 320  
 
These data suggest an inotropic role for apelin. Although I have shown that apelin did 
increase over time, plasma concentrations remained lower than in healthy controls 
remote from the infarction phase and bore no relation to LV function. The reasons for 
this are unclear but may relate to the lack of adverse remodelling seen in the study 
population and possible inter-species differences in myocardial response to apelin. 
In response to experimental AMI and systemic hypoxaemia in murine models, 
myocardial apelin expression is modestly increased, although this upregulation tends 
to diminish over time.
326  Apelin expression after experimental AMI is thus variable 
and possibly time-dependent. That plasma apelin was reduced compared to healthy 
controls when measured early after AMI may relate to such time-dependent 
expression, although we have no data on myocardial apelin expression in our patients. 
Plasma apelin has been demonstrated to be elevated in early/mild CHF but reduced in 
advanced symptomatic CHF; my findings, in a cohort of patients with coronary artery 
disease and LVSD, are consistent with these prior human studies.
171, 172  
 
NA is an important effector molecule of the sympathetic nervous system, and may 
play an important role in the pathogenesis of LV remodelling.
40, 41 I found significant   222 
inverse correlations between NA and LVEF early and late after AMI. That apelin 
concentrations were greatest in those with the highest NA – i.e. those displaying the 
highest sympathetic stress response (likely to represent the most unwell) – suggests 
indirectly a possible protective role for apelin early after AMI, although this requires 
further investigation. 
 
Eplerenone reduces cardiovascular morbidity and mortality in patients with LVSD 
and heart failure (or diabetes) early after AMI although the mechanism of this effect is 
unclear.
123 94% of the patients in this study were treated with an ACE inhibitor, thus 
the majority of the patients in the eplerenone group were receiving two antagonists of 
the RAAS. Angiotensin II concentrations were not measured in this study, but it is 
feasible that aldosterone antagonism may have promoted feedback upregulation of 
angiotensin II production. An interaction exists between apelin and angiotensin II in 
animal models.
323 The elevated apelin concentrations seen after 24 weeks of 
eplerenone therapy compared to placebo in this study may reflect this interaction 
although, in the absence of angiotensin II concentrations, these opinions are 
speculative. That eplerenone therapy was associated with less remodelling and greater 
apelin concentrations over time, however, supports a potential protective effect of 
eplerenone following AMI. 
 
I have therefore shown for the first time that plasma apelin concentration is reduced 
after AMI in patients with LVSD but without heart failure, and that although it 
increases over time, it remains low at 24 weeks. The plasma concentration of apelin 
has no relationship with LV volumes, mass or function and does not appear to 
influence remodelling although I cannot comment on local tissue effects of apelin. A   223 
weak relationship exists between plasma concentrations of apelin and NA early after 
AMI which may suggest a possible inotropic role for apelin but further studies are 
required to investigate these findings. It is, however, unlikely that apelin will be of use 
as a prognostic marker after AMI. 
 
7.4.2  Limitations 
The lack of remodelling in this cohort of patients has already been mentioned. The 
parent study was powered for CMR end-points, but a larger population would allow 
adequate power to determine conclusively the role, if any, of apelin after AMI. 
Patients in the control group were age-matched but more frequently female (p=0.071) 
than the AMI patients. Only apelin was measured in controls; NTproBNP, NA and 
AVP were sampled in the AMI group alone. The apelin assay measured apelin-12, -13 
and -16 but not other members of the apelin family (including apelin-17), which may 
have influenced the results. Finally, it is possible that apelin levels fluctuate after AMI; 
I collected samples once in the first few days then again at 24 weeks and therefore 
have no data on serial change in circulating apelin concentrations in the acute phase. I 
cannot therefore comment on any possible temporal variations during the sampling 
interval.  
 
7.4.3  Conclusions 
I have shown for the first time that plasma apelin concentration is reduced after AMI 
in patients with LVSD but without heart failure compared to healthy controls, and that 
although it increases over time, it remains low at 24 weeks. I have also shown for the 
first time in humans that eplerenone therapy was associated with higher circulating 
apelin levels. The plasma concentration of apelin has no relationship with LV   224 
volumes, mass or function and does not appear to influence remodelling although I 
cannot comment on local tissue effects of apelin.  
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Chapter 8 
 
A study characterising serum soluble ST2 concentrations 
after acute myocardial infarction in man 
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8.1  Introduction 
Risk stratification of patients admitted with acute coronary syndromes is increasingly 
dependent on measurement of prognostically significant cardiac biomarkers, as 
discussed in Chapter 4. Serum ST2 may be such a biomarker. ST2 is a member of the 
interleukin-1 receptor (IL-1R) family and exists in two isoforms – ST2L and soluble 
ST2 (sST2) – as described in Chapter 1.9. sST2 is thought to function as a decoy 
receptor which neutralises IL-33, which has recently been demonstrated to be the 
ligand for this receptor.
210 A possible cardioprotective role for the IL-33/ST2 
signalling pathway has been suggested by animal studies, and in human studies 
correlations have been found between sST2 and cardiac biomarker release (such as 
creatine kinase), NTproBNP and (pre-discharge) LVEF, as discussed in Chapter 1.9. 
These observations suggest that sST2 may be related to, or even play a role in, post-
infarction LV remodelling but this had not previously been evaluated at the time of 
my research project.  
 
The aims of this study were therefore to examine for the first time the relationships 
between serum sST2, parameters of LV function, and a variety of circulating 
mediators of pathophysiological significance in post-infarction remodelling in my trial 
cohort of 100 AMI patients with LVEF <40% but neither heart failure nor diabetes 
mellitus, using LGE-CMR as the imaging modality. 
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8.3  Methods 
 
8.2.1  Study patients and trial protocol 
All 100 patients enrolled in the primary study of this thesis (Chapter 3) were included 
in this study examining the role (if any) of sST2 in post-infarction remodelling. The 
screening, recruitment, randomisation process and trial outline are described in detail 
in Chapter 2 (2.1 – 2.3), and baseline demographic data of the study cohort are shown 
in Table 3.1.  
 
Each patient underwent LGE-CMR imaging at baseline, 12 and 24 weeks; detailed 
methodological protocols and analytic techniques are described in Chapter 2 (2.5 – 
2.6). Measurement of sST2 was performed at baseline (mean 3.7 [1.8] days after AMI) 
and at 12 and 24 weeks. In order to examine further the role (if any) of sST2 in post-
infarction remodelling, I also assessed its relationships with NTproBNP, NA and 
aldosterone (each measured at the same three time-points), biomarkers related to 
remodelling as described in Chapter 1. Detailed methods of collection, storage and 
measurement of each of these biomarkers are described in Chapter 2.8. Finally, I 
assessed whether eplerenone affected sST2 concentrations over time. 
 
8.2.2  Statistical methods 
The relationships between sST2 and parameters of LV remodelling were examined, in 
addition to the correlations between ST2 and NTproBNP, aldosterone and NA. All 
baseline biomarker measurements were taken prior to randomisation, and serial 
biomarker data were initially analysed regardless of parent study treatment allocation, 
then by treatment group. Inter-group comparisons were made using paired sample t-  228 
tests or Mann-Whitney-U tests as appropriate for continuous variables and Chi-
squared test for categorical variables. Paired t tests were used to detect changes in 
ceCMR measurements and biomarkers within each treatment group over the 24 weeks 
of the study, and differences between these changes were analysed using an unpaired t 
test.  
 
Non-normal data were logarithmic-transformed prior to analysis; Pearson’s and 
Spearman’s correlation coefficients were used for parametric and non-parametric 
variables respectively. Comparison of mean ceCMR parameters within tertiles of 
serum sST2 was then performed using separate Kruskal-Wallis tests. All statistical 
analyses were performed using SPSS version 15.0 (SPSS Inc., Chicago, Illinois, 
USA).  
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8.3  sST2 following AMI in man 
 
8.3.1  Changes in sST2 concentration after AMI 
Serum sST2 concentration, expressed as median [interquartile range], decreased 
significantly from 263.3 [139.4-491.5] pg/mL at baseline to 140.0 [83.0-196.2] pg/mL 
at 24 weeks (p<0.001). This decrease occurred between baseline and 12 weeks – from 
12 to 24 weeks there was no significant change in serum sST2 concentration (Figure 
8.1).  
 
Figure 8.1  Boxplot depicting median serum sST2 concentrations sampled at baseline, 12 and 
24 weeks after AMI. Boxes represent interquartile ranges. 
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8.3.2  sST2 concentrations and LV function after AMI 
Serum sST2 concentrations were non-normally distributed and accordingly were 
logarithmic-transformed prior to analysis. Baseline sST2 correlated inversely with 
baseline LVEF (r = -0.30, p = 0.002) and baseline infarct volume index (r = 0.26, p = 
0.005) but not with baseline LVESVI, LVEDVI or LVMI (Table 3). Baseline sST2 
correlated significantly with 24-week LVEF (r = -0.23, p = 0.026) and infarct volume 
index (r = 0.22, p = 0.037) but not with 24-week LV volumes or LVMI. Baseline 
sST2 correlated inversely with change in (∆) infarct volume index (r = -0.28, p = 
0.009) but not with change in any other LGE-CMR parameter. 
 
∆sST2 from baseline to 24 weeks correlated significantly with ∆LVEDVI (r = -0.24, p 
= 0.023) and with ∆infarct volume index (r = 0.21, p = 0.043) but not with ∆LVESVI, 
∆LVEF or ∆LVMI (Table 8.1). 
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Table 8.1  Spearman correlation coefficients for circulating biomarkers, sampled at baseline, and LGE-CMR parameters of LV remodeling. 
Units: LVESVI, LVEDVI, infarct volume index (Inf Vol): ml/m
2; LVEF: %; LVMI g/m
2         Key: *p<0.05    **p<0.01    †Change in each biomarker 
between baseline and 24 weeks 
 
                 Baseline              Baseline              Baseline              Baseline 
            log10 (serum sST2)    log10 (NTproBNP)     log10 (noradrenaline)   log10 (aldosterone) 
   
Baseline 
  LVESVI         0.17         0.33**       0.17         0.25* 
  LVEDVI         0.01         0.19         0.10         0.15 
  LVEF          -0.30**      -0.39**      -0.22*       -0.31** 
  LVMI          0.05         0.05         0.23*         0.22* 
  Inf Volume        0.26**       0.26**       0.17         0.39** 
 
24 weeks 
  LVESVI         0.17         0.43**       0.23*         0.34** 
  LVEDVI         0.06         0.30**       0.09         0.18 
  LVEF         -0.23**      -0.45**      -0.31**      -0.41** 
  LVMI        0.03         0.02         0.16         0.22* 
  Inf Volume        0.22*         0.33**       0.17         0.41** 
 
∆ceCMR parameter (0 – 24 weeks)     ∆sST2
†          ∆NTproBNP
†      ∆Noradrenaline
†          ∆Aldosterone
† 
  ∆LVESVI       0.11    -0.13     0.26**  -0.14     0.10     0.08     0.28**  -0.23* 
  ∆LVEDVI       0.18    -0.24*    0.19    -0.06     0.01    -0.02     0.20    -0.33** 
  ∆LVEF       -0.01     0.01    -0.19     0.08    -0.15    -0.12    -0.21*    0.07 
  ∆LVMI         0.03    -0.01    -0.06     0.12    -0.19     0.07    -0.07    -0.07 
  ∆Inf Volume      -0.28**   0.21*    -0.08     0.10    -0.14     0.15    -0.34**   0.19   
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The change over time in LV volumes, LVEF, LVMI and infarct volume index was 
compared according to tertiles of baseline serum sST2 (Figure 8.2). Compared to 
patients in the highest tertile of baseline serum sST2, those in the lowest tertile 
displayed a significantly lower ∆LVEDVI and less reduction in infarct volume index 
over time; there was a trend towards a lower ∆LVESVI but this was not significant. 
There were no significant inter-tertile differences in ∆LVEF or ∆LVMI. 
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Figure 8.2  Comparison of change in LGE-CMR parameters between 0 and 24 weeks 
according to tertiles of baseline serum sST2: (A) ∆LVESVI (B) ∆LVEDVI, (C) ∆LVEF, (D) 
∆LVMI, (E) ∆Infarct volume index. [Serum sST2 tertile concentration ranges: tertile 1 – 0-
174.4 pg/ml; tertile 2 – 174.41-372.3 pg/ml; tertile 3 – ≥372.3 pg/ml] 
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8.3.3  sST2 concentrations and infarct characteristics after AMI 
 
Figure 8.3  Comparison of mean serum sST2 concentrations according to (A) LGE-CMR-
measured anatomical infarct site (note: lateral infarct site not used in comparative analysis 
with other infarct sites as n = 4), (B) presence of late microvascular obstruction, (C) median 
transmurality score. Error bars indicate SEM. Median transmurality score in (C) was 3.44   235 
Baseline infarct characteristics are shown in Table 6.1. There were no significant 
differences in serum sST2 between anterior/anterolateral (n = 55, mean 367.4 [335.3] 
pg/mL), inferior/inferolateral (n = 41, mean 441.9 [372.2] pg/mL) and lateral (n = 4, 
mean 474.5 [638.0] pg/mL) sites of infarction (Figure 8.3 A). Serum sST2 correlated 
significantly with the endocardial extent of the infarct (r = 0.26, p = 0.008). The 
presence of late MVO was associated with a significantly higher serum sST2 (520.1 
[512.5] vs. 253.0 [206.9] pg/mL without MVO, p=0.001) – Figure 8.3 B. Serum sST2 
was significantly higher in patients with a transmurality score at or above the median 
compared to those below the median (493.2 [537.4] vs. 316.4 [261.1] pg/mL, p=0.038) 
– Figure 8.3 C 
 
8.3.4  sST2 and neurohormones after AMI 
The relationships between (log-transformed) plasma NTproBNP, NA and aldosterone 
at baseline and parameters of LV function and infarct volume over time are shown in 
Table 8.1. Baseline sST2 correlated significantly with baseline NA (r = 0.21, p = 
0.034) and aldosterone (r = 0.28, p = 0.006) but not with NTproBNP (r = 0.14, p = 
0.15) – Figure 8.4. Baseline sST2 also correlated with ∆NA (r = -0.25, p = 0.014) but 
not with ∆aldosterone or ∆NTproBNP. 
 
∆sST2 correlated significantly with ∆aldosterone (r = 0.26, p = 0.012) and ∆NA (r = 
0.23, p = 0.024) but not with ∆NTproBNP (r = 0.15, p = 0.14). 
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Figure 8.4  Scatterplots depicting the relationship of baseline (logarithmic-transformed) serum 
sST2 with baseline noradrenaline (A), aldosterone (B) and NTproBNP (C). Correlation 
coefficients and significance values are shown. 
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8.3.5  Treatment effect of eplerenone on sST2 
Eplerenone, the study drug in the primary trial on which this thesis is based, had no 
significant effect on serum sST2 concentration over time. Baseline serum sST2 
concentration, expressed as mean ± SD, was similar within both randomisation groups 
(394.3 ± 322.6 pg/mL in the placebo group vs. 411.8 ± 514.0 pg/mL in the eplerenone 
group, p = 0.84). Over 24 weeks, the change in serum sST2 concentration was -251.7 
± 323.9 pg/mL in the placebo group and -208.1 ± 448.0 pg/mL in the eplerenone 
group (p = 0.59).   
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8.4  Discussion 
 
8.4.1  Serum sST2 and LV function after AMI 
In this study, I not only confirmed that there is a relationship between sST2 and LV 
function early after AMI, but also showed that sST2 is associated with medium-term 
LV function, and additionally that sST2 is related to infarct magnitude and infarct 
remodelling over time. I also provided novel data on potential interactions between 
sST2, aldosterone and noradrenaline, and suggest that sST2 may play a 
pathophysiological role in post-infarction remodelling. 
 
Both sST2 isoforms – ST2L and sST2 – are transcriptionally induced by the 
application of biomechanical strain to rodent cardiomyocytes and cardiac fibroblasts 
in vitro.
209, 212 Not only is sST2 elevated in vivo following experimental AMI in mice, 
it has also been shown to be elevated in the serum of human subjects following AMI, 
in acute and chronic heart failure.
209, 211-216 When measured early after AMI, 
significant associations have been found between sST2, higher creatine kinase 
concentrations and lower pre-discharge LVEF.
209, 214 Moreover, baseline sST2 
predicts 30-day occurrence of heart failure or death following STEMI and, when 
combined with NTproBNP, significantly improves risk stratification in this 
condition.
213, 214 sST2 is also of prognostic benefit in both acute and chronic heart 
failure, in which it is associated with poorer LV function and higher NYHA class.
211, 
215, 216 Prior to this study, the relationship between sST2 and serial change in LV 
function following AMI had not been characterised. Using a gold-standard technology 
for LV functional assessment, LGE-CMR, which additionally affords detailed infarct   239 
examination, I report for the first time on the relationship between sST2, LV 
remodelling and infarct characteristics following AMI. 
 
In the study cohort, all of whom were required to have depressed LVEF, I found a 
significant correlation between sST2 (measured in the first few days after AMI) and 
pre-discharge LVEF, in keeping with recent clinical studies. In the largest published 
study examining sST2 in AMI, a correlation (albeit weak) was found between sST2 
and lower LVEF early after STEMI in 551 patients enrolled in the CLARITY-TIMI 
28 trial.
214 A similar relationship was seen in 69 predominantly STEMI patients 
enrolled in the HEART study.
209 My findings, that baseline sST2 correlates with 
medium-term (24-week) LVEF, and moreover that greater adverse LV remodelling 
was seen in patients with the highest baseline sST2, are novel. Whether sST2 has a 
pathophysiological role in post-infarction remodelling or whether it simply identifies 
a population with poorer LV function who would be more likely to remodel, is 
unclear; data from infarct characteristics and biomarker analysis provide further 
insights. 
 
I assessed the relationship between sST2, baseline infarct characteristics and infarct 
evolution over time. Although I did not find any relationship with infarct location, I 
have shown that sST2, measured early after AMI, was associated with greater 
baseline infarct volume, correlated with the endocardial extent of infarction and was 
higher in patients with greater infarct transmurality, all parameters of large infarction. 
I also found that sST2 was higher in patients displaying MVO, which is known to be 
associated with greater baseline LV volumes, more significant remodelling and 
adverse cardiovascular outcome after AMI.
254, 255 Over time, I found a correlation   240 
between sST2 and 24-week infarct volume, and an inverse relationship with ∆ infarct 
volume which occurs as peri-infarct oedema resolves and the infarcted myocardium 
remodels.
309 These data suggest not only a link between the magnitude of infarcted 
myocardium and serum sST2 release, but also point towards a possible role for sST2 
in infarct healing/scar formation. 
 
A role for serum sST2 in ventricular (and infarct) remodelling is further suggested by 
its observed correlation with plasma aldosterone. Aldosterone, as described previously 
in this thesis, has strong pro-fibrotic effects on the heart – both reparative fibrosis in 
the infarct zone and reactive fibrosis in non-infarct myocardium – some of which are 
thought to be mediated by mineralocorticoid receptor activation on cardiac 
fibroblasts.
84, 101 Aldosterone antagonism can attenuate or even reverse myocardial 
fibrosis, with concomitant improvement in LV function.
106, 107 Significant 
improvements in cardiovascular outcomes have been demonstrated using aldosterone 
antagonists in survivors of AMI with resultant LVSD and heart failure (or diabetes 
mellitus) and in advanced CHF.
121, 123 Statistically significant associations between 
plasma aldosterone and parameters of LV remodelling were found in my cohort. 
 
The mechanism of a possible relationship between sST2 and circulating aldosterone is 
unclear. That significant interplay occurs between cytokines and other systems 
integral to LV remodelling, including the RAAS, is well-documented.
81, 207 IL-33, 
recently demonstrated to be the ligand for serum sST2, antagonises angiotensin II- 
and phenylephrine-induced hypertrophy in cardiomyocytes; sST2 blocks these 
effects.
210, 212 Serum sST2 may therefore function as a soluble decoy receptor for IL-
33, and it appears likely that the IL-33:sST2 ratio determines IL-33-mediated   241 
signalling.
212 This theory may be relevant to the observed correlation between sST2 
and aldosterone seen in this study – as sST2 rises, it may disinhibit the effects of 
angiotensin II on cardiomyocytes by reducing the concentration of free, unbound IL-
33, resulting in cardiomyocyte hypertrophy, greater aldosterone biosynthesis and 
more significant remodelling, although in the absence of simultaneous IL-33 
measurement these views are purely speculative. That change in sST2 over time 
correlated inversely with ∆LVEDVI is surprising, but may simply reflect my earlier 
findings – that although sST2 falls over time, those with the highest sST2 at baseline 
are more likely to remodel adversely and thus undergo progressive ventricular 
dilatation.  
 
I found that a higher sST2 was associated with higher baseline noradrenaline and a 
greater reduction in noradrenaline over time. A similar relationship between sST2 and 
noradrenaline has been reported in a cohort of patients with advanced CHF.
215 
Noradrenaline is a surrogate marker of neurohormonal activation and can stimulate 
the release of pro-inflammatory cytokines.
42 I was unable to assess whether 
noradrenaline has any effect on the IL-33:sST2 ratio in this study; no published 
studies on IL-33 to date have analysed the effects of noradrenaline on its release. It is 
theoretically possible, however, that a significantly elevated noradrenaline may 
influence the balance between sST2 and its ligand, perhaps reducing the concentration 
of unbound IL-33 and diminishing its protective effects on cardiomyocytes. 
Noradrenaline was associated with increasing LV volumes and poorer LV function 
over the course of our study. 
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I did not find any correlation between sST2 and NTproBNP. While I acknowledge 
that, in a more appropriately powered study, an association was found between sST2 
and natriuretic peptides – a significant correlation between sST2 and NTproBNP was 
observed in more than 1200 patients following STEMI in the CLARITY-TIMI 28 trial 
– this correlation was weak, and indeed no significant correlation was observed 
between sST2 and BNP in a smaller study of 810 STEMI patients.
213, 214 sST2 has 
been shown to correlate with natriuretic peptides in acute and chronic heart failure 
although again these associations were weak.
215, 216 Rather than replacing natriuretic 
peptides, perhaps the most promising future role for sST2 following AMI and in heart 
failure is the enhancement of risk stratification when combined with natriuretic 
peptides.
214, 216  
 
That median baseline sST2 in the study cohort (263 pg/mL) was higher than that seen 
in two recent studies of AMI (80 pg/mL and 235 pg/mL) but lower than in several 
recent AHF studies (490, 500 and 570 pg/mL) may relate to inter-study variation in 
timing of sST2 sampling and analysis kit used.
211, 213, 214, 216, 327 However, unlike in the 
quoted AMI trials, each patient in this study was required to have LVSD, which 
presumably contributed to the higher sST2 concentrations given the correlation 
between sST2 and LVEF, and reinforces my (and others’) findings that sST2 and LV 
function are related following AMI.  
 
8.4.2  Limitations 
The above findings with respect to sST2 must be considered in light of some 
important limitations. The parent study was powered for CMR end-points, hence the 
relatively small sample size (n=100). Where relevant, findings from more   243 
appropriately powered studies examining sST2 in AMI have been acknowledged. 
These results pertain only to patients with LVSD after AMI, as all patients were 
required to have a reduced LVEF prior to study inclusion. Serum sST2 was sampled 
only once in the early post-infarction phase, at a mean 46 hours after AMI. The 
precise temporal profile of serum sST2 concentration following AMI in humans has 
yet to be characterised, but data from the CLARITY-TIMI 28 trial show a small but 
significant decrease in sST2 between admission with STEMI and angiography 96 
hours later.
214 I cannot assume that I measured “peak” sST2 following AMI, merely a 
“pre-discharge” serum concentration. I did not simultaneously measure IL-33 and thus 
cannot comment on the IL-33:sST2 ratio, but this is a clear focus for future research 
in both AMI and heart failure. Finally, serum sST2 concentrations are elevated in non-
cardiac conditions including asthma, trauma, sepsis, malignancy and autoimmune 
disease; while I did not adjust for these conditions, they are only applicable to a very 
small number of the trial cohort and would thus be unlikely to influence the results.
328    
 
8.4.3  Conclusions 
I have shown that measurement of sST2 early after AMI assists in the prediction of 
medium-term LV functional recovery following AMI, and that direct relationships 
exist between sST2, infarct magnitude and infarct remodelling. I also, for the first 
time, report on a relationship between sST2 and circulating aldosterone, and suggest 
that the IL-33:sST2 signalling system and the RAAS may be interlinked, raising the 
possibility of a direct role for the IL-33:sST2 system in the pathogenesis of post-
infarction remodeling. Further studies to examine in more detail the potential role of 
this system are warranted, as it may not only serve as a prognostic marker but also 
provide a therapeutic target in conditions of myocardial injury and/or strain.   244 
 
 
 
Chapter 9 
 
Additional intracardiac and extracardiac abnormalities 
detected by pre-discharge ceCMR imaging following acute 
myocardial infarction 
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9.1  Introduction 
Following AMI, 25 to 60% of patients will have sustained sufficient myocardial 
damage to cause LVSD, thus it is predictable that European and American guidelines 
recommend that all AMI patients should undergo a formal evaluation of LV function, 
ideally pre-discharge.
11, 127, 128 TTE is the most commonly used imaging modality for 
this purpose. However, TTE carries significant inter- and intra-observer variability 
that limit its applicability, and for a variety of reasons CMR is now considered the 
gold-standard means of assessment of LV volumes and ejection fraction, as discussed 
in Chapter 1.11. CMR also allows imaging of the thorax and upper abdominal viscera, 
and through the use of contrast additionally also allows assessment of myocardial 
viability and perfusion (LGE-CMR).  
 
The aim of this observational study was to assess the influence of pre-discharge LGE-
CMR imaging on patient management in the 100 patients admitted with AMI with 
resultant LVSD that constitute the patient cohort for the studies on which this thesis is 
based. Each patient had undergone unenhanced TTE prior to LGE-CMR, i.e. each 
patient had had an assessment of cardiac function as occurs in ‘standard’ post-MI 
management. 
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9.2  Methods 
 
9.2.1  Patients and imaging protocols 
All 100 patients enrolled in the primary study of this thesis (Chapter 3) were included 
in this observational study. Screening, recruitment and the trial outline are described 
in detail in Chapter 2 (2.1 – 2.3), and baseline demographic data are shown in Table 
3.1. 
 
Each patient underwent a single screening TTE as per trial protocol, although a 
minority underwent repeat TTE imaging for clinical indications – these are detailed 
below where relevant. LGE-CMR imaging took place at baseline, 12 and 24 weeks. 
Details of the imaging techniques and analysis are provided in Chapter 2 (2.4 – 2.6). 
 
9.2.2  Statistical analysis 
All discrete variables are expressed as percentages within the study population. 
Continuous variables are expressed as means with standard deviations. All statistical 
analysis was performed using SPSS version 15.0 
 
9.3   Additional findings detected by ceCMR 
 
1.4.1  Intracardiac abnormalities 
The addition of LGE-CMR as part of the pre-discharge investigations in patients 
admitted with AMI in the study cohort afforded the detection of a variety of additional 
abnormalities, which have been divided into ‘intracardiac’ and ‘extracardiac’. 
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LV thrombus 
Thrombus within the LV apex was detected or strongly suspected on screening TTE 
in 5/100 patients (5%). Using LGE-CMR, LV apical thrombus was definitely present 
in 15/100 (15%). All cases with LV thrombus had presented with anterior AMI; 
within this subgroup (of 55 patients) the incidence of LV thrombus was 27.3%. TTE 
was deliberately repeated after LGE-CMR in 8 of the 10 patients who were “TTE 
negative, LGE-CMR positive” for LV thrombus (2 were transferred back to the 
referring hospital before repeat TTE could be performed): in 3 out of 8 the thrombus 
had become apparent on unenhanced TTE but in the remaining 5 there was still no 
echocardiographic evidence of thrombus (note: echocardiographic contrast agents 
were not used). All patients with LV thrombus were formally anticoagulated with 
warfarin for a period of time decided by the admitting cardiology team. In no case 
was there any evidence of thromboembolism during the 6 month follow up period for 
each patient. An extreme example of a LV thrombus developing late during the 
admission is shown in Figure 9.1. 
 
Figure 9.1  CMR scan performed 4 days after anterior AMI displaying LV apical thrombus. 
(A) Horizontal long-axis view showing extensive apical thrombus formation (arrow) within 
LV cavity. (B) Short-axis view through LV apex in Figure 28A reveals a thin pedicle (arrow) 
by which the thrombus inserts onto the endocardial aspect of the anteroapical wall. 
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Right ventricular infarction 
Right ventricular infarction (RVI) was detected on TTE in 10 patients (10%), all of 
whom had been admitted with inferior STEMI (n=45); the incidence within this group 
was therefore 22.2%. In only 4 cases was RVI clinically apparent (raised jugular 
venous pulse, hypotension, oliguria with no evidence of pulmonary rales). LGE-CMR 
confirmed RVI (defined as RV regional hypokinesis with congruent delayed hyper-
enhancement after gadolinium DTPA administration [Figure 9.2]) in these 10 patients 
but also detected RVI in an additional 11 patients, thus overall 21% of the study 
population suffered RVI (19/45 [42.2%] inferior STEMI, 2/55 [3.6%] anterior AMI). 
In 6 of these 11 additional patients with significant RVI on LGE-CMR, loop diuretics 
(which had been commenced due to relative oliguria in the context of 
echocardiographic LVSD by the ward staff) were with-held following the LGE-CMR 
findings of both RVSD and LVSD. Cautious volume loading with intravenous 
crystalloids was used successfully in 4 of these 6 patients to improve urine output 
without precipitating clinical heart failure.  
 
Figure 9.2  Right ventricular infarction. (A) CMR short-axis view of a patient admitted with 
an inferior STEMI. The RV is slightly dilated on this still image, while the cine showed 
significant RV dysfunction in addition to inferoseptal hypokinesia of the LV. (B) Delayed-
enhancement CMR image (slice position copied from 29A) 20 minutes after gadolinium-
DTPA injection. LV inferoseptal infarct visible (with involvement of the posteromedial 
papillary muscle); extensive late contrast uptake within the RV (arrows) consistent with RV 
infarction.   249 
Intracardiac mass 
An intracardiac mass was detected in one patient, a 67-year-old female admitted with 
an inferoposterolateral STEMI on ECG in whom screening TTE was rendered 
difficult by both kyphoscoliosis and a minor anterior chest wall deformity. Apical 
views were acceptable but parasternal views obscured. LGE-CMR revealed not only 
extensive infarction of the lateral wall of the LV and both papillary muscles (Figure 
9.3 A) but also identified a small mass within the left atrium, adherent to the 
interatrial septum (Figure 9.3 B) that had not been detected on TTE. Subsequent 
investigation by transoesophageal echocardiography confirmed the presence of a 
small atrial myxoma (2.8 x 2.0 cm) which was ultimately surgically resected 6 weeks 
after the AMI. 
 
 
 
Figure 9.3  Left atrial myxoma. (A) CMR short-axis slice at mid-ventricular level, 20 minutes 
after gadolinium-DTPA injection, of a 67-year-old female patient presenting with an 
inferolateral STEMI. Obvious infarction of the lateral wall of the LV (arrows), and both 
papillary muscles (PM) visible. (B) CMR horizontal long-axis view of same patient showing 
mass adherent to the interatrial septum, confirmed after excision as a benign myxoma (arrow). 
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9.3.2  Extracardiac abnormalities 
The thorax and upper abdomen are necessarily imaged during CMR scanning. In 5 
patients (5% of the cohort) abnormalities of varying clinical relevance were detected 
on CMR. These included: mesothelioma in a 69-year-old smoker whose chest X-ray 
had shown probable consolidation at the right lung base, but respiratory opinion and 
subsequent diagnosis were prompted by the abnormal CMR appearances (Figure 9.4 
A); prominent bullae within the lung fields of a 48-year-old non-smoker (Figure 9.4 
B,C) with subsequent diagnosis of mild airflow obstruction on spirometry and a low-
normal alpha-1-antitrypsin level of 102 mg/ml (normal range 100-300 mg/ml); a 
pancreatic pseudocyst in a 50-year-old man with chronic pancreatitis but no previous 
pseudocyst, who described weight loss and early satiety prior to his admission with 
AMI (Figure 9.4 D,E); and asymptomatic renal cysts in two elderly patients whose 
management was not directly influenced by this discovery. 
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Figure 9.4  Extracardiac abnormalities. (A) Oblique vertical long-axis CMR view of a 69-
year-old patient admitted with an inferior STEMI. Admission chest X-ray suggested 
consolidation at the right lung base, but CMR suggests diffuse pleural thickening consistent 
with mesothelioma (arrows). (B) Horizontal and (C) short-axis CMR views of a 48-year-old 
non-smoker admitted with an anterior NSTEMI. Bullous hyper-expansion of both lung fields 
apparent (more marked on the left), with medial displacement of the mediastinum and its 
contents. (D) CMR short-axis view of 50-year-old patient with chronic pancreatitis, admitted 
with an inferior STEMI. A large pancreatic pseudocyst (PS) is present, visibly compressing 
the stomach. (E) After 3 months of conservative therapy, there is a marked reduction in the 
size of the PS, with less compression of the stomach and visible gastric contents (GC). 
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9.4  Discussion 
 
9.4.1  The benefits of pre-discharge ceCMR imaging following AMI 
All patients should undergo assessment of ventricular function following AMI. I 
compared standard practice – unenhanced TTE – with standard practice plus pre-
discharge CMR imaging in 100 patients with extensive AMI and resultant LVSD. The 
clinical management of 19% of the cohort (ie. the combined number of patients with 
LV thrombus absent on initial TTE, RVI on LGE-CMR resulting in with-holding of 
diuretic and/or commencement of intravenous fluids, and undiagnosed atrial myxoma, 
emphysema and mesothelioma) was directly influenced by the LGE-CMR findings. 
An additional 5% were found to have sub-clinical RVI on LGE-CMR that did not 
directly influence acute management but which led to a more cautious approach to up-
titration of ACE inhibitors and β blockers, thus in almost one-quarter of this post-
AMI population the LGE-CMR scan added significant therapeutic and prognostic 
information that would have been unavailable if the “standard care” approach had 
been taken. 
 
Studies from the pre- and early reperfusion eras reported that LV thrombus occurred 
in 15-56% of anterior AMIs, while contemporary studies suggest a lower overall 
incidence in general (c. 4%), skewed towards the anterior AMI subgroup within 
which the incidence approaches 10%.
329-334 I found that the overall incidence of LV 
thrombus in AMI patients with LVSD was 15% in this study cohort. Within the 
subgroup of patients with anterior AMI and LVSD the incidence was 27.3%. More 
than half of LV thrombi undetected on initial TTE remained undetected on repeat 
TTE. While there has been debate as to the actual incidence of embolic events in   253 
cases of LV thrombus after AMI, its detection is of relevance as it is associated with 
poorer LV function, adverse remodelling and greater mortality.
333-336 Our 
departmental policy was to anticoagulate formally all patients with identified LV 
thrombus; in all cases the thrombus had resolved by the 3 month follow-up scan, and 
in no case was there evidence of an embolic event during the 6 month follow-up. I 
therefore suggest that LV thrombus formation remains common after anterior AMI, 
particularly in the context of LVSD, and should be excluded by serial TTE and, in 
cases of uncertainty, LGE-CMR. 
 
RVI complicates up to 50% of inferior AMI yet remains subclinical in the majority.
337 
RVI, whether clinically apparent or not, remains a significant independent risk factor 
for increased mortality after AMI, even following primary PCI.
338 Many imaging 
methods struggle to visualise the RV, including TTE. LGE-CMR not only allows 
formal qualitative and quantitative assessment of RV function, but also allows 
accurate identification and quantification of RV infarction.
226, 233, 234 Identification of 
RV dysfunction in patients with LV infarction aids risk stratification and targeted 
secondary preventive therapy, while in the acute phase knowledge of RVI may assist 
in the management of these high-risk patients.
337 I found that TTE failed to detect 
more than 50% of those patients with RVI on LGE-CMR. 
 
One patient in the study cohort had an atrial myxoma which was only detected on 
CMR. I acknowledge that the overall incidence of primary intracardiac tumours is low 
(incidence of 0.02% on post-mortem studies) thus routine CMR imaging for the 
detection of such neoplasms is not justified.
339 I simply report the incidental detection 
of an intracardiac myxoma in this observational retrospective report.   254 
 
The wider imaging field of view afforded by CMR subtends further benefits over TTE. 
I detected extracardiac abnormalities in 5% of our cohort, of which 3/5 (60%) were 
clinically significant and led to targeted investigation and appropriate referral. These 
data are similar to the non-cardiac abnormal findings in a recent series of patients with 
suspected coronary artery disease, undergoing CMR (2% of 108 patients had 
‘significant’ non-cardiac abnormalities, defined as requiring further clinical or 
radiological follow-up, with ‘non-significant’ non-cardiac abnormalities detected in a 
further 6%).
340 Cardiologists in training in the field of non-invasive imaging need pay 
particular attention to the non-cardiac abnormalities that modalities such as CMR and 
computed tomography will reveal, from both a medical and legal standpoint. 
Multidisciplinary reporting sessions involving cardiologists and experienced 
radiologists are to be encouraged. 
 
9.4.2  Limitations 
The predominant limitation in this study is the time delay between TTE and CMR. 
The primary study of this thesis (Chapter 3) mandated that the screening TTE be 
performed prior to randomisation but did not stipulate that repeat TTE be performed 
on the same day as the CMR. This would have allowed more direct comparison of the 
two separate imaging techniques in terms of volumetric and functional measurements, 
and additional abnormalities detected. However, the purpose of this report is to 
highlight the overall benefit to patient care of adding a pre-discharge LGE-CMR 
rather than to compare directly TTE and LGE-CMR. 
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9.4.3  Conclusions      
Through the detection of both intra- and extra-cardiac abnormalities, LGE-CMR 
significantly enhanced the management of 24% of patients with AMI and LVSD. In 
no case was patient safety compromised by transfer from the coronary care unit to the 
CMR department early after AMI. With faster, more refined imaging sequences, and 
increasing availability of CMR, greater numbers of AMI patients will be able to 
undergo CMR scanning pre-discharge. I suggest, based on this cohort of patients, that 
a solitary TTE performed in the first few days after AMI is insufficient for formal 
cardiac assessment following AMI, and that at the very least a repeat TTE should be 
performed prior to discharge; where possible LGE-CMR should be used as an adjunct 
to routine post-AMI care. 
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Chapter 10 
 
General discussion and conclusions 
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10  General discussion 
 
10.1  Eplerenone – an anti-remodelling agent? 
Aldosterone has a number of detrimental effects on the cardiovascular system in 
general, demonstrated directly through experimental in vitro and in vivo 
(predominantly animal) studies and indirectly through the beneficial effects of 
aldosterone antagonism in humans with hypertension, AMI or CHF. The specific role 
of circulating aldosterone in LV remodelling following AMI is unclear, however, and 
recent trial data have been inconsistent. The primary aim of this thesis was to 
determine the effect of selective mineralocorticoid receptor blockade with eplerenone 
compared to placebo on LV remodelling over 24 weeks in a cohort of patients 
admitted with extensive AMI resulting in LVSD but without clinical or radiological 
heart failure (or diabetes mellitus) using LGE-CMR, the gold standard imaging 
modality for assessment of LV function. In comparison to EPHESUS, I found that 
eplerenone continued to exert a treatment effect in a less unwell population with a 
greater revascularisation rate and higher uptake of ACE inhibitors/ARBs and beta 
blockers (although statistical adjustment of the primary results was necessary); the 
greater clinical stability of the patients in this study allowed earlier commencement of 
eplerenone (4.8 versus 7.3 days in EPHESUS) which was safe and well-tolerated. 
These CMR-based results were supported by a covariate-adjusted treatment effect of 
eplerenone on MMP-2 and MMP-9, enzymes of critical importance in ECM turnover 
and matrix remodelling. This is, to the best of my knowledge, the first time that 
eplerenone has been shown to exert an anti-remodelling effect in ‘asymptomatic’ 
LVSD after AMI. 
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Although eplerenone confers significant reductions in cardiovascular morbidity and 
mortality upon EPHESUS-like patients, its prescription in such patients at the time of 
writing this thesis has been surprisingly low in the West of Scotland, and indeed 
worldwide. Concerns over the safety of dual inhibition of the RAAS early after AMI, 
and cost issues, compounded by a general impression that spironolactone (an off-
patent and thus substantially cheaper drug) would be just as effective in AMI patients 
with reduced LVEF and heart failure, have contributed to this under-prescription.  
 
The primary results of this thesis, as detailed in Chapter 3, require to be confirmed in 
larger studies powered to detect an improvement in clinical outcomes in 
‘asymptomatic’ LVSD after AMI prior to the possible use of eplerenone in a broader 
patient population than that enrolled in EPHESUS, i.e. irrespective of heart failure 
status or diabetes. These results, in which the addition of eplerenone on day ~5 after 
AMI attenuated remodelling to an extent, taken together with previous data 
confirming the safety and anti-remodelling efficacy of aldosterone blockade (with 
spironolactone) on day 1 after AMI, suggest that aldosterone antagonism should be 
instituted as early as possible after AMI in order to maximise its anti-remodelling 
potential.
94 While these data provide information that would be of use in the design of 
a large-scale clinical study assessing eplerenone in ‘asymptomatic’ LVSD after AMI, 
such a study appears unlikely at present for a variety of reasons, not least of which is 
the current global financial climate. Eplerenone, a Pfizer-produced and marketed drug, 
will be off-patent in 2011 and it is unlikely that the company will sponsor further 
large-scale trials using eplerenone in view of the relatively poor global uptake of 
eplerenone despite the overwhelmingly positive results of EPHESUS, and in light of 
the disappointing provisional results of the REMODEL study, in which eplerenone   259 
was not associated with an anti-remodelling effect in stable CHF.
130  The ongoing 
EMPHASIS-HF study will assess the effects on major clinical end-points of 
eplerenone in CHF but the results have yet to be reported. Additionally, the previously 
discussed non-significant trend towards a higher occurrence of stroke in eplerenone-
treated patients in EPHESUS has led to concerns over its safety; EMPHASIS-HF 
should provide further information in that regard in a patient population at higher risk 
of stroke than that enrolled in EPHESUS. 
 
10.2  Predictors of post-infarction remodelling 
Prediction of LV functional recovery following AMI is of critical importance, as 
patients with a persistently reduced LVEF represent a high-risk population that not 
only warrants stringent monitoring but may also be considered for ICD therapy. I 
found that, based on a single sample taken on (mean) day 3 after AMI, an elevated 
plasma BNP, NTproBNP, TIMP-2, TIMP-4, tPA antigen and vWF, and a reduced 
plasma eotaxin and IL-7, correlated with poorer LV function over time. Moreover I 
found that TIMP-4 and tPA antigen were independent predictors of LV remodelling, 
findings that are novel. Additionally, I detected correlations between MMP-3 and the 
haemostatic biomarkers tPA antigen and vWF. While correlations do not imply 
definite biologic effect, these results nonetheless suggest a potential 
pathophysiological link from the coagulation-fibrinolytic system to collagen matrix 
turnover and consequent adverse remodelling after AMI. 
 
The studies described in Chapter 4 were not powered to determine the predictive 
efficacy of biomarkers in post-infarction remodelling, thus the results would require 
confirmation in larger, more appropriately-powered studies. That TIMP-4 and tPA   260 
antigen were independent predictors of remodelling was surprising, however, and 
merits further investigation.  
 
TIMP-4 has been relatively under-studied, particularly post-AMI, but might be 
expected to inhibit certain MMPs which, in theory, should limit ECM turnover and 
remodelling. One hypothesis to explain the results in Chapter 4, that an elevated 
TIMP-4 level predicted greater remodelling, is that the enzyme switches off certain 
MMPs (and other enzymes) that are protective against ECM turnover in the early 
post-infarction period, but has no effect on some of the more aggressive proteolytic 
MMPs. Previous attempts to limit remodelling using oral MMP inhibition have been 
disappointing; if the findings regarding TIMP-4 in this thesis are confirmed in larger-
scale trials, then future attempts to modulate the MMP:TIMP system to limit 
remodelling may focus on TIMPs in addition to or even instead of targeting MMPs. 
 
Previous studies have shown that vWF and PAI-1 are elevated and of considerable 
prognostic significance following acute coronary syndromes.
219, 220 The findings of 
this thesis, detailed in Chapter 4, reinforce these data:  tPA antigen (a surrogate 
marker of PAI-1 complexed to free tPA) predicted remodelling, and furthermore was 
related to MMP-3. Additional investigations are now needed to determine whether 
tPA antigen (and vWF) are simply markers of infarcted/necrotic myocardium, indices 
of ischaemia or reperfusion, markers of endothelial-platelet interaction or simply 
representative of the general pro-coagulant state that exists after AMI. Whether these 
haemostatic biomarkers may represent potential pharmacological targets in the future 
is unclear, although interestingly studies of ACE inhibitors in AMI have shown a   261 
reduction in PAI-1 in association with improved outcome, although whether this is 
coincidence as opposed to a definite biologic effect is unclear.
341  
 
10.3  Aldosterone in post-infarction remodelling 
The role of aldosterone in LV remodelling following AMI was examined in detail 
across the study population as a whole, and according to treatment group. I analysed 
the relationships between aldosterone and serial change in LV structure and function 
at three levels: genetic polymorphisms in aldosterone synthase, plasma aldosterone 
activity and urinary steroid metabolites. Through such detailed examination of 
aldosterone production, activity and degradation, and utilising the current gold 
standard means of LV functional assessment in patients with LVSD, the results 
detailed in Chapter 5 provide further insights into the actions of this important 
hormone in the pathophysiology of short-to-medium term post-infarction LV 
remodelling. 
 
There has been considerable debate as to whether the effects of aldosterone 
antagonism on the heart are due to mineralocorticoid receptor blockade independently 
of aldosterone effects, in other words that circulating aldosterone is a bystander.
304 
The results detailed in Chapter 5 suggest that circulating aldosterone exhibits a 
temporal variation in activity. Aldosterone, when measured at an average 3 days after 
AMI (prior to randomisation to placebo or eplerenone but in most cases after the 
commencement of a small dose of ACE inhibitor) correlated directly with parameters 
of adverse remodelling. Aldosterone then rose in the eplerenone-treated group but this 
change over time did not relate to adverse remodelling, suggesting that occupation of 
the mineralocorticoid receptor was preventing aldosterone (and cortisol) from   262 
activating the receptor and promoting remodelling. Conversely, aldosterone tended to 
decrease in placebo-treated patients, but this change correlated with increasing 
ventricular dilatation and more significant remodelling. The reasons for this are 
unclear, but I propose that, as 11β-hydroxysteroid dehydrogenase is not expressed to 
any great extent in the heart, the cardiac mineralocortocoid receptors in placebo-
treated patients were likely to be occupied and activated by cortisol, and that it was 
cortisol rather than aldosterone that potentiated the remodelling process via 
mineralocorticoid receptor activation.
99  
 
One hypothesis that arises from these results is that circulating aldosterone has a role 
in selecting a remodelling pathway in the first few days after AMI, but that 
subsequently it is mineralocorticoid receptor activation, largely by cortisol, that is the 
key determinant of progressive remodelling. The finding that, although under-
powered as a genetic study, the presence of the -344T allele in CYP112B in the study 
patients was associated with a trend towards greater aldosterone but also superior LV 
function indirectly supports this hypothesis. If our results (and hypothesis) were to be 
confirmed, this would provide further evidence for the very early initiation of 
mineralocorticoid receptor antagonists following (large) AMI.  
 
10.4  Micovascular obstruction as a determinant of LV outcomes after AMI 
The presence of MVO after non-reperfused AMI strongly predicts adverse 
cardiovascular outcome and ventricular remodelling. A recent small (n=40) study in 
reperfused AMI suggested that MVO in the presence of an open IRA did not predict 
adverse remodelling.
257 The vast majority of infarcts in the study population 
investigated in this thesis were reperfused, and through the use of LGE-CMR I was   263 
able not only to determine the presence of MVO but also to quantify MVO volume. I 
therefore examined the predictive value of presence of late MVO on medium-term LV 
remodelling. 
 
Despite a very high uptake of acute reperfusion therapy and a very high prescription 
of contemporary secondary preventative therapies, late MVO remained common, 
occurring in 56% of the study cohort. Additionally, the presence or absence of late 
MVO divided patients into two distinct groups with very different remodelling 
outcomes. Moreover, three-quarters of patients with late MVO on baseline LGE-CMR 
had TIMI 3 flow within the IRA, an observation of considerable significance as TIMI 
3 flow is accepted as the optimal angiographic result from coronary artery reperfusion 
therapy. From the results detailed in Chapter 6, I propose that the demonstration of 
late MVO on a pre-discharge LGE-CMR in patients admitted with AMI, should serve 
as a serious indicator of impending adverse remodelling irrespective of final 
angiographic result, and is of considerable potential as a predictor of remodelling. 
Indeed, MVO (and infarct characteristics such as magnitude, transmurality and 
endocardial extent) may be more appropriate end-points in clinical studies assessing 
success of reperfusion therapy in AMI than angiographic appearances, or even 
LVEF.
310 
 
The issues surrounding measurement of infarct volume on LGE-CMR were discussed 
in detail in Chapter 6, and the need for a global consensus highlighted. Through the 
Magnetic And eLectrical Technologies (MALT) society, incorporating colleagues in 
USA, Canada, Sweden, the Netherlands and France, the study population investigated   264 
in this thesis is currently being used as part of an international collaboration, with the 
goal of standardising infarct volume measurement on LGE-CMR. 
 
10.5  Novel biomarkers: apelin and serum sST2 
The study population which provides the focus of this thesis represents a 
contemporary, thoroughly investigated and aggressively treated cohort of AMI 
patients, and as such provides an excellent population in which to study the (potential) 
roles of novel mediators in acute coronary syndromes. Two such mediators are plasma 
apelin and serum sST2.  
 
Since its discovery a decade ago, a number of actions have been demonstrated that 
suggest that apelin may be of theoretical benefit in humans following AMI, as 
described in Chapter 1. In my study population, I found that plasma concentrations of 
apelin were reduced after AMI, and that although apelin concentration increased over 
time, it remained lower than in healthy controls even at 24 weeks. I observed no 
relationship between apelin and any parameter of LV function over time. There was a 
weak relationship between apelin and NA, a potent inotrope, which may provide some 
support for the inotropic activity demonstrated in animal models, and eplerenone 
significantly increased plasma concentrations of apelin over time, possibly due to its 
known interaction with angiotensin II. However, from these results it would appear 
unlikely that apelin will be of use as a prognostic marker after AMI. 
 
The results in Chapter 7 are based on measurement of apelin at only two time-points: 
at baseline (~4 days after AMI) and at 24 weeks. Future studies should include serial 
measurement of apelin, in order to characterise whether circulating apelin displays a   265 
temporal profile in activity. Also, measurement of apelin in a broader population of 
AMI patients would be of interest, in particular those with preserved LVEF, which 
would allow testing of the hypothesis made in Chapter 7 – that geometric change 
following large AMI acts as a trigger for variations in apelin expression. Simultaneous 
measurement of angiotensin II would also allow greater insight into the inter-relations 
of apelin and RAAS hormones after AMI. 
 
Serum sST2 is elevated after AMI and in heart failure, and is gaining popularity as a 
predictor of major adverse cardiovascular events in these conditions, as described in 
Chapter 1. The findings described in Chapter 8 build upon previous data regarding the 
relationship between sST2 and LV function after AMI. Specifically, novel 
relationships were detected between sST2 and medium-term (24 week) LV function, 
and interestingly between sST2 and parameters of large infarction. Moreover, a 
potential link to aldosterone, a hormone of considerable importance in post-infarction 
remodelling, was suggested. 
 
There are ongoing studies examining the predictive value of sST2 in cardiovascular 
disease and in a variety of conditions, including chronic lung disease, rheumatological 
disease, sepsis, trauma and autoimmune disease. The results of this thesis suggest that 
further studies specifically designed to determine whether sST2 has a role in the 
pathophysiology of remodelling, rather than simply serving as a marker of adverse 
prognosis, are warranted. The possible link between sST2 (and thus the IL-33:sST2 
signalling pathway) and the RAAS merits particular attention – if a biologic 
relationship between sST2 and aldosterone is confirmed, it may represent a potential 
therapeutic target in the treatment and limitation of post-infarction remodelling.   266 
 
10.6  ‘Routine’ use of LGE-CMR in patients admitted with AMI 
The ‘standard care’ approach to cardiac imaging in patients admitted with AMI at the 
time of writing this thesis (and during the recruitment phase of the study) consists of 
at most a single TTE, usually in the early stages of the acute admission and often 
performed in suboptimal conditions in non-expert hands. Through description of 
additional intra- and extra-cardiac abnormalities of variable clinical significance 
detected using LGE-CMR scanning in almost one-quarter of the study population that 
would otherwise have been missed had the ‘standard care’ approach been followed, I 
suggest that LGE-CMR be used where possible as an adjunct to the standard 
management of AMI.  
 
It is noteworthy that these results, outlined in Chapter 9, have contributed to the 
greater and more frequent use of LGE-CMR imaging in patients admitted with AMI 
in Glasgow since completion of the clinical work pertaining to this thesis. 
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10.7   Conclusions 
•  Eplerenone did not attenuate LV remodelling in patients with reduced LVEF but 
without heart failure or diabetes mellitus after AMI, although there was, by chance, 
a significant imbalance in baseline LV function between randomisation groups. 
Following pre-specified covariate-adjustment of the results, eplerenone did, 
however, exert a significant anti-remodelling effect in this population. 
•  Eplerenone exerted a (covariate-adjusted) effect on MMP-2 and MMP-9, supporting 
an anti-remodelling effect for this drug. 
•  Larger studies powered to detect a benefit on clinical outcomes using eplerenone in 
patients with ‘asymptomatic’ LVSD after AMI would be valuable. 
•  A single measurement of tPA antigen or TIMP-4 early after AMI may be of use in 
the prediction of medium-term LV remodelling after AMI. 
•  Aldosterone appears to display a temporal variation in its cardiac effects after AMI, 
playing a role in the selection of a remodelling pathway in the early phase, but 
thereafter it seems that cardiac mineralocorticoid receptor activation (probably by 
cortisol rather than aldosterone) potentiates the remodelling process. This 
hypothesis would support the very early initiation of aldosterone antagonists in 
patients with AMI and LVSD. 
•  The presence of (late) MVO on a pre-discharge covariate-adjustment of the results 
was necessary scan is a portent of adverse remodelling after AMI irrespective of 
angiographic TIMI III flow within the IRA. 
•  Plasma apelin is reduced (compared to healthy controls) after AMI and, although it 
increases over time, remains low at 24 weeks. Apelin has no relationship to LV 
function/remodelling.   268 
•  Serum sST2 correlated with baseline and pre-discharge LVEF and infarct volume, 
and also with aldosterone, suggesting a possible role for this mediator in post-
infarction remodelling. 
•  The performance of a pre-discharge covariate-adjustment of the results was 
necessary scan positively influenced patient management in 24% of the study cohort 
and is a useful and safe adjunct to the standard management and investigation of 
patients admitted with AMI. 
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Appendix I      Consent Form 
    
 
  
WEST ETHICS COMMITTEE 
 
FORM OF CONSENT FOR PATIENTS IN CLINICAL RESEARCH 
PROJECT 
 
 
 
Title of Project:  The effects of eplerenone on left ventricular remodelling post- 
acute myocardial infarction: a double-blind placebo-controlled 
cardiac-MR based study 
 
 
 
Investigators:    Dr. Robin Weir, Clinical Research Fellow, Western Inf. 
      Prof. HJ Dargie, Professor of Cardiology, Western Inf. 
      Prof. JJV McMurray, Professor of Cardiology, Western Inf. 
 
 
 
By signing this form you give consent to your participation in the project whose title 
is at the top of this page. You should have been given a complete explanation of the 
project to your satisfaction and have been given the opportunity to ask questions. You 
should have been given a copy of the patient information sheet approved by the West 
Ethics Committee to read and to keep. Even though you have agreed to take part in 
the research procedures you may withdraw this consent at any time without the need 
to explain why and without any prejudice to your care. 
 
Consent: 
 
 
I,……………………………………………………………………………….(PRINT) 
 
of……………………………………………………………………………… 
 
give  my  consent  to  the  research  procedures  above,  the  nature,  purpose  and 
possible consequences of which have been described to me 
 
by……………………………………………………………………………... 
 
Patient’s signature…………………………………………………………… 
 
Doctor’s signature…………………………………………………………… 
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Appendix II    Patient Information Sheet 
 
All patients were provided with the following document prior to formal 
recruitment into the trial: 
 
You  are  being  invited  to  take  part  in  a  research  study.    Before  you  decide  it  is 
important  for  you  to  understand  why  the  research  is  being  done  and  what  it  will 
involve.  Please take time to read the following information carefully and discuss it 
with others if you wish.  Ask us if there is anything that is not clear or if you would 
like more information.  Take time to decide whether or not you wish to take part. 
 
Thank you for reading this. 
 
 
Study Title 
The  effects  of  the  drug  eplerenone  on  left  ventricular  remodelling  post-acute 
myocardial infarction (a double-blind, placebo-controlled, cardiac MRI study) 
 
What does this title mean? 
Following a heart attack, patients are usually prescribed a number of tablets to help 
the heart recover. What we want to know is whether taking an extra tablet (a drug 
called eplerenone) – in addition to these other tablets – further reduces or prevents the 
ongoing damage to the heart muscle that can occur following the heart attack. We 
plan to compare the drug eplerenone against a dummy pill (placebo) to see if this is 
the case, with neither you nor us knowing which of the two you are taking. 
 
What is the purpose of the study? 
Coronary artery disease or “hardening of the arteries” is very common worldwide, 
especially in the West of Scotland. Despite all the advances in medicine, we still see 
large numbers of patients who develop angina and/or heart attacks. 
 
Our understanding of heart attacks has come on leaps and bounds in the last few 
decades. We now know that the best current treatment involves a combination of 
attempting to improve the blood flow to the heart muscle as quickly as possible (either 
by  clot-dissolving  drugs  straight  into  the  veins  –  “thrombolysis”  –  or  by  directly 
inserting stents into narrowed or blocked arteries – “angioplasty”) and putting patients 
on appropriate tablets to help the heart heal and reduce the chances of another heart 
attack. 
 
Unfortunately,  despite  us  putting  patients  who  have  had  heart  attacks  on  a 
combination of 3 or 4 (sometimes more) tablets – usually including aspirin, a beta-
blocker drug, a cholesterol-lowering drug and an ACE inhibitor, which protects the 
heart and helps it heal (usually ends in –pril) – there are some patients whose heart 
muscle does not recover as well as we would hope. Indeed despite these tablets, in 
some people the heart muscle continues to get weaker with time, the heart swells up 
and ultimately its pumping function deteriorates. This is called “remodelling” and 
leads  to  fluid  retention  (known  as  “heart  failure”),  poorer  quality  of  life,  and 
premature death. 
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The drug we are using, eplerenone, has been shown in big trials already to reduce this 
remodelling  process  in  patients  who  have  significant  enough  damage  to  the  heart 
muscle following a heart attack that the muscle is struggling to cope – these patients 
have developed heart failure. What we plan to do is to look at how eplerenone affects 
this remodelling process in patients who, like yourself, have had a heart attack which 
has caused heart muscle damage but who have not developed heart failure. 
 
If you agree to be involved in this study, the maximum planned study duration is 6 
months for each patient. 
 
Why have I been chosen? 
You have been chosen because you have had a heart attack which we know (based on 
the ultrasound scan of your heart – the “echo”) has caused damage to the heart muscle, 
but we also know that you have not had heart failure (fluid retention). You fall into 
exactly the group of patients that we would like to study, to see if the eplerenone drug 
has any further beneficial effect in helping the heart to recover. 
 
We plan to study a total of 100 patients. We are selecting patients by performing 
ultrasound scans on all new heart attack patients in the Coronary Care Units within 
the Western Infirmary, Southern General and Royal Alexandria Hospital, and looking 
out for those who have heart muscle damage (like yourself). 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part.  If you do decide to take part 
you will be given this information sheet to keep and be asked to sign a consent form. 
If you decide to take part you are still free to withdraw at any time and without giving 
a reason.  A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive. 
 
What will happen to me if I take part? 
If  you  take  part,  we  will  perform  some  extra  tests  while  you  are  still  in  hospital 
recovering  from  the  heart  attack  (this  will  in  no  way  delay  your  discharge  from 
hospital),  and  then  ask  you  to  come  back  for  a  follow-up  visit  to  the Cardiology 
Department at the Western Infirmary at two separate times – 3 months on from the 
heart attack and 6 months on. The 3 month visit will actually involve a short (less than 
1 hour) visit one morning, then  a slightly longer (c. 2.5 hour) visit the following 
morning. The 6 month visit will take one morning only and will last around 3 hours, 
after which your involvement in the trial will be finished. 
 
In  addition,  we  will  ask  you  to  attend  for  a  blood  test  on  2-3  separate  occasions 
(usually around week 4 and week 5 after the heart attack). Each visit will take only 5 
minutes, and travel expenses or taxis will be provided free of charge if necessary. 
 
If I volunteer, what is the first thing that will happen? 
While you are still in hospital (within the first few days after your heart attack), the 
following will occur. Please note that, as soon as you agree to the trial, you will be 
randomly assigned a number which will be unique to you, and the number (not your 
name etc.) will be used on all blood tests and other tests planned for trial purposes. 
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(i)  An extra sample of around 50ml (10 teaspoons) of blood will be taken 
from a vein in the arm. This blood will be stored prior to analysis at the 
end of the study. We will look at lots of different blood components that 
are known to be involved in the “remodelling” process. 
 
Note: A proportion of the blood will be used to look at one of your genes, 
as  some  people  might  naturally  be  less  susceptible  to  eplerenone  than 
others – this is “DNA analysis”. The sample will only have your unique 
number  (not  your  name  etc.)  and  we  plan  to  keep  all  genetic  analysis 
anonymous.  Please  note  that  we  are  looking  at  very  minor  differences 
between patients in this one gene, and there should be no impact to other 
members in the family based on our studies. If we wanted to identify you, 
there is a master copy of the key-code which would allow us to do this, but 
it is not planned. 
 
(ii)  You will be asked to wear a 24 hour ECG monitor. This is basically a belt 
that holds a small recording box, from which a few wires run to the chest. 
They are attached to sticky labels on the chest (just like when you get a 
heart tracing or ECG). You will be expected to wear this while you are on 
the ward for 24 hours, although it should not restrict your movements nor 
activities at all. After 24 hours, the device will be removed. It tells us how 
fast or slow the heart has been going over the 24 hour period. 
 
(iii)  You will be given a plastic bottle into which we would ask you to collect 
all urine that you pass over a 24 hour period. We will try to synchronise 
this with the 24 hour ECG to minimise inconvenience. We are looking at 
salts and hormone levels in the urine. 
 
(iv)  A  cardiac  MRI  scan  will  be  performed.  MRI  scans  give  us  very  clear 
pictures  of  the  heart  (much  better  than  any  other  test  which  we  have 
available at present). Unlike X-rays and CAT scans, MRI scans do not use 
any radiation – they use magnets to allow excellent quality pictures. As 
they use magnets, you should not have a scan if you have any metallic 
implants (eg. pacemakers, hip replacements, metal plates, aneurysm clips 
etc.) nor any history of any potential eye injuries that may involve metal 
objects. All of this will be discussed with you before the scan. 
 
 
 
You will be taken from the ward of your hospital to Level 4 Cardiology at 
the Western Infirmary, where the scan is performed. All you will be asked 
to do is lie flat on your back and follow requests to breathe in, hold, then 
breathe out while we take pictures. You will be lying partly in a cylindrical 
tube (the magnet) while we take the pictures, and the whole scan will last 
around 45 minutes although may last up to 1 hour. We will also inject a 
chemical dye (called gadolinium) into the veins via a plastic tube (cannula 
or venflon) in the arm, which should show up the area of damaged heart 
muscle very clearly. 
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Once these tests have been performed, you will be given the trial drug. It is a once-
daily tablet (usually taken in the morning). This type of trial is a randomised, double-
blind trial involving a placebo – these terms are defined as follows: 
 
Randomised Trial 
 
Sometimes  because  we  do  not  know  which  way  of  treating  patients  is  best,  we  need  to  make 
comparisons.    People  will  be  put  into  groups  and  then  compared.    The  groups  are  selected  by  a 
computer which has no information about the individual – i.e. by chance.  Patients in each group then 
have a different treatment and these are compared. You will have a 50:50 chance of receiving the study 
drug (ie. 1 in 2). 
 
Blind trial 
 
In a blind trial you will not know which treatment group you are in.  If the trial is a double blind trial, 
neither you nor your doctor will know in which treatment group you are (although, if your doctor needs 
to find out he/she can do so). 
 
Placebo 
 
A placebo is a dummy treatment such as a pill which looks like the real thing but is not.  It contains no 
active ingredient. 
 
 
Eplerenone can occasionally cause an upset to the salts in your blood and the kidney 
function (much like some of the other tablets you will be on following a heart attack), 
so  we  plan  to  keep  an  eye  on  these  by  performing  a  single  blood  test  on  a  few 
occasions, namely just before you are discharged from hospital following the heart 
attack, then at 4 weeks after starting the tablet. The reason we check the salts in the 
blood at 4 weeks is because we plan to increase the dose of the trial drug at that time. 
For the same reason we will also check a single blood test 1 week after the dose 
increase (ie. 5 weeks after starting the drug). Each of these two visits will only take 
around 5 minutes in the hospital, and travel expenses and/or free taxis are available if 
needed. 
 
Your GP will be informed in writing of your participation in the trial. 
 
The 3 month follow-up visit 
You will be asked to come up for a short period of time on two successive mornings 
around 3 months after the heart attack. 
 
On the first morning, you will be asked to attend for at most 1 hour. We will ask you 
to come up to Western Infirmary (Level 4) fasted from midnight the previous night, 
and will simply repeat some of the tests you had done when you first joined the trial: 
 
(i)  your blood pressure will be taken 
(ii)  around 40ml of blood (8 teaspoons) will be removed from a vein in the 
arm 
(iii)  you will have a heart tracing (ECG) 
(iv)  a 24 hour ECG monitor will again be attached 
(v)  you will be given another plastic bottle and asked to start collecting all the 
urine you pass over the next 24 hours. 
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As soon as the blood test is done, you can eat whatever you want! You can then leave 
the hospital and are asked to return the next day (no fasting necessary). This visit 
includes a second MRI scan of the heart and will last around 2.5 hours. At this visit: 
 
(i)  the 24 hour tape will be removed 
(ii)  you can hand in the 24 hour urine collection 
(iii)  we will perform the MRI scan (exactly as above) – again, 45-60 minutes 
are set aside for this 
 
You  will  then  be  free  to  leave.  As  before,  travel  expenses  and/or  free  taxis  are 
available if needed. 
 
The 6 month follow-up visit 
This takes one morning only, and is expected to last around 3 hours. You are asked to 
turn up fasted from midnight the night before, and the following will occur: 
 
(i)  your blood pressure will be checked 
(ii)  40ml of blood (8 teaspoons) will be removed from a vein in the arm 
(iii)  you will have another heart tracing (ECG)  
(iv)  you will have a third and final MRI scan of the heart (identical to above) 
 
Finally you will be asked to complete a short questionnaire about what symptoms (if 
any) you have had over the course of the study. The study will then be finished, and 
the trial drug will be stopped. Your GP will be informed that you have completed the 
trial. 
 
Summary of your involvement 
 
During your hospital admission  Recruitment,  blood  test,  MRI,  24hr  tape,  24hr 
urine 
4 weeks        Single blood test 
5 weeks        Single blood test 
3 months        Day 1: blood test, 24hr tape, 24hr urine, ECG 
          Day 2: remove 24hr tape, return urine, MRI scan 
6 months        Blood tests, ECG, MRI scan 
 
        END OF TRIAL 
 
 
 
What are my commitments? Will the trial affect my lifestyle? 
There are no new restrictions on your lifestyle while in the trial other than the general 
lifestyle advice and restrictions on driving/working/heavy exercise which you will be 
given by the medical team looking after you following your heart attack. Eplerenone 
can  occasionally  cause  dizziness,  and  driving  should  be  avoided  if  you  are 
experiencing this symptom. 
 
We ask you simply to take the trial drug as a once-daily tablet (it is important that you 
take it every day unless advised by us to the contrary) and attend for the blood tests 
and follow-up visits as above.   276 
 
What is eplerenone? 
Eplerenone is a drug that blocks the activity of a naturally-occurring hormone called 
aldosterone. Following a heart attack, aldosterone levels are increased and are known 
to contribute to the detrimental “remodelling” process. It has mild diuretic (“water 
tablet”) properties also. 
 
Eplerenone is already licensed in the UK for people with heart attacks, heart muscle 
damage and fluid retention or heart failure, but not (yet) for those who, like you, who 
have heart muscle damage but no heart failure. It is a once daily tablet with a dose of 
25mg  daily  for  the  first  month,  and  then  50mg  daily  for  the  rest  of  the  trial. 
Occasionally we have to reduce the dose of the trial drug, or even stop it for a short 
while, depending on the salt levels in your blood and your kidney function – this is 
why we ask you to attend for the blood tests and follow-up visits. 
 
 
What are the alternatives to eplerenone? 
We are not changing any of the other tablets that you would normally be taking after 
your  heart  attack.  We  simply  plan  to  add  an  extra  tablet  to  these,  not  replace  or 
substitute any tablet. 
 
Does eplerenone have any side-effects that I should know about? 
Every tablet has potential side-effects. Most of eplerenone’s side-effects pertain to 
your blood salts/kidney function which we will be monitoring closely with blood tests. 
Side-effects that are not uncommon include dizziness, nausea, loose bowel motions 
and low blood pressure (often asymptomatic). Rare side-effects include dehydration, 
headache,  sweating,  flatulence,  vomiting,  leg  cramps,  irregular  heart  beats,  and 
damage to the heart muscle (only in very high doses – around 10x higher than we are 
using). 
 
Patients with pre-existing significant kidney disease or severe liver disease should not 
take eplerenone. 
 
As it is a relatively new drug there may be some as yet unknown side-effects. 
 
 
What are the possible disadvantages or risks of my taking part in the trial? 
 
•  Although  blood  sampling  is  quick  and  straight-forward,  it  is  a  little 
uncomfortable and some patients feel faint. There is a minor risk of bleeding, 
bruising or infection at the puncture site. 
•  Some  patients  find  the  MRI  machine  claustrophobic  although  most  can 
tolerate the scan. 
•  Eplerenone can cause the side-effects listed above. 
•  The  “dye”  that  we  inject  (gadolinium)  can  occasionally  cause  headache, 
nausea, injection site coldness and, rarely, allergic reactions. 
•  It is possible that if the treatment is given to a pregnant woman it will harm the 
unborn  child.    Pregnant  women  must  not  therefore  take  part  in  this  study, 
neither should women who plan to become pregnant during the study.  Women 
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taking  part  to  exclude  the  possibility  of  pregnancy.    Women  who  could 
become pregnant must use an effective contraceptive during the course of this 
study.  Any woman who finds that she has become pregnant while taking part 
in the study should immediately tell her research doctor. 
•  If you hold private medical insurance, you should check with your company if 
involvement in this trial will affect your contract. 
 
 
What are the possible benefits of taking part? 
The purpose of this study is to find out if eplerenone gives added benefit to patients 
like yourself who have had a heart attack and have heart muscle damage. We strongly 
suspect  it  will  do,  and  moreover  this  study  will  give  insight  into  exactly  how 
eplerenone does exert this predicted beneficial effect. Obviously half of the patients in 
this trial will receive the placebo, so we cannot say that we guarantee to improve the 
well-being  of  all  patients  over  the  6  month  period.  What  we  can  say  is  that  the 
information from this trial will be used ultimately to decide whether patients like 
yourself (indeed, including yourself) should routinely be prescribed eplerenone in the 
longer term. 
 
We also monitor your blood tests very closely, which is beneficial for you as not only 
eplerenone but also some of the other drugs you are likely to be taking can cause 
subtle upset to your blood tests. 
 
What if new information about the drug or my condition becomes available? 
Sometimes during the course of a research project, new information becomes 
available about the treatment/drug that is being studied.  If this happens, we will 
tell you about it and discuss with you whether you want to continue in the study.  If 
you decide to withdraw we will make arrangements for your care to continue.  If 
you decide to continue in the study you will be asked to sign an updated consent 
form. 
 
Also, on receiving new information we might consider it to be in your best interests to 
withdraw you from the study.  If this occurs, we will explain the reasons and arrange 
for your care to continue. 
 
What happens when the research study stops? 
At the end of the 6 months, the trial drug will be withdrawn. Neither you nor us will 
find out which of the two (eplerenone or placebo) you were taking. It will be left to 
the  discretion  of  your  GP  and/or  any  doctors  who  see  you  at  hospital  out-patient 
clinics as to whether eplerenone is formally prescribed in the longer-term. 
 
What if something goes wrong? 
If  you  are  harmed  by  taking  part  in  this  research  project,  there  are  no  special 
compensation arrangements.  If you are harmed due to someone’s negligence, then 
you may have grounds for a legal action but you may have to pay for it.  Regardless of 
this, if you wish to complain, or have any concerns about any aspect of the way you 
have been approached or treated during the course of this study, the normal National 
Health Service complaints mechanisms should be available to you. 
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Will my taking part in the trial be kept confidential? 
If  you  consent  to  take  part  in  the  research  any  of  your  medical  records  may  be 
inspected by the company sponsoring (and/or the company organising) the research 
for purposes of analysing the results.  They may also be looked at by people from the 
company and from regulatory authorities to check that the study is being carried out 
correctly.  Your name, however, will not be disclosed outside the hospital/GP surgery. 
Please note that your GP will be made aware of your participation in the trial. 
 
What will happen to the results of the research study? 
We plan to publish the results of this study in a variety of medical journals, all of 
which are generally available to the public on the internet. Please note that you will 
not be identified in any report/publication. 
 
Who is funding the study? 
The study is funded by the drug company Pfizer, who produce eplerenone. Pfizer will 
pay money into Professor Dargie’s funding account for including you in this study. 
The principal investigator (Dr. Robin Weir) will not receive any additional payment 
for including you in the study. 
 
Has this study been reviewed? 
The  West  Ethics  Committee,  who  meet  twice  monthly,  have  reviewed  the  study 
protocol. 
 
Thank you very much for your participation in this study. You will be given a copy of 
this document and a copy of the signed consent form for your records. 
 
 
 
Contacts for further information 
 
Principal Investigator     Dr. Robin Weir 
 
  Working hrs (9am-5pm)  0141-211-2000 and ask for page no. 3295 
          0141-211-8527 (Direct Line) 
  Out-with working hrs   0141-211-2594 (Coronary Care Unit) 
 
If you are unable to contact Dr. Weir, a message can be left on his answering machine 
on his direct line as above. Failing this, a message can be left with Professor Dargie’s 
secretary on 0141-211-2803 
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Appendix III    MRI Safety Questionnaire 
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Appendix IV    Letter For General Practitioner 
 
 
 
 
              Glasgow Cardiac Magnetic Resonance Unit, 
              Level 4 Cardiology, 
              Western Infirmary, 
              Glasgow G11 6NT 
 
              [date] 
Dear Dr., 
 
Patient:      DOB:            Address:      
 
The  above-named  patient  was  recently  admitted  to  hospital  with  an  acute  MI. 
Although a separate discharge summary will be sent to you by the hospital medical 
team detailing the admission, the purpose of this letter is to inform you that Mr(s) 
***** has kindly agreed to participate in a drug trial, in which I am the principal 
investigator, using the new selective mineralocorticoid receptor antagonist eplerenone 
(“Inspra”). 
 
Eplerenone reduces morbidity and mortality in patients with left ventricular systolic 
dysfunction  (LVSD)  and  heart  failure  or  diabetes  after  a  recent  MI.  We  plan  to 
examine the effect of eplerenone on LV remodelling post-MI using sequential cardiac 
MRI scans, compared with placebo. 
 
Your  patient  has  LVSD  following  his/her  recent  MI.  He/she  has  consented  to  be 
involved in a double-blind placebo-controlled study in which he/she will participate 
for a total of 6 months. We plan to perform three CMR scans, together with a host of 
bloods pertaining to remodelling, at baseline, 3 months and 6 months. 
 
After the first CMR scan, the patient is randomised to eplerenone or placebo. The 
patient is asked to continue the study drug (a once daily tablet) for the duration of the 
6 month follow-up. The dosage regime is as follows: 25mg daily for 4 weeks then 
increased to a target 50mg daily for the rest of the study. All U&Es monitoring 
and dosage alterations will be performed by the research team at the Western. GPs 
should not have to perform any extra blood analysis for the purposes of this research 
project.  Likewise  all  monitoring  of  the  trial  will  be  performed  by  the  Chief 
Investigator (Dr. R. Weir). 
 
The  patient  will  take  eplerenone  or  placebo  in  addition  to  standard  post-MI 
medications decided upon by the hospital medical team and yourself (including 
ACE inhibitors, β β β β-blockers, ARBs). Caution is advised in its concurrent use with 
trimethoprim, lithium, α α α α-blockers, tricyclics, neuroleptics, NSAIDs and steroids, 
while it is absolutely contra-indicated with K-sparing diuretics, clarithromycin, 
cyclosporin,  tacrolimus,  itraconazole,  ketoconazole,  nefazodone,  ritonavir  and 
nelfinavir. Eplerenone contains lactose thus should be avoided by those who are 
lactose-intolerant. The maximum daily dose of eplerenone should be 25mg (not 
50mg) in those on amiodarone, verapamil or diltiazem. The effect of eplerenone is   281 
reduced  by  phenytoin,  carbamazepine,  rifampicin  and  St.  John’s  Wort  thus  these 
should  be  avoided  if  possible.  Your  patient  has  been  given  a  “Trial  Card” 
summarising the above. 
 
Relatively  common  side-effects  include  dizziness,  hypotension,  diarrhoea  and 
nausea in addition to electrolyte disturbance/renal dysfunction. Uncommon side-
effects  include  headache,  insomnia,  pruritus,  sweating,  dehydration, 
hypercholesterolaemia,  leg  cramps,  pyelonephritis,  pharyngitis  and 
flatulence/vomiting. As eplerenone should be used with caution in pregnancy, as must 
CMR scanning, we have excluded pregnant females from the study. As there is a 
lack of information on the penetration of eplerenone into breast milk, breast-feeding 
should be discouraged. 
 
At the end of the 6 month study the trial drug will be withdrawn and you will be 
informed  in  writing  of  the  patient's  completion  of  the  trial.  It  will  be  left  to  the 
discretion of yourself and/or any hospital medical team looking after the patient at that 
time as to whether eplerenone be prescribed regularly. 
 
If you have any queries about the contents of this letter, or if any issues arise during 
the trial, please do not hesitate to contact me using one of the modes below; if within 
office hours the best way to contact me is via the Western Infirmary switchboard. 
 
The patient is aware that I have informed you of his/her inclusion in the trial. 
 
 
 
 
Direct line:  0141-211-8527          Yours sincerely, 
Page :          #3295 via switchboard (0141-211-2000) 
E-mail:        robinweir75@hotmail.com 
 
                 Dr. Robin Weir 
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Appendix V       Adverse Events – Definitions/Reporting Forms
     
An adverse event is any undesirable experience associated with the use of a medical 
product in a patient. The event is SERIOUS and should be reported when the patient 
outcome is:  
Death  
Report if the patient's death is suspected as being a direct outcome of the adverse 
event. 
Life-Threatening  
Report if the patient was at substantial risk of dying at the time of the adverse event or 
it is suspected that the use or continued use of the product would result in the patient's 
death. 
Hospitalization (initial or prolonged)  
Report if admission to the hospital or prolongation of a hospital stay results because 
of the adverse event. 
Disability  
Report if the adverse event resulted in a significant, persistent, or permanent change, 
impairment, damage or disruption in the patient's body function/structure, physical 
activities or quality of life. 
Congenital Anomaly  
Report if there are suspicions that exposure to a medical product prior to conception 
or during pregnancy resulted in an adverse outcome in the child. 
Requires Intervention to Prevent Permanent Impairment or Damage  
Report if you suspect that the use of a medical product may result in a condition 
which required medical or surgical intervention to preclude permanent impairment or 
damage to a patient. 
 
Unexpected Adverse Event 
 
This is an adverse drug experience that has not been previously observed, for example 
an adverse reaction that does not appear on the list of known adverse reactions of 
eplerenone but which is suspected to be related to its use, or else a reaction that is 
much  more  severe  than  would  be  expected  from  the  list  of  “common”  and 
“uncommon” adverse events. 
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Serious Adverse Event form 
 
 
THE EFFECTS OF EPLERENONE ON LEFT VENTRICULAR REMODELLING 
POST-ACUTE MYOCARDIAL INFARCTION: A DOUBLE-BLIND PLACEBO-
CONTROLLED CARDIAC MR-BASED TRIAL 
Protocol no. Pfi-RW-2005-01  Eudract no.  2004-004399-35  Version 2 
 
 
1.  Date reported to Chief Investigator: 
 
2.  Patient details:  Initials: ________  Date of birth:  ___/____/_____ 
Sex:  M/F (circle as appropriate) 
 
3.  Details of investigational medicinal product (IMP), ie. the study drug: 
-  dose:    ____________________ 
-  time last taken: ____________________ 
-  start date:  ____________________ 
-  concomitant medications/doses: 
    ______________________________________________ 
    ______________________________________________ 
    ______________________________________________ 
    ______________________________________________ 
    ______________________________________________ 
   
 
4.  Serious adverse event (SAE) reporting criteria (check all appropriate to the event) 
 
 
￿  Resulted in death 
￿  Was life-threatening 
￿  Required or prolonged in-patient hospitalisation 
￿  Resulted in persistent or significant disability/incapacity 
￿  Was a congenital anomaly/birth defect 
￿  Was important medical event jeopardising the patient or requiring 
intervention to prevent serious outcome 
 
 
5.  Onset of SAE:    _______________    _______________ 
          date      time (if applicable) 
 
6.  SAE(s) in medical terms (diagnosis if possible): 
 
 
 
 
 
7.  Description of the above SAE(s) – include related symptoms/signs, course, 
relevant treatment of the event etc.: 
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8.  Findings and lab values relevant to the above SAE(s) [if applicable]: 
 
 
 
 
 
9.  Outcome of the SAE(s) described in [5] above: 
 
a.  Resolved on ___________________________ 
b.  Improved 
c.  Unchanged 
d.  Deteriorated 
e.  Died of _______________________________   on   
_____________________ 
f.  Other, please specify: 
______________________________________________ 
 
 
10.  GP:   Dr.                 
_______________________________________ 
Practice address :
  _______________________________________ 
Phone no.: 
  _______________________________________ 
 
11.  Chief Investigator details: 
 
Chief Investigator:
  ________________________________ 
Address: 
  ________________________________ 
   
  ________________________________ 
   
  ________________________________ 
Phone no.: 
  ________________________________ 
e-mail address: 
  ________________________________ 
Fax no.: 
  ________________________________ 
 
         
        Chief Investigator’s comments: 
 
 
 
 
 
For suspected SAE, above form to be filled out as completely as possible by the 
Chief Investigator (Dr. Robin Weir, Level 4 Cardiology, Western Infirmary, 
Glasgow G11 6NT, fax no. 0141-211-1791, phone no. 0141-211-8527) within 24 
hours of receipt of the information and sent as soon as possible (maximally 7 
working days) to the MHRA.    285 
Appendix VI    Pharmacovigilance 
 
1.  Eplerenone was produced in film-coated tablets (pharmaceutical form). 
 
2.  Although  both  25mg  and  50mg  tablets  were  available,  we  used  25mg 
tablets  only,  to  reduce  the  risk  of  accidental  over-  or  under-dosing  if 
patients have both strengths of tablet in their possession. Thus when the 
dose was up-titrated from 25mg to 50mg, two 25mg tablets were taken to 
constitute the latter dose. 
 
3.  Absolute contraindications to eplerenone: 
 
(a)  hypersensitivity to eplerenone or one of its excipients 
(b)  serum potassium > 5.0mmol/l at initiation 
(c)  moderate/severe renal impairment (creatinine >220µmol/l) 
(d)  severe hepatic insufficiency 
(e)  concurrent  use  of  potassium  supplements,  potassium-sparing 
diuretics  or  strong  inhibitors  of  the  enzyme  CYP3A4  – 
clarithromycin,  telithromycin,  nefazodone,  itraconazole, 
ketoconazole, ritonavir, nelfinavir. 
 
4.  Major pharmacodynamic interactions with other drugs: 
 
(a)  lithium toxicity has been reported in patients also taking diuretics 
and ACE inhibitors, but direct interaction studies have never been 
performed  with  eplerenone.  Nonetheless,  concomitant  use  of 
lithium and eplerenone should be avoided. If absolutely necessary, 
serum lithium levels should be monitored. 
(b)  due  to  the  potential  nephrotoxic  effects  of  tacrolimus  and 
cyclosporin,  their  use  with  eplerenone  should  be  avoided.  If 
absolutely necessary, serum levels of tacrolimus and cyclosporin 
should be monitored. 
(c)  concomitant use of trimethoprim and eplerenone increases the risk 
of hyperkalaemia thus U&Es monitoring is necessary. 
(d)  α-1 blockers (eg. prazosin, doxazosin) increase the risk of postural 
hypotension when combined with eplerenone, thus lying/standing 
BP  measurements  should  be  performed  in  these  patients,  with 
similar  measurements  being  made  in  those  who  take  tricyclic 
antidepressants or neuroleptics with eplerenone. 
 
5.  Major pharmacokinetic interactions with other drugs: 
 
(a)  strong inhibitors of CYP3A4 potentiate the effects of eplerenone, 
thus the drugs listed in 3(e) above should be avoided. 
(b)  less powerful inhibitors of CYP3A4 can increase the bioavailability 
of  eplerenone.  It  is  therefore  recommended  that  25mg  be  the 
maximum  dose  of  eplerenone  when  administered  concomitantly 
with  such  drugs  –  mainly  amiodarone,  diltiazem,  verapamil, 
erythromycin.   286 
(c)  strong  inducers  of  CYP3A4  can  lead  to  reduced  efficacy  of 
eplerenone and should thus be avoided. These include rifampicin, 
carbamazepine, phenytoin and St. John’s Wort. 
(d)  systemic  exposure  to  digoxin  is  increased  by  16%  when  co-
administered  with  eplerenone,  therefore  caution  is  warranted  at 
doses near the upper limit of the normal range. 
(e)  NO interaction with warfarin has been demonstrated. 
 
 
Pregnancy / Lactation 
 
Insufficient data exist on the use of eplerenone in these situations, thus its use should 
be avoided. 
 
 
Recognised adverse effects 
 
The overall incidence of adverse events in the EPHESUS trial (ref) was similar to 
placebo (78.9% v 79.5%) and the discontinuation rate was 4.4% for the eplerenone 
group and 4.3% for the placebo group. 
 
The following recognised side effects are sub-divided into common (ie. between 1:10 
and 1:100) and uncommon (between 1:100 and 1:1000): 
 
Common    Hyperkalaemia 
      Dizziness 
      Hypotension 
      Abnormal renal function 
      Diarrhoea, nausea 
 
Uncommon    Headache 
      Insomnia 
      Postural hypotension 
      Flatulence, vomiting 
      Sweating, pruritus 
      Back pain, leg cramps 
      AF, MI, heart failure 
      Pharyngitis 
      Eosinophilia 
      Pyelonephritis 
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Appendix VII    Angiographic Data 
 
 
 
 
Vessels  with  at  least  50%  luminal  stenosis  included  in  the  above  analysis,  as 
described in the Statistical Methods section (Chapter 2.7). 
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Appendix VIII    Safety Data 
 
Renal function: 
 
  EPLERENONE  PLACEBO 
  Baseline  24 weeks  p  Baseline  24 
weeks 
p 
Serum 
potassium 
(mmol/l) 
4.10 
(0.35) 
4.12 
(0.72) 
0.84  4.17 
(0.35) 
4.02 
(0.67) 
0.15 
Serum 
creatinine 
(µmol/l) 
101.7 
(18.7) 
100.1 
(19.0) 
0.44  98.1 
(23.6) 
97.5 
(24.1) 
0.77 
eGFR 
(ml/min/m
2) 
67.3 
(16.0) 
68.6 
(16.0) 
0.39  73.3 
(18.9) 
73.9 
(18.1) 
0.74 
 
There were no significant changes in serum potassium, creatinine or eGFR between 
baseline and 24 weeks in either randomisation group (data expressed as mean [SD]). 
 
 
Serious adverse events: 
 
  Eplerenone 
(n=50) 
Placebo 
(n=50) 
Death  3 (6%)  0 (0%) 
Heart failure hospitalisation  1 (2%)  1 (2%) 
Chest pain admission (biomarker negative)  3 (6%)  3 (6%) 
Recurrent AMI  1 (2%)  1 (2%) 
Stroke  3 (6%)  0 (0%) 
Hospitalisation with possible arrhythmia  2 (4%)  3 (6%) 
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Appendix IX    TIMI Grade Scale for angiography  
 
 
 
A grading scale for coronary blood flow based on visual assessment of the rate of 
contrast opacification of the IRA at angiography.
342 
 
TIMI 0 flow  -  absence of antegrade flow beyond a coronary occlusion 
TIMI 1 flow   -  faint antegrade coronary flow beyond an occlusion, with  
incomplete filling of distal coronary bed 
TIMI 2 flow  -  delayed or sluggish antegrade flow with complete filling of the  
distal coronary bed 
TIMI 3 flow  -  normal flow which fills distal coronary bed completely 
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